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Embryonic stem cells (ESCs) derived from the inner cell mass (ICM) of murine 
blastocysts are characterised by their ability to self-renew and their potential to 
differentiate into many different cell types. These unique properties are governed by a 
complex transcription regulatory network, including master regulators 
Oct4/Sox2/Nanog and other pluripotency factors. Interestingly, depletion of a single 
transcription factor of this network will alter ESC pluripotency. Thus it would be vital 
to decipher the delicate transcription regulation of pluripotent state in mESCs. The 
importance of this transcription regulatory network was highlighted by the remarkable 
discovery that overexpression of transcription factors can reprogram the differentiated 
somatic cells to pluripotent cells, i.e. induced pluripotent stem cells (iPSCs). This 
process was therefore known as somatic cell reprogramming. Recent studies have 
found numerous transcription factors important for ESC identity maintainance or 
pluripotency induction in somatic cell reprogramming, including many zinc finger 
proteins.  
In this thesis, we identified two zinc finger proteins, Zfp322a and Patz1, which are 
important regulators of ES cell identity Our results revealed Zfp322a as a novel 
pluripotency factor which is not only required for maintaining ES cell identity but also 
can enhance somatic cell reprogramming. On the other hand, Patz1, though previously 
reported as a pluripotency factor in mESCs, modulates the reprogramming process in a 
dosage-dependent manner, possibly through its regulation of c-Myc, cell senescence, 
mesenchymal to epithelial transition (MET) and chromatin modification. Together, 
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1.2 Pluripotent stem cells from the early embryo 
1.1.1 Early embryo development 
During preimplantation development in mammals, the embryo develops from a 
totipotent zygote into a developing organism that is composed of three germ layers. It 
has been demonstrated that only one-cell zygote and 2-cell stage blastomeres are 
totipotent since they are capable to develop all by the cell itself into a fertile organism 
(Tarkowski, 1959). From the 2-cell stage to the 16-cell stage, each individual 
blastomere still possesses totipotency, i.e. the ability to contribute to all lineages of an 
entire organism including the extraembryonic tissues (Posfai et al., 2014; Suwińska et 
al., 2008). When the blastomeres further divide, the embryo undergoes compaction 
and polarization to form a blastocyst containing a fluid-filled cavity (blastocoel). 
Thereafter the first cell fate decision occurs and totipotency no longer persists. At this 
stage (~E3.5), the embryo is comprised of two distinct populations of cells: the outer 
layer, which becomes trophectoderm (TE) surrounding a fluid-filled cavity 
(blastocoel); the inner cells, which forms the inner cell mass (ICM) inside the 
blastocoel. The inner cell mass can be isolated and outgrown in vitro, known as 
embryonic stem cells (ESCs)(Evans and Kaufman, 1981; Martin, 1981). At the late 
blastocyst stage (~E4.5), ICM cells further undergo another cell fate decision prior to 
uterine implantation, whereby cells become restricted to either the primitive 
endoderm (PE) in contact with the blastocoel or pluripotent epiblast formed in the 
inner layer. Epiblast cells from post-implantation embryo can also be cultured in vitro 
and are known as epiblast stem cells (EpiSCs) (Tesar et al., 2007). As the embryo 
implants and enters gastrulation stage, epiblast cells gradually lose their pluripotency, 
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form primitive streak, and develop to all three distinctive developmental germ layers 
of the embryo, i.e. mesoderm, endoderm and ectoderm, as well as the primordial germ 
cells (PGCs). In contrast, PE and TE are exclusively to form extraembryogenic 
tissues, such as the parietal yolk sacs and the placenta (Arnold and Robertson, 2009). 
 
In general, there are two types of pluripotent cells which can derived from the early 
embryo: ESCs derived from the preimplantation ICM or early epiblast and EpiSCs 
isolated after post-implantation epiblast. They are pluripotent since they possess the 
potential to differentiate into all three germ layers and the germ line in vitro and in 
vivo. In addition, they are able to self-renew when cultured with leukemia inhibitory 
factor (LIF) and bone morphogenetic protein 4 (BMP4) (murine ESCs), or basic 
fibroblast growth factor (bFGF) and transforming growth factor β (TGFβ) (human 
ESCs and mouse EpiSCs) (Beattie et al., 2005; Vallier, 2005; Williams et al., 1988; 




Figure 1.1 Preimplantation embryo development in mouse. (Taken from Appendix A: 
Early Development. In Stem Cell Information; 
http://stemcells.nih.gov/info/scireport/pages/appendixA.aspx) 
 
1.1.2 Mouse embryonic stem cells 
The isolation of pluripotent embryonic stem cells from mouse blastocysts was first 
reported by Evans and Kaufman in 1981 (Evans and Kaufman, 1981). They delayed 
embryo implantation to increase ICM, from which they isolated ICM and expanded 
them in vitro. In the same year, Dr. Gail Martin successfully extracted ICM from late 
blastocyst using microsurgery (Martin, 1981). These ICM cells were demonstrated to 
retain infinite self-renewal and pluripotent characteristics by their ability to form 
teratoma and differentiate in vitro and thus are designated as ESCs. Although ESCs 
are derived from in vivo ICM, some differences between ICM and ESCs have been 
identified, such as that the expression of Pramel5, Pramel6 and Pramel7 are repressed 
in ESCs but not in ICM (Kaji et al., 2007). It has been reported that mESCs are more 
similar to 4.5 dpc ICM other than 3.5 dpc ICM, when mESCs are derived (Brook and 
Gardner, 1997; Kaji et al., 2007). Moreover, ICM cells proliferate rather slowly and 
no evidence supports that ICM cells can self-renew extensively. How mESCs are 
derived from ICM (or early epiblast cells) and the molecular differences between 
these two cell types warrant further investigations. 
 
Mouse ESCs are distinguished for their high nucleus-cytoplasm ratio. They maintain a 
high proliferative and undifferentiated state in vitro by culturing on feeder cells with 
conventional culture media containing 10-20% fetal bovine serum (FBS) (Evans and 
Kaufman, 1981). mESCs needs no feeder layer if leukemia inhibitory factor (LIF) is 
added into the culture media (Williams et al., 1988). When plated at a low density, 
each undifferentiated ES cell is able to propagate in the same pluripotent state and 
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forms a rounded, compact and multi-layer clump, which is the characteristic and 
unique morphology of ESC colonies.  
 
Besides their ability to self-renew, mESCs are also pluripotent, which means they are 
able to differentiate into all three germ layers in response to developmental cues. This 
has been demonstrated in numerous studies. For instance, teratoma can be formed if 
ESCs are injected into mice. Furthermore, when mESCs were cultured on a 
nonadherent surface in the absence of LIF, they will spontaneously form embryoid 
body (EB), a spheroid structure comprised of somatic cells from all three germ layers-
endoderm, mesoderm and ectoderm. EB generation is an in vitro imitation of 
embryonic development, and, together with teratoma formation, has been considered 
as defined features of pluripotent cells. 
 
At molecular level, mouse ESCs express a panel of markers that are used to 
distinguish themselves from other differentiated cell lineages, including cell surface 
makers SSEA-1 and Thy-1; transcription factors Oct4, Nanog, Sox2, Rex1, Stella etc.; 
signaling pathway-related intracellular markers Smad 1/5/8 ; enzymatic markers 
alkaline phosphatase, whose expression can be easily visualized by an enzymatic-
based reaction and therefore is widely used for pluripotency examination (Zhao et al., 
2012). 
 
It has been commonly believed that pluripotent cells cultured in vitro fluctuate 
between ground state pluripotency, a.k.a. naïve pluripotency, and a state primed for 
lineage commitment (Graf and Stadtfeld, 2008; Takana, 2009). Many studies have 
established that mESCs are heterogeneous in the expressions of Rex1, Nanog, Klf4 
and Stella, hallmarks of naïve pluripotent mESCs (Chambers et al., 2007; Hayashi et 
al., 2008; Kalmar et al., 2009; Toyooka et al., 2008). Cells which express high levels 
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of those genes are in a ground pluripotent state while cells with low levels are more 
prone to exit pluripotency permanently. Interestingly, Ying et al. found that inhibitors 
of Extracelluar-Signal-Regulated Kinases (ERK) and Glycogen Synthase Kinase 3 
(GSK3) pathways, which has been termed “2i”, eliminate the heterogeneity and 
robustly support mESCs in a ground state pluripotency, expressing high and 
homogeneous levels of Oct4, Sox2 and Nanog and conferring ESCs with totipotency 
(Morgani et al., 2013; Ying et al., 2008). Accordingly, mESCs cultured in 2i display 
higher colony formation and chimaera contribution rates. 
 
1.1.3 Mouse epiblast stem cells 
Mouse EpiSCs are isolated by direct culture of epiblast tissue from early 
postimplantation embryos (between E4.5 and E8.0) (Brons et al., 2007; Tesar et al., 
2007). These cells are capable of infinite propagation in an undifferentiated state 
when cultured in vitro with defined media. The morphology of EpiSCs is different 
from mouse ESCs. They grow as flattened, monolayered epithelial-like colony with 
sharp and defined borders. Passaging of EpiSCs using trypsin or other single-cell 
dissociation methods will induce widespread cell death. Therefore EpiSC colonies are 
split as small cell clusters by collagenase- or mechanical-mediated passaging (Tesar et 
al., 2007).  
 
Like mouse ESCs, EpiSCs also express pluripotency markers Oct4, Nanog, Sox2, 
SSEA-1 and exhibit pluripotency features of forming three primary germ layers in 
vivo teratoma assay and in vitro EB formation assay (Brons et al., 2007; Tesar et al., 
2007; Zhao et al., 2012). But compared with mESCs, EpiSCs are inefficient to give 
rise to germ-line contributing chimeras if injected into blastocyst, indicating that they 
are not naïve pluripotent. Interestingly, female EpiSCs have undergone X 
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chromosome inactivation, which is not observed in mESCs (Lopes et al., 2008). 
Furthermore, EpiSC lines cannot be derived in the presence of LIF and BMP4 as 
mESCs. Instead they are dependent on FGF/ERK and Nodal/Activin signals for long-
term maintenance in vitro culture (Brons et al., 2007; Greber et al., 2007; Tesar et al., 
2007). Given that FGF and Nodal signaling pathways are required for the formation 
of primitive streak establishment, it is hypothesized that EpiSCs may have acquired 
some lineage properties of primitive streak cells, thus resulting in a primed state other 
than naïve pluripotent (F.L. Conlon et al., 1994; Feldman et al., 1995; Verfaillie et al., 
2010). 
 
Epiblast, which recapitulates the in vivo postimplantation epiblast, is the most 
immediate pluripotent precursor for all the cell types of the embryo. Therefore 
EpiSCs provide a unique system to study the transitions from pluripotency to the 
differentiated lineages. However, the molecular mechanism of regulating EpiSCs has 
not yet well-defined, which could be attributed to the restriction in accessing this early 
postimplantation developmental stage and the lack of a robust in vitro culture system. 
 
1.1.4 Human embryonic stem cells 
In 1998, Thomson et al. reported the derivation of human embryonic stem cells 
(hESC) for the first time (Thomson, 1998). Donated cleavage stage human embryos, 
produced by in vitro fertilization for clinical purpose, were cultured in vitro to the 
blastocyst stage, from which the ICM were isolated and hESC lines were thus 
established. Initially, hESCs were cultured on murine or human feeder cells, which 
served to support hESC expansion and prevent differentiation (Thomson, 1998). 
Subsequently It was found that hESCs can be maintained in feeder-free condition 
using optimized culture system, which therefore eliminates the contamination of other 
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cell types and improves hESC purity (Beattie et al., 2005). Like mESCs, hESCs also 
grow in colony morphology. However, the morphology of hESCs is similar to 
mEpiSCs, other than mESCs; and hESCs cannot be derived by clonal expansion of a 
single cell as mESCs. 
 
The origin of hESCs remains elusive although they are ICM derivatives. In fact 
hESCs are not fully equivalent to in vivo ICM. The transcription profiles of these two 
cell types are strikingly different (Reijo Pera et al., 2009). There were only 3664 out 
of 7385 genes expressed in both ICM and hESCs. Indeed, it has been brought up that 
hESCs actually bear much resemblance to mEpiSCs over mESCs in terms of their 
morphology, culture condition, growth factor requirements, gene expression profiles 
and differentiation potentials (Brons et al., 2007; Tesar et al., 2007). Thus it is 
generally believed that hESCs may not represent the naïve pluripotent state but a 
rather developmentally primed state. One explanation is that the ICM cells may 
undergo further differentiation during the derivation of hESCs, and hESCs may be 
more closely related to a more advanced developmental cell type, such as epiblast 
cells (Reijo Pera et al., 2009). This notion is supported by the report that hESCs can 
also be derived from a post-ICM intermediate (PICMI), which is necessary and 
sufficient for hESC derivation (O'Leary et al., 2012). Interestingly, it has been 
reported that with ectopic expression of several transcription factors or simply by 
culturing under physiological oxygen conditions, conventional hESCs can acquire the 
mESC-like ground pluripotent state (Lengner et al., 2010; Yeo and Ng, 2012).  
 
hESCs express cell surface markers that are characterized for other pluripotent cells, 
including SSEA-3, SSEA-4, THY-1, TRA1-60, alkaline phosphatase etc. They also 
express high levels of pluripotency genes OCT4, SOX2, NANOG etc. (Zhao et al., 
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2012). hESCs are able to produce teratoma after injected into severe combined 
immunodeficient (SCID) mice, but due to legal and ethical reasons, hESCs cannot be 
injected into a human embryo to test their chimera formation capacity (Thomson, 
1998). Notably, hESCs are competent to differentiate into trophectoderm, while 
mESCs not (Thomson, 1998). 
 
hESCs are significant for their huge potential in translational medicine, human 
developmental research and drug discovery. Despite the exciting progresses in hESC 
research in recent years, there is still much basic work required and many obstacles to 
overcome. Yet due to the limited source of human embryo materials and the ethical 
restrictions of human embryo manipulations, our current understanding on human 
preimplantation development and the underlying mechanisms regulating pluripotency 
and differentiation is rather limited.  
 
Overall, ESCs serve as a powerful model to study cell potential and developmental 
biology. Genomic modifications by homologous recombination or insertions can be 
easily manipulated in ESCs. The genetically engineered ESCs then can be used for the 
generation of knock-in, knock-out or transgenic mice, which are invaluable animal 
models to study developmental process or genetic diseases. Notably, regarding their 
robust potential to give rise to all three primary germ cell types, hESCs hold great 





Table 1.1 Comparison of mESCs, mEpiSCs and hESCs properties. Table modified 
from “Pluripotent Stem Cells”, book edited by Deepa Bhartiya and Nibedita Lenka, 
2013 (Han et al., 2013b).  dpc, days postcoitus.  
 
 
Figure 1.2 Representative figures showing mESCs, mEpiSCs and hESCs morphology 




1.3 Molecular mechanisms underlying ESC pluripotency 
The capacity of self-renewal and pluripotency distinguishes ESCs from differentiated 
cell types. It is generally believed that the unique properties of ESCs are governed by 
both extrinsic signaling pathways and intrinsic genetic, epigenetic regulators. The past 
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decade has witnessed tremendous progress in understanding molecular basis of ESC 
pluripotency regulation. In this section, I will review these essential signaling and 
intra-cellular regulators that have been identified to be essential for ESC pluripotency. 
 
1.2.1 Extrinsic signaling pathways required for ESCs 
Through binding to cell-membrane receptors, extracellular factors can induce nucleus-
directed signaling pathways to modulate gene expression. In ESCs, external growth 
factors are required to maintain ES pluripotency in vitro. The signaling pathways that 
are required for hESCs are distinctive from mESCs. As shown in Figure 1.3 and Table 
1.1, mESCs are responsive to LIF/STAT3 and BMP4 signaling pathways, while 
hESCs are mainly dependent on two other important signals:  FGF/MEK and TGF-
β/Activin/Nodal signaling pathways. Interestingly, some of these signaling pathways 
have completely opposite effect on maintaining ESC phenotype in mouse and human. 
For instance, FGF/MEK pathway is required to maintain hESC while activation of 
this pathway drives mESCs towards differentiation; activation of BMP signaling 
pathway promotes mESC self-renewal but induces hESC differentiation. These 
differences may reflect the disparities of molecular mechanisms in hESCs and 
mESCs. 
 
1.2.1.1 LIF/Stat3 signaling pathway 
The importance of LIF/Stat3 signaling pathway in mESC has long been recognized. 
Initially, mouse embryonic fibroblast (MEF) feeder layers were needed to support 
mESC in an undifferentiated state in vitro culture, which indicates that fibroblasts can 
produce some essential factors for ESC to propagate effectively (Martin, 1981). Later 
it was revealed that leukemia inhibitor factor (LIF) is the active component that 
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promotes self-renewal property and maintains the developmental potential of mESCs 
in the presence of serum (Austin G. Smith et al., 1988; Williams et al., 1988). mESCs 
differentiate easily without culturing in LIF or on feeder layer. Likewise, MEFs 
lacking LIF gene are deficient to support mESC culture in vitro (Colin L. Stewart et 
al., 1992).   
 
LIF, a member of Interleukin (IL)-6-type cytokine family, was initially discovered to 
inhibit mouse leukemia cell proliferation and induce their differentiate into 
macrophages (Chew et al., 2005).  Subsequent studies reported its pleiotropic roles in 
various biological processes such as embryogenesis, cell proliferation, survival, 
differentiation and apoptosis depending on cell types (Mathieu et al., 2011).  In 
mESCs, LIF transduces its signal through binding to the transmembrane receptor 
LIFR, which is a low-affinity ligand specific for LIF, and gp130, a common co-
receptor shared by all IL6 family members. The binding of LIF to its receptors leads 
to the activation of several pathways-the JAK (receptor-associated Janus kinase)/Stat, 
PI3K (phosphatidylinositol-3-OH kinase) and MAPK (mitogen-activated protein 
kinases)/ERK pathways. Activated JAKs in turn phosphorylate the tyrosine residues 
in gp130 and facilitate the recruitment of signal transducer and activator of 
transcription 3 (Stat3). The following phosphorylation of Stat3 by JAKs leads to Stat3 
dimerization and translocation into nucleus, where it binds to specific DNA elements 
to regulate gene transcriptions, such as activation of Klf4, c-Myc etc. (Boeuf et al., 
1997; Hitoshi Niwa et al., 1998). Activated PI3K/AKT activates transcription factor 
Tbx3 (Niwa et al., 2009). Both Klf4 and Tbx3 can activate pluripotency genes Oct4, 
Nanog and Sox2, to prevent mESC differentiation. Interestingly, MAPK/ERK 
pathway drives differentiation through negatively regulating Tbx3 and it may be 
negatively regulated by PI3K, yet the precise mechanism remain elusive (Niwa et al., 
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2009; Paling et al., 2004). This suggests that the parallel activations of these pathways 
are precisely regulated to balance between the pluripotent and primed state. 
 
Among these downstream pathways that LIF signal activates, JAK/Stat has exhibited 
a predominant role in self-renewal and pluripotency regulation. Mastuda et al. 
reported that constant activation of Stat3 can maintain mESC in self-renewal state 
independent of LIF, while inactivation of Stat3 drove mESC differentiation (Matsuda 
et al., 1999). Thus the role of Stat3 as a downstream effector of LIF signal was 
demonstrated. Interestingly, studies in recent years also suggests that direct 
downstream targets of Stat3 (such as c-Myc, Klf4, Nanog) can bypass the requirement 
of LIF when they were ectopically expressed in mESCs (Cartwright, 2005; Niwa et 
al., 2009; Suzuki et al., 2006). In addition, ChIP-seq analysis have revealed that Stat3 
binding sites are co-occupied by pluripotency factors Oct4, Sox2 and Nanog and 
knockdown of Stat3 upregulates endoderm and mesoderm genes, implying that Stat3 
prevents mESC differentiation by activating pluripotency genes and suppressing 
lineage specific genes (Bourillot et al., 2009; Chen et al., 2008). Yet the precise 
mechanism by which activated Stat3 controls its responsive genes and their 
involvement in pluripotency regulation remains to be further elucidated.   
 
The importance of LIF signaling pathway has led researchers to investigate its roles in 
preimplantation development. It was found that LIF is only detected in TE while 
LIFR and gp130 are expressed in ICM cells, which suggests that LIF may contribute 
to the lineage segregation of differentiated TE and pluripotent ICM (Nichols et al., 
1996). Knockout animal models have showed that embryos ablated of LIF/Stat 
pathways, such as disruption of LIF, LIFR, gp130, Stat3 or Jak1/2, survived beyond 
blastocyst stage. It has been proposed that there are alternative signaling pathways 
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that can compensate LIF signaling pathways in vivo embryo development (Posfai et 
al., 2014).  
 
Interestingly, LIF is not sufficient for maintenance of hESCs. If human ES cells are 
grown without feeder cells but in the presence of LIF, they either differentiate or die 
(Thomson, 1998). This indicates the distinctive signaling requirements in hESCs and 
mESCs. 
 
1.2.1.2 BMP/SMAD signaling pathway 
In serum-free cultures, LIF alone, however, is insufficient to maintain ESC self-
renewal and block neuronal differentiation. It has been found that the requirement of 
serum can be replaced by BMPs, which hence was identified as another critical 
component in mESC culture system besides LIF (Ying et al., 2003). 
 
Bone Morphogenetic Protein (BMP) is a subset of the transforming growth factor beta 
(TGFβ) superfamily, which is comprised of 40 members including BMP, Activin, 
Nodal etc., and regulates various cellular processes in animal development (Itoh et al., 
2014). BMP ligand initiates signaling by binding to the type II BMP receptor, 
followed by recruitment and phosphorylation of type I BMP receptor, which then 
leads to the phosphorylation of  BMP-responsive SMAD 1/5/8. The activated SMAD 
1/5/8 form a heteromeric complex with SMAD4 and translocate into the nucleus to 
regulate gene transcriptions(Itoh et al., 2014; Shi and Massagué, 2003). Ying et al. 
reported that inhibitors of differentiation (Ids), which inhibits basic helix-loop-helix 
transcription factors, are important mediators of BMP signaling cascade, as forced 
expression of Id2 can replace BMP signals and inhibit neuronal differentiation in the 
absence of serum (Ying et al., 2003). 
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Bmprla is the only type I BMP receptor that has been detected in undifferentiated 
mESCs and pluripotent ICM (Qi et al., 2004; Ying et al., 2003). Although Bmprla-
null embryos can survive beyond blastocyst stage, they are deficient to derive mESCs, 
reaffirming that BMP signaling pathway is essentially needed to sustain ESC 
pluripotency whereas there may be additional pathways to compensate BMPs for in 
vivo ICM formation. Interestingly, inhibition of MAPK/p38 pathway allows the 
derivation of ESCs from Bmprla
-/- 
blastocysts (Qi et al., 2004). This suggests that 
BMPs may act through inhibition of MAPK pathway to maintain mESC self-renewal, 
which needs to be addressed in future studies.  
 
Despite its synergetic roles of LIF pathway in maintaining mESCs, BMPs seem to be 
implicated in hESC differentiation. Xu et al. reported that BMP stimulation induced 
trophoblast differentiation in the presence of bFGF while inhibition of BMP signaling 
sustained hESC in undifferentiated state (Pera, 2004; Xu et al., 2005; Xu et al., 2008). 
Other studies also showed that BMPs are involved in primitive endoderm 
differentiation and promote mesoderm commitment possibly via activation of 
SLUG/MSX2 mediated EMT (Pera, 2004; Richter et al., 2014; Teo et al., 2012).  
 
1.2.1.4 TGF-β/Activin/Nodal signaling pathway 
TGF- β, Activin and Nodal are other three members of TGF- β family. Nodal, Activin 
and TGF- β act through binding to their receptors (Nodal and Activin share type I and 
type II activin-like kinase receptors while TGF- β uses TGF β receptor) and propagate 
the signals through phosphorylation of downstream effector SMAD2/3. Like 
SMAD1/5/8 in BMP pathway, SMAD2/3 can also form a complex with SMAD4 and 




It was first discovered that TGF- β and Nodal are highly expressed in undifferentiated 
hESCs and study afterwards showed that Activin A can replace fibroblast feeder layer 
to sustain hESC in vitro culture (Beattie et al., 2005; Sato et al., 2003b; Vallier, 2005). 
The notion that TGF-β/Activin/Nodal signaling pathway is important in hESC was 
further demonstrated by the finding that SMAD2/3 activated by this pathway can up-
regulate pluripotency factor Nanog, while inhibition of this pathway by follistatin 
(inhibitor of Activin pathway), Lefty or Cerberus overexpression (known endogenous 
inhibitors of Nodal pathway), or SB431542 (inhibitor of Activin/Nodal type I 
receptor) down-regulates pluripotency genes and drives neuroectoderm specification 
of hESCs(Smith et al., 2008; Vallier, 2005; Vallier et al., 2009; Vallier et al., 2004; 
Xu et al., 2008).  Interestingly, overexpression of Lefty alone could not induce hESC 
differentiation in the presence of feeder layers and follistatin has no effect on Nodal-
overexpressed hESCs, suggesting that Nodal and Activin can act independently to 
synergistically maintain hESC pluripotency in vitro (Vallier, 2005). TGF- β pathway, 
however, appeared far less efficient in prevention of hESC differentiation in feeder-
and serum- free conditions than Activin or Nodal (Vallier, 2005). 
 
The role of Nodal/Activin is much less clear in mouse pluripotent cells. Expression of 
Activin can be detected in the mouse blastocysts while Nodal starts to be expressed in 
the epiblast after implantation and has been shown to regulate proper embryo 
development (Albano et al., 1993; F.L. Conlon et al., 1994; Robertson et al., 2003). 
Knockout of Nodal caused gastrulation lethality in mouse embryo development 
(Ouwens et al., 2002). Given high similarities between hESC and mEpiSCs, 
Nodal/Activin pathway has been shown to be important in mEpiSCs. Disruption of 
Nodal signaling resulted in decreased proliferation of epiblast with very low Oct4 
level in mice embryos (Robertson et al., 2003). Nodal/Activin maintained Nanog 
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expression (Vallier et al., 2009) and inhibition of this pathway drove rapid 
differentiation of EpiSCs, implying a strict dependence of this pathway for 
pluripotency maintenance in EpiSCs (Brons et al., 2007). 
 
Nodal/Activin signaling has been proven to promote mESC self-renewal as well. In 
serum-free cultured mESCs, Nodal/Activin is constitutively activated (Ogawa et al., 
2006).  Inhibition of Nodal/Activin signals decreased proliferation rate without 
affecting mESC pluripotency, while stimulation of Nodal/Activin signals, but not 
TGF-β, increased mESC propagation in a pluripotent state (Ogawa et al., 2006). 
However, it was reported in another study that overexpression of Nodal in mESCs led 
to upregulation of mesoderm and endoderm markers but down-regulated 
neuroectoderm lineages (Pfendler et al., 2005). Galvin et al. recently reported that 
autocrine Nodal/SMAD2 pathway attenuates, but not abolish, BMP signaling 
pathway, which may contribute to repression of mesoderm and perhaps 
trophectoderm specification in mESCs (Aloia et al., 2009; Galvin et al., 2010). Thus 
the multifaceted roles of these pathways in differentiation and self-renewal would 
require a delicate balance to control the ESC phenotype. Further investigations are 
needed to examine the distinct roles of Nodal/Activin signaling pathway in human 
and mouse pluripotent cells and how it cooperates with other pathways or 
transcription networks to regulate pluripotency. 
 
1.2.1.3 FGF/MEK signal pathway 
FGF ligands and heparan sulfate (HS) bind to the FGF receptor (FGFR) forming the 
FGF/FGFR/HS signalling complex, resulting in receptor dimerization, subsequent 
autophosphorylation of receptor tyrosine residues and activation of downstream 
signaling pathways, including classic mitogen-activated protein kinase (MAPK) 
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(Erk1/2), Jak/Stat, PI3K and phospholipase C (PLC)γ pathways (Mohammadi et al., 
2005),  
 
Fibroblast growth factor (FGF) appears to be of central significance to human ESC 
self-renewal, since FGF2 is essentially required for hESCs in traditional culture 
medium with fibroblast feeder layers or fibroblast-conditioned medium (Amit et al., 
2000; Xu et al., 2005). FGF2 together with a commercially available serum substitute 
can support hESC clonal propagation on fibroblasts and even in the absence of feeder 
layers (Amit et al., 2000; Xu et al., 2001). Likewise, withdraw or suppression of FGF 
signaling will rapidly trigger hESC differentiation (Dvorak et al., 2005). 
 
With gene expression profile analysis, several groups have reported the high 
expressions of FGF receptors and their downstream effectors in undifferentiated 
hESCs, including FGFR-1,-2,-3,-4, SOS1, PTPN11, RAF1 (Brandenberger et al., 
2004; Dvorak et al., 2005; Sato et al., 2003b; Sperger et al., 2003). In hESCs, it has 
been found that FGF2 can promote self-renewal and pluripotency in several aspects. 
Firstly, Vallier et al. discovered that FGF cooperates with Nodal/Activin to sustain 
pluripotency markers for prolonged periods in the absence of serum, Matrigel or 
feeders. Although FGF signaling is necessary, FGF itself cannot maintain hESC in 
undifferentiated state if Nodal/Activin signaling pathway is inhibited (Vallier, 2005).  
More recently, it was found that FGF signaling acts as a direct activator of Nanog 
promoter in hESCs (Xu et al., 2008; Yu et al., 2011). Thirdly, FGF and TGFβ 
signaling synergize to suppress BMP pathway to sustain pluripotency genes Oct4, 
Sox2 and Nanog, preventing hESC from differentiation (Levenstein et al., 2005; Xu et 
al., 2008; Yu et al., 2011). Moreover, several studies have demonstrated that FGF 
signals act mainly through FGF/MEK cascade. MEK/ERK pathway is a downstream 
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cascade of FGF signaling, which functions cooperatively with PI3K/AKT pathway in 
maintaining hESC pluripotency (Li et al., 2007). In addition, FGF2 indirectly induces 
TGFβ and IGF2 secretion in feeder cells, which together support hESC pluripotency 
(Bendall et al., 2007; Greber et al., 2007). Interestingly, FGF2 is also implicated in 
trophectoderm differentiation and early stage endoderm development in human. This 
may be attributed to the different roles of FGF2 in different cell context. 
 
In mESCs, FGF signal pathway displays a completely opposing effect. It is not a 
pluripotency keeper but is well known for its pro-differentiation roles in lineage 
commitment (Kunath et al., 2007; Lanner and Rossant, 2010). Autocrine FGF-
induced ERK1/2 signaling is required for mESCs to exit self-renewal and initiate 
multi-lineage commitment (Kunath et al., 2007; Stavridis et al., 2007). Fgf4-Fgfr2 
pathway drives the epiblast and PE segregation and the PE lineage-primed population 
is reduced if ERK signaling is blocked (Lanner and Rossant, 2010; Villegas et al., 
2010). Indeed, some studies showed that the self-renewal promoting role of LIF and 
BMP pathways in mESC may act through counterbalancing the autocrine FGF/ERK 
signaling. Smith and his colleagues discovered that chemicals “2i”, which inhibit 
endogeneous FGF4 and GSK3 signals, can substitute for the growth factor 
requirement of LIF and BMPs in mESC culture. More recently, another group also 
reported that inhibitors of FGF/MEK and TGF-β pathways, designated as “R2i”, can 
promote the homogenous, ground state pluripotency in mESCs (Hassani et al., 2013).  
 
1.2.1.5 Other signaling pathways 
Although ESCs can be cultured in defined media supplemented with growth factors, it 
is still recommended to culture ESCs on feeder layers, which will supply complete 
nutrition, creating a complex microenvironment that favors better pluripotency and 
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eliminates prevents culture deterioration. In fact, despite these essential growth factors 
that have been discussed above, fibroblasts secrete multiple other growth factors, 
which altogether contribute to long-term maintenance of ESCs in vitro (Prowse et al., 
2007). These multiple signaling pathways crosstalk with each other to form a 
pluripotent signaling network and maintain a delicate balance among themselves, 
whereby potently sustaining undifferentiated ESC phenotype.  
 
Eras, for example, is highly expressed in mESCs. Eras-null ESCs showed decreased 
growth rate and tumorigenecity (Takahashi et al., 2003).  It activates PI3K/AKT 
pathway to mediate ESC proliferation, possibly via interacting with mTOR pathway 
(Murakami et al., 2004; Takahashi et al., 2005). The wingless-related MMTV 
integration site (Wnt) signaling pathway, has been reported to be active in both mouse 
and human ESC maintenance (Sato et al., 2003a). Despite its various roles in embryo 
development, Wnt signaling pathway was shown to promote mESC pluripotency, 
attenuate neurecotoderm commitment and prevent transition to primed EpiSCs (Berge 
et al., 2011; Merrill, 2012; Miki et al., 2011; Sato et al., 2003a). Moreover, Wnt 
pathway has been shown to interconnect with LIF, BMP, GSK, TGF-β/Nodal/Activin 
pathways to synergize pluripotency regulation (Berge et al., 2011; James, 2005; Lee 
et al., 2009; Sato et al., 2003a). Therefore Wnt signaling appears to be implicated in 
keeping ESC pluripotent. However, contradicting results have been published as well, 
demonstrating that Wnt pathway is inhibited and dispensable in pluripotency 
maintenance; whereas activation of this pathway stimulates differentiation (Davidson 
et al., 2012; Kielman et al., 2002; Lyashenko et al., 2011). Hence more efforts are 




Figure 1.3 Exogenous signaling pathways required for pluripotency maintenance in 
ESCs. (A) Requirement of LIF and BMP4 signaling in mESCs. (B) Requirement of 




1.2.2 Intrinsic signaling pathways in ESC maintenance 
Besides these signaling pathways which transduce the external signals into the 
nucleus and lead to transcriptional regulation of their downstream genes, intrinsic 
regulators, such as transcription factors and epigenetic factors, play crucial roles in 
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pluripotent cells. Extensive studies have documented that Oct4, Sox2, Nanog are the 
three master regulators in the core transcriptional network, which mainly contributes 
to hallmarks of ESC pluripotency and self-renewal. 
 
1.2.2.1 Core transcription factors Oct4/Sox2/Nanog 
Oct4 (octamer binding transcription factor-4) 
Oct4 (also known as Oct3), encoded by the gene Pou5f1, is one of the first 
transcription factors that have been identified in maintaining ESC pluripotency and 
proper embryo development. Oct4 belongs to the POU (Pit-Oct-Unc) domain 
transcription factor family. Like other members of the POU family of transcription 
factors, Oct4 regulates the expression of their target genes through the binding of its 
POU-domain to an octameric sequence AGTCAAAT (Pan et al., 2002). Oct4 is 
known to control downstream genes in synergy with Sox2 via the octamer–sox motif 
(Oct–Sox enhancer) (Chew et al., 2005) (see more in the following Sox2 section). The 
other two domains of Oct4, the C-terminal and N-terminal domains, are not 
responsible for DNA binding but have transactivation activities in transcription 
regulation (Brehm et al., 1997). 
 
The expression of Oct4 can be initially detected at maternal unfertilized egg, zygote, 
and all the blastomeres till 8-cell stage. As embryo develops, its expression is 
restricted to ICM cells, remains in epiblast and then is strictly in PGCs (Palmieri et 
al., 1994). In vitro, Oct4 is expressed at high levels in undifferentiated cells, such as 
ESCs, embryonal carcinoma cells (ECCs) and embryonic germ cells (EGCs) but 
limited in lineage cells (Palmieri et al., 1994). Upon differentiation, Oct4 level in ES 
cells decreases rapidly. Therefore, this expression pattern indicates its essential roles 
in pluripotency establishment and maintenance. Indeed, knockout of Oct4 caused 
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preimplantation lethality at 3.5 dpc. The embryo displayed blastocyst-structure but 
lacked genuine pluripotent ICM, thus no ESCs could be derived (Nichols et al., 1998).  
Oct4 is also essential for PGC formation and depletion of Oct4 in PGCs resulted in 
cell apoptosis and differentiation defect (Kehler et al., 2004; Okamura et al., 2008). 
 
In pluripotent cells, Oct4 functions in a dose-dependent manner. Reduction of Oct4 
expression in ESCs triggers trophectoderm differentiation, while a 2-fold 
overexpression of Oct4 causes ESC differentiate into mesoderm and primitive 
endoderm (Hough et al., 2006; Niwa et al., 2000b). Furthermore, a recent study 
revealed that a defined level of Oct4 is required for pluripotency acquisition of 
induced pluripotent stem cells (iPSCs), as well as their lineage commitment 
(Radzisheuskaya et al., 2013). Once pluripotency is established in iPSCs, Oct4 is no 
longer required for self-renewal. Interestingly, Oct4-low iPSCs sustain self-renewal 
but are deficient to differentiate; the ESC-level Oct4 is required for their in vitro and 
in vivo differentiation.  Thus an appropriate level of Oct4 is critical to govern the 
property of pluripotency. 
 
Given its critical role in pluripotency, Oct4 expression is tightly controlled by two 
distal enhancers (DEs), which are mainly active in ICM, ESCs and PGCs, and its 
proximal promoter, which drives Oct4 in epiblast (Yeom et al., 1996). Comparative 
studies have discovered that there are four conserved regions in Oct4 promoter, 
namely, CR1 (immediate upstream of Oct4), CR2, CR3 and CR4 (overlapping with 
DEs) (Frankenberg et al., 2010). Extensive studies have reported that these conserved 
regions are occupied by many transcription factors and epigenetic factors to either 




Sox2 (sex determining region Y box-2) 
Sox2 belongs to the Sox transcription factor family which harbors a conserved HMG 
DNA-binding domain.  During embryogenesis, the expression pattern of Sox2 is quite 
similar to Oct4, which is detected in all the blastomeres till 8-cell stage, subsequently 
restricted to ICM and epiblast (Avilion, 2003). Unlike to Oct4, Sox2 is also expressed 
in extraembryonic ectoderm and nervous system (Avilion, 2003). Similarly, 
disruption of Sox2 expression led to peri-implantation lethality due to the lack of 
epiblast (Avilion, 2003). It appears that Sox2 plays a role in maintaining epiblast, 
while Oct4 is essential for ICM development, which is at an earlier developmental 
stage. Yet both Sox2- and Oct4-null embryos were unable to give rise to ESCs 
(Avilion, 2003; Nichols et al., 1998). In ESCs, knockdown of Sox2 resulted in 
polyploidy and differentiation into trophectoderm lineage, as Oct4-null ESCs do 
(Chew et al., 2005; Niwa et al., 2000b). These results suggest that Oct4 and Sox2 may 
function together in embryogenesis and pluripotency maintenance. 
 
Indeed, subsequent studies showed that Sox2 and Oct4 can interact with each other, 
form an Oct4-Sox2 complex and bind to a specific cis-regulatory element that consists 
of neighboring Oct (ATGCAAAT) and Sox (CATTGTA) motif (Chew et al., 2005; 
Loh et al., 2006; Okumura-Nakanishi et al., 2004). Genome-wide studies further 
revealed that Sox2 and Oct4 occupy same binding sties of their targets, including 
many silent genes (Chen et al., 2008). Importantly, these oct-sox targets include many 
pluripotency associated genes, such as Oct4, Sox2, Nanog, Utf1, Fgf4 etc.(Okumura-
Nakanishi et al., 2004; Remenyi, 2003; Rodda, 2005).  However, Sox2 has been 
found dispensable for the activation of sox-oct enhancers and forced expression of 
Oct4 was able to restore the loss of pluripotency in Sox2 null ES cells, suggesting that 
24 
 




Nanog is another core transcription factor and a key pluripotency marker in ESCs and 
EpiSCs. The importance of Nanog was first uncovered by the finding that Nanog is 
highly expressed in ESCs and its overexpression is able to safeguard ESC self-
renewal in the absence of LIF (Chambers et al., 2003; Mitsui et al., 2003). In mouse 
embryos, Nanog is firstly detected in the compacted morula, subsequently localized to 
ICM and later confined to epiblast (Chambers et al., 2003). Nanog deficient embryos 
failed to generate epiblast and Nanog-null ICM cannot proliferate and produce only 
endoderm-like cells (Mitsui et al., 2003). In ESCs, Nanog faithfully maintains ESC 
pluripotency and Nanog knocked-out in ESCs resulted in differentiation into extra 
embryonic endoderm (Mitsui et al., 2003). It has been proposed that Nanog can 
suppress Gata4 and Gata6, which promote lineage commitment of extra embryonic 
endoderm (Shimosato et al., 2007). Meanwhile, Nanog can activate other pluripotency 
factors to drive ESC self-renewal, such as Oct4, Rex1 Ids etc.. mESCs cultured in 
2i/LIF system, which confers ESC ground state pluripotency, increase Nanog 
expression, indicating that Nanog promotes the transition to naïve pluripotency (Ying 
et al., 2008).  
 
Although it is widely accepted that Nanog, like Oct4 and Sox2, plays a central role in 
pluripotency maintenance, Chamber et al. subsequently reported that Nanog-null 
ESCs can be propagated in a self-renewal state (Chambers et al., 2007). Nanog is also 
dispensable for pluripotency reacquisition during reprogramming process (Schwarz et 
al., 2014). Several other studies reported that Nanog expression is not homogeneous 
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at single-cell level in ESC population, which may be explained by the variable allelic 
expression of Nanog (MacArthur et al., 2012; Miyanari and Torres-Padilla, 2012; 
Singh et al., 2007). Biallelic expression of Nanog is important for the establishment of 
ground state pluripotency of ICM in embryo development. Thus it appears that Nanog 
is not required for maintaining pluripotency once it has been established. Future 
studies are of great significance to delineate the exact role of Nanog in ESCs. 
 
Notably, in undifferentiated hESCs and mESCs, a large portion of promoters bound 
by Oct4/Sox2 are also bound by Nanog, suggesting that Nanog cooperates with 
Oct4/Sox2 heterodimers to exert its roles (Boyer et al., 2005; Loh et al., 2006). In 
addition, these three factors form a regulatory circuit to modulate their own 
transcriptions. It has been proposed that the core transcription factor trio of 
Oct4/Sox2/Nanog collaboratively establish and govern the pluripotent state by 
directly and indirectly: 1) repressing lineage specific genes; 2) activating pluripotency 
associated factors, including each of their own (Young, 2011). 
 
1.2.2.2 Epigenetic regulators 
Apart from transcription factors, epigenetic regulators have shown to be important in 
maintaining ESC pluripotency and cell fate decision for the past decade. Different 
from somatic cells, ESCs are characterized by a highly plastic and dynamic chromatin 
configuration with a higher ratio of transcriptionally active marks (e.g., H3K4me3, 
H3K36me3, H3K27Ac) to repressive marks (e.g., H3K27me3, H3K9me3, 5-mc DNA 
methylation) (Gaspar-Maia et al., 2011; Zhou et al., 2011). This unique chromatin 
state is governed by a set of epigenetic regulatory proteins, which are required to 




With large-scale RNAi screening and protein-protein interactome investigations, it 
was uncovered that the core transcription factors are integrated with multiple 
epigenetic pathways for pluripotency regulation in ESCs (which will be discussed in a 
greater detail in the next section). The interplay between central transcription factors 
and epigenetic regulators has been extensively studied in recent years. 
Oct4/Sox2/Nanog maintain ESC identity by activating transcription of pluripotency-
associated genes via recruitment of co-activators (e.g. p300), chromatin remodelling 
complexes and the transcriptional machinery, while repressing developmental 
regulators by engaging Polycomb-group (PcG) protein complexes (e.g., Ring1b, 
Rybp) as well as other co-repressor complexes, including NuRD, Sin3A and Pml 
complexes (Chen et al., 2008; Ding et al., 2012; Pardo et al., 2010; van den Berg et 
al., 2010; Wang et al., 2006). Many transcriptional cofactors, including cohesin, 
mediators and condensin, have been implicated ESC maintenance as well (Young, 
2011). In addition, Oct4, in cooperation with Nanog and Sox2, represses Xist (X-
inactive specific transcript) and activates Tsix, thus contributing to the X chromosome 
activation in pluripotent ESCs (Navarro et al., 2011).  
 
Furthermore, Oct4 governs ESC specific chromatin architecture by the direct 
regulation of other epigenetic modifiers. For example, it can activate H3K9 
demethylases Jmjd1a and Jmjd2c to modulate H3K9 methylation status of its target 
genes (e.g., Nanog, Tcl1, Zfp57) (Loh et al., 2007). On the other hand, Oct4 
expression is critically controlled by epigenetic mechanisms as well. G9a, a histone 
H3 lysine 9 methyltransferase, irreversibly represses Oct4 expression by H3K9 
methylation at its regulatory region (Feldman et al., 2006). Dnmt3a and Dnmt3b are 
two de novo methyltransferases which establish the DNA methylation patterns during 
normal embryo development. ESCs lacking of Dnmt3a or Mbd3 were unable to 
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differentiate properly due to the hypomethylated DNA at Oct4 promoter (Feldman et 
al., 2006; Gu et al., 2011). It was proposed that transcription silence by H3K9 
methylation and the subsequent incorperation of DNA methylation at Oct4 promoter 
regulatory region is required for proper ESC differentiation (Feldman et al., 2006). 
SNF5, a core subunit of Brahma-associated factor (BAF) complexes, negatively 
regulates Oct4 and activates Oct4 repressed targets by affecting chromatin landscapes 
during hESC differentiation (Madhani et al., 2013). 
 
In ESCs, many developmental genes harbor the unique “bivalent” domains, marked 
by the presence of active H3K4me3 and repressive H3K27me3, which is catalyzed by 
SET/MLL and PRC2 respectively (Bernstein et al., 2006; Pan et al., 2007; Zhao et al., 
2007). This chromatin signature allows a “transcription-ready” state permissive for 
rapid activation in response to developmental cues. PcG proteins, consisting of PRC1 
and PRC2, are important epigenetic players that repress developmental genes by 
adding repressive chromatin marks at the promoters of these genes (Laugesen and 
Helin, 2014; Pethe et al., 2014). Deletion of Eed, Suz12 or Ezh2, which are 
components of PRC2, is lethal in embryo development and compromises the ESC 
self-renewal capacity (O'Carroll et al., 2001; Pasini et al., 2004).    
 
1.2.2.3 The expanded pluripotency network in ESCs 
As reviewed above, Oct4/Sox2 and Nanog have been documented to be central to the 
transcriptional regulatory hierarchy that specifies ESC identity because of their unique 
expression patterns and vital roles in early development and ESCs. In fact, this core 
transcription circuit, together with many transcription factors, epigenetic regulators 
and microRNAs (miRNAs), form a complex and multifaceted regulatory network that 
fine tunes the delicate pluripotent state in ESCs (Yeo and Ng, 2012).  
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With large-scale RNAi knockdown studies, many novel important transcription 
regulators have been screened out. It has been demonstrated that depletion of Tbx3, 
Esrrb, Tcl1, Dppa4, SetDB1, Tip60-400, Cnot3, Trim28 etc. in mESCs, and INO80 
chromatin remodeling complex, TAF complex, PRDM14 etc. in hESCs results in 
differentiation (Yeo and Ng, 2012). Extensive studies have uncovered that many of 
these factors act either upstream or downstream of the core transcription trio factors.  
Esrrb, for example, is activated and recruited by Oct4 (van den Berg et al., 2010) and 
also a direct downstream target of Nanog and is capable to substitute for Nanog 
functions in pluripotency regulation (Festuccia et al., 2012). Knockout of Esrrb 
abolished Nanog’s ability to guard ESC self-renewal in LIF withdrawal conditions. 
Taken together, it is implied that these factors are inter-connected to form a network 
and perturbation of any factors tend to destroy the stabilized pluripotency program to 
induce differentiation. 
   
Exploring protein interacting partners is another method to expand the transcriptional 
regulatory network. Proteins that can interact with Oct4/Sox2 dimer or Nanog have 
been identified (Ding et al., 2012; Pardo et al., 2010; van den Berg et al., 2010; Wang 
et al., 2006). This protein-protein interactome encompasses other well-documented 
pluripotency regulators, and particularly many DNA methyltransfereases, chromatin 
remodeling and modifying factors. Their roles in maintaining ESCs have been 
supported by multiple independent studies (Yeo and Ng, 2012; Young, 2011).   
 
Moreover genome-wide studies such as ChIP-seq and microarray analysis serve as 
powerful tools to dissect this transcription regulatory network. Interestingly, it was 
found that Smad1 and Stat3, the key effector of BMP and LIF pathway respectively, 
co-bind to many core transcription factors bound sites, which demonstrates the 
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crosstalk between transcription factors and extrinsic signaling pathways (Chen et al., 
2008). Chen et al. also observed that these pluripotency transcription factors can be 
grouped into either Myc- or Oct4-centric module based on their similarities of 
genomic locations (Chen et al., 2008). c-Myc is dispensable for pluripotency 
maintenance in ESCs, but it was  found to be implicated in chromatin modulations 
and differentiation suppression (Neri et al., 2011; Varlakhanova et al., 2010). In 
addition, it was recently reported that c-Myc acts as an amplifier for active 
transcription rather than activates new genes (Lin et al., 2012; Nie et al., 2012). Thus 
c-Myc seems to have some roles independently of core transcription trio factors. 
 
Notably, through ChIP-seq analysis, Marson et al. uncovered that the core 
transcription trio factors co-occupy promoters of some stem cell related miRNAs and 
PcG occupied tissue-specific miRNAs, to activate or repress their transcriptions 
(Marson et al., 2008). This therefore incorporates miRNAs as components of the ES 
cell regulatory network. Indeed, recent studies have provided strong evidence that 
miRNAs have some essential roles in ESC proliferation and pluripotency, as well as 
in differentiation. Undifferentiated ESCs have a unique set of miRNA expression 
pattern, including some ESC-preferentially expressed miRNAs (e.g. miR302-367 
cluster, miR290) and silent differentiation-associated miRNAs (e.g., let-7, miR 
134)(Barroso-delJesus et al., 2008; Marson et al., 2008). ESCs with miRNA 
processing enzymes disrupted were compromised in their proliferation and 
differentiation (Fukuda et al., 2007; Kanellopoulou, 2005; Wang et al., 2007a). ESCs 
lacking Dicer, an enzyme critical for microRNA biogenesis, displayed change in 
epigenomic landscape and exited self-renewal to differentiate (Asakura et al., 2013). 
miR290 family regulates G1/S transition in ESCs to promote their rapid proliferation 
and is able to rescue the DNA methylation defects in Dnmt-null ESCs (Sinkkonen et 
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al., 2008; Wang et al., 2008). miR302, specifically activated by core transcription 
factors in hESCs, was found to promote BMP signaling and negatively regulate lefty, 
the inhibitor of Nodal/Activin signaling pathway, thus favoring the pluripotent state of 
hESCs (Barroso-delJesus et al., 2011; Barroso-delJesus et al., 2008; Lipchina et al., 
2011). Moreover, some miRNAs are able to specifically target the core transcription 
factors and induce transcription silencing of these genes during ESC 
differentiation(Tay et al., 2008).  
 
In addition, large intergenic non-coding RNAs (lincRNAs) expressed in mESCs are 
also known targets of pluripotency-associated transcription factors, including Oct4, 
Sox2, Nanog, cMyc, Klf4 (Guttman et al., 2011). lincRNAs are critical for 
maintaining Oct4 and Nanog levels in ESCs and suppressing lineage specifications 
possibly through their associations with multiple epigenetic regulating complexes 
(e.g. coactivators, mediators) (Lu et al., 2014). It is suggested that lincRNAs serve as 
a scaffold unit in recruitment of these protein complexes to modulate gene expression 
(Yeo and Ng, 2012). 
 
The dominant effect of this transcription regulatory network in pluripotency was 
highlighted by the remarkable discovery that the expression of just four transcription 
factors, Oct4, Sox2, c-Myc and Klf4 (OSKM) was sufficient to transform somatic 
MEFs back to pluripotent stem cells, and the expression of OCT4, SOX2, NANOG 
and LIN28 was sufficient for in human somatic cell reprogramming (Takahashi and 
Yamanaka, 2006; Yu et al., 2007). This reprogramming process, i.e. the restoration of 
pluripotency in differentiated cells, serves as a valuable model to decipher the 
mechanism as how these transcription regulators work together to achieve 
pluripotency acquisition and maintenance.  
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1.4 Induced pluripotent stem cells 
In the field of developmental biology, cell differentiation is generally thought to be an 
irreversible process. Once terminally differentiated, specified cell types are non-
switchable among each other. However, this concept was challenged by significant 
breakthroughs that somatic cells can reacquire the pluripotency property by a variety 
of methods, suggesting that cell fate specification is not a fixed decision, but is a 
reversible process. 
 
1.3.1 Methods of inducing ESC-like cells 
Date back to 1960s, Gurdon and his colleagues first demonstrated that transferring the 
nucleus of a differentiated frog into an enucleated egg could restore the cell with 
totipotency (Gurdon, 1962).  Subsequent studies have demonstrated the feasibility of 
somatic nuclear transfer in mammals and the generated pluripotent cells are 
indistinguishable to ESCs. In 1997, the birth of first cloned mammal Dolly was 
reported, which was exciting news in stem cell research (I. Wilmut et al., 1997). Cell 
fusion is another method to regain pluripotency potentials. In 1976, Miller and 
Ruddler showed that pluripotent hybrids could be derived by fusion of primary 
thymocyte with pluripotent teractocarcinoma cells (Miller and Ruddle, 1976). Similar 
finding was observed in fusion of somatic cells with human ESCs (Tada et al., 2001; 
Terada et al., 2002). Further studies revealed that this method could be simplified by 
exposure somatic nucleus to ES cell extract (Cowan, 2005). However, these methods 
have been demonstrated to be very inefficient and the generated pluripotent cells were 
defective. 
 
In 2006, Takahashi and Yamanaka reported a landmark discovery that reprogramming 
mouse fibroblasts into pluripotent stem cells can be achieved by viral mediated 
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transinduction of four transcription factors associated with pluripotency, i.e. Oct4, 
Klf4, Sox2 and c-Myc (Takahashi and Yamanaka, 2006). These reprogrammed cells 
resemble ESCs in terms of their morphology, gene expression profile and chromatin 
configuration. They possess the self-sustained pluripotency to differentiate into many 
cell types and hence were designated as induced pluripotent stem cells (iPSCs). Yu et 
al. subsequently reported the successful reprogramming in human somatic cells with 
ectopic expression of Oct4, Sox2, Nanog and Lin28 (Yu et al., 2007). Compared with 
traditional methods of pluripotency induction, reprogramming with defined 
transcription factors is easier to manipulate and makes the process less complex to 
examine. This breakthrough inding has led to blooming progress in stem cell and 
developmental biology field. Sir John Gurdon and Dr. Shinya Yamanaka were 
awarded with 2012 Nobel Prize in Physiology or Medicine for these striking 
achievements. 
 
1.3.2 Mechanism of reprogramming 
Studies in past several years have revealed that the cell fate conversion from somatic 
cells to iPSCs is a dynamic process that involves a cascade of cellular events, such as 
silencing lineage-specific genes, mesenchymal to epithelial transition (MET), 
metabolic switch, overcoming cellular senescence and acquisition of cell immortality, 
reactivation of X-chromosome and reactivation of pluripotency genes,  as well as 
resetting the chromatin signatures (Apostolou and Hochedlinger, 2013; Buganim et al., 
2013; David and Polo, 2014).  The mature iPSCs generated are transgene-silent, 
possess self-sustain pluripotency, erase somatic “memories” and acquire all the 




MET, a reversed process to EMT, is one of the requisite cellular events during early 
stage of reprogramming process (Li et al., 2010b; Liu et al., 2013a). Upon OKSM 
induction, fibroblasts must undergo MET, a process including shutting down the 
mesenchymal genes, overcoming the EMT epigenetic barrier and epithelial program 
activation, to successfully initiate the reprogramming. Factors that promote MET, 
including Klf4, miR302 and E-cad, can enhance pluripotency acquisition; while 
factors that drive EMT or prevent MET, such as TGF-β and some mesenchymal 
markers, impede the reprogramming at the initial stage(Li et al., 2010b; Samavarchi-
Tehrani et al., 2010; Subramanyam et al., 2011). 
 
Cellular senescence has been reported as another barrier which restricts 
reprogramming rate at the initial stage (Banito et al., 2009; Li et al., 2009; Utikal et al., 
2009b). The Ink4a/Arf tumor suppressor locus has a critical role in regulating cellular 
senescence in many types of cells (Collado et al., 2007). For instance, silencing 
Ink4a/Arf locus, or ablation of its activators Jmjd3, hasd been shown to reduce 
cellular senescence and significantly improve reprogramming efficiency (Banito et al., 
2009; Zhao et al., 2013). Utikal et al. reported that after deletion of Ink4a/Arf locus, 
which resulted in immortalisation, almost every fibroblast has the potential to 
generate iPSCs. Thus cellular senescence is crucial and efficiency-limiting during 
reprogramming (Utikal et al., 2009b). 
 
Besides, the glycolytic metabotype transition is required for induction of pluripotency. 
Unlike quiescent somatic cells, pluripotent cells depend on anaerobic glycolysis to 
meet their high energetic and biosynthetic demands for rapid cell division (Zhang et 
al., 2012). Somatic cells reprogrammed to pluripotency need to switch from an 
oxidative to glycolytic state in metabolism (Folmes et al., 2011; Panopoulos et al., 
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2011). Studies have revealed that genes involved in glycolysis and oxidative 
phosphorylation pathways were changed in their epigenetic and gene expression 
levels during reprogramming process (Panopoulos et al., 2011). Metabolic switching 
towards glycolysis by chemical compound treatment or HIF1α activation can 
facilitate reprogramming (Zhou et al., 2012; Zhu et al., 2010). Notably, 
reprogramming factors Lin28 and c-Myc have been recently shown to stimulate 
glycolysis and promote metabolism resetting (Singh and Dalton, 2009; Zhu et al., 
2011).  
 
Another important issue in reprogramming process is to overcome the “epigenetic 
memory” of somatic cells. Compare to somatic cells, pluripotent cells possess a 
highly plastic chromatin structure which is globally more dynamic and decondensed 
with a higher ratio of active to repressive histone marks. The establishment of unique 
“bivalent” domains of H3K4me3 and H3K27me3 is prerequisite for successful 
generation of iPSCs (Polo et al., 2012). Switch of epigenetic landscape is therefore 
another layer of reprogramming barrier. ChIP-seq results and gene expression profiles 
uncovered that the epigenetic reprogramming events occur sequentially (Koche et al., 
2011). H3K4me2 mark is accumulated at the promoters of many pluripotency genes 
and lost at repressed somatic genes immediately after induction. These H3K4me2 
enriched regions are significantly enriched for Oct4/Sox2 and H3K4me3 targets. 
H3K4 methylation is also initially deposited at some poised genes, which however is 
accompanied with a corresponding loss of H3K27me3, thus creating the bivalent 
domains. ESC-like DNA methylation pattern (i.e. hypomethylated pluripotency gene 
promoters and hypermethylated somatic gene promoters) and X chromosome 
reactivation are only fully established at a later stage when the cells have acquired 
stable pluripotency (Koche et al., 2011; Polo et al., 2012). 
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The current understanding on reprogramming has brought the model that the 
induction of pluripotency follows a step-wise process (Buganim et al., 2013; David 
and Polo, 2014; Yamanaka, 2009).  Single-cell cloning experiments have 
demonstrated that reprogramming starts with a long stochastic phase of gene 
activation (inducted by reprogramming factors) to adopt one type of the cell fates, 
such as dedifferentiation, trans-differentiation, senescence, etc. This process is very 
inefficient and is the major rate-limiting step for reprogramming. Cells undergoing 
dedifferentiation are the ones prepared for pluripotency induction. Next, these 
reprogrammable cells are rendered with the susceptibility to gain some early features 
of pluripotency, including rapid proliferation, MET transition, glycolytic metabotype 
and silencing of MEF-specific genes and even activation of pluripotency genes. 
Thereby, these cells undergo a second more deterministic phase and eventually 
become mature iPSCs (Buganim et al., 2012).  
 
The stochastic model at the initial stage of reprogramming indicates that the 
compacted chromatin of somatic cells has to be destabilized to become more 
“hyperdynamic”, the characteristic of ESC chromatin, whereby rendering the 
promoters more accessible for the stochastic gene activation. This is evidenced by the 
observation that epigenetic factors and chemical compounds which promote a 
globally active chromatin environment can enhance iPSC generation as discussed 
previously. In addition, c-Myc, a proto-oncogene that enhance cell proliferation, 
increases the generation of partially reprogrammed iPSCs when combined with OSK, 
supporting the notion that higher cell proliferation rate accelerates reprogramming at 
the early stochastic phase (Nakagawa et al., 2007; Wernig et al., 2008). Nevertheless, 





Figure 1.4 Dynamics of key molecular events during reprogramming process 
(Apostolou and Hochedlinger, 2013). 
 
1.3.3 Reprogramming factors and their replacements 
Initially, Takahashi and Yamanaka selected 24 pluripotency genes to assess their 
capacity to induce pluripotency and found that only the combination of Oct4, Klf4, 
Sox2 and c-Myc could successfully generate iPSCs, spotlighting their significance in 
the reprogramming process (Takahashi and Yamanaka, 2006). The OKSM are 
therefore termed as “Yamanaka factors”. Studies in recent year have revealed that 
OKS function as pioneers for pluripotency induction and maintenance while c-Myc is 
not absolutely required for reprogramming and seems to act independently of OKS 
(Soufi et al., 2012; Wernig et al., 2008). 
 
Given its prime requirement in pluripotency (as reviewed in section 1.2.2.1), Oct4 is 
the pivotal factor in imparting pluripotency. In combination with small molecules, 
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ectopic induction of Oct4 alone is sufficient for pluripotency induction(Li et al., 
2010c). Notably, very few factors can replace Oct4 in iPSC generation, except for 
DNA hydroxymethylase Tet1 and orphan nuclear receptors Nr5a2, Nr5a1 (Gao et al., 
2013; Heng et al., 2010).  
 
As an Oct4-interacting partner, Sox2 generally acts in conjunction with Oct4. Sox2 
level is determined in driving reprogrammable cells towards pluripotency acquisition 
during the later stage of reprogramming (Buganim et al., 2012; Han et al., 2013a). It 
has been shown to be dispensable for reprogramming using neuronal progenitor cells 
in which an endogenous Sox2 exists (Eminli et al., 2008). Sox2 could be replaced by 
other Sox factors or inhibitors of TGFβ-, SFK- pathway and not required for 
reprogramming of melanocytes and melanoma cells, which collectively suggest a 
redundant role of Sox2 in reprogramming process (Ichida et al., 2009; Maherali and 
Hochedlinger, 2009; Nakagawa et al., 2007; Staerk et al., 2011; Utikal et al., 2009a).   
 
Likewise, Klf4 is also not essentially required for pluripotency induction.  Klf4 is a 
Krüppel-like transcription factor and is dispensable for pluripotency maintenance in 
ESCs (Jiang et al., 2008). It is possible to produce iPSCs without ectopic Klf4 
expression in the presence of some small molecules, other Klf members or other 
factors, but with Klf4 the efficiency could be significantly higher (Chen et al., 2010; 
Feng et al., 2009; Huangfu et al., 2008b; Lyssiotis et al., 2009; Nakagawa et al., 
2007). In reprogramming, Klf4 activates epithelial gene expression program to 
promote MET at the initial stage (Chen et al., 2010; Li et al., 2010b). However, Klf4 
was recently found to counteract Oct4-mediated activation of Mgarp at early 
reprogramming stage (Tiemann et al., 2014). Hence the role of Klf4 in pluripotency 
induction needs to be further examined. 
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c-myc was previously reported to be engaged in pluripotency induction, but it is now 
accepted that c-myc is only an enhancing, not a necessary factor for producing iPSCs. 
Its family members, n-Myc and l-Myc are also enhancers for reprogramming 
(Nakagawa et al., 2007). Although dispensable for reprogramming, the Myc family 
contribute to multiple cellular processes to facilitate iPSC generation, more likely at  
the early stage, such as MET initiation, silencing of developmental genes, metabolic 
switch, cell cycle remodeling, chromatin resetting, etc.(Cho et al., 2010; Nakagawa 
and Yamanaka, 2012; Neri et al., 2011; Singh and Dalton, 2009; Soufi et al., 2012). 
 
Genomic wide mapping of their binding sites in ESCs and iPSCs reveal that OKS 
factors are more closely associated, while c-Myc bound promoters are distinct from 
the OKS group (Chen et al., 2008; Sridharan et al., 2009). In the reprogramming 
process, it is uncovered that OKS are pioneers in opening and binding chromatin and 
c-Myc aids in the engagement of OKS to the chromatin (Soufi et al., 2012; Sridharan 
et al., 2009). Moreover, c-Myc and Klf4 are the major contributors for the initial 
reprogramming events, particularly the silencing of lineage-specific genes, while Oct4 
and Sox2, as well as Klf4, are important for the activation of pluripotency genes and 
facilitate pluripotency reacquisition at a later stage (Polo et al., 2012; Soufi et al., 
2012; Sridharan et al., 2009). 
 
1.3.4 Reprogramming enhancers and inhibitors 
The OKSM-mediated reprogramming is a long and low-efficient process and iPSCs 
that are yielded vary in their differentiation potential. Therefore, many endeavors 
have been put into improving the quality and efficiency of resulting pluripotent cells. 
For example, many small molecules have been proven to modulate the 
reprogramming process. Small molecules, such as HDAC inhibitors (e.g. Valproic 
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acid), SFK inhibitors (e.g. iPYrazine), GSK3β inhibitors (e.g. Alsterpaullone, 
CHIR99021), TGFβ inhibitors (e.g. Kenpaullone, E-616452, LY-364947), Vitamin C, 
PI3K/Akt activator (e.g. PS48) etc. can accelerate the reprogramming and are able to 
replace one or more of the four reprogramming factors (Esteban and Pei, 2012; 
Huangfu et al., 2008b; Ichida et al., 2009; Li and Rana, 2012; Lyashenko et al., 2011; 
Staerk et al., 2011; Zhu et al., 2010). Reprogramming with small molecules shows 
distinctive advantages, such as simpler, transgene-free, controllable, tractable and 
other features. Furthermore, they make large-scale iPSC production possible. Thus 
far, they have attracted much interest in steering a faster and efficient reprogramming.  
 
Investigations of the molecular kinetics have demonstrated that reprogramming 
initiation are largely dependent on pre-existing, accessible chromatin environment so 
that ectopic inducted reprogramming factors can bind to and exert their specific 
functions. It is noteworthy that recent studies have highlighted the importance of the 
interplay between epigenetic factors and reprogramming transcription factors to 
facilitate the chromatin resetting for pluripotency acquisition. Generally, Inhibition of 
chromatin condensation, for example, ablation of NuRD/Mbd3 repressor complex, 
inhibition of HDAC activity, H3K4me3, H3K79me2 (mediated by DOT1L) or 
H3K9me3 (mediated by SUV39H), strongly increases iPSC induction (Chen et al., 
2012; Huangfu et al., 2008a; Luo et al., 2013; Rais et al., 2013). Likewise, factors 
which have been proposed to promote active chromatin, such as H3K4me3 effector 
Wdr5 and H3K27me3 “eraser” Utx, facilitate the acquisition of pluripotency (Ang et 
al., 2011; Mansour et al., 2012).  
 
Besides the canonical “Yamanaka factors” OKSM, many other transcription factors 
which are involved in pluripotency maintenance, also display emerging roles in 
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pluripotency acquisition. Nanog, for example, is essential for the establishment of 
ground state pluripotency during somatic cell reprogramming and its expression is 
inducted by many reprogramming factors (Silva et al., 2009). Although it is 
dispensable for somatic cell reprogramming, iPSCs could not be generated from 
Nanog-null fibroblasts (Schwarz et al., 2014; Silva et al., 2009). On the contrary, 
factors that are implicated in lineage specification or developmental processes display 
an inhibitory impact during reprogramming. One example is TGFβ signaling 
pathway, which is implicated in mESC differentiation and embryo development, 
counteracts reprogramming (Ichida et al., 2009; Maherali and Hochedlinger, 2009; 
Puceat, 2007). p53 is also identified as a transcription factor that can inhibit 
reprogramming process.  Studies in recent years have proposed some mechanisms by 
which p53 inhibits reprogramming, such as inducing cell cycle arrest and apoptosis, 
inhibiting MET, etc.(Banito et al., 2009; Brosh et al., 2012; Wang et al., 2012).  
 
Finally, it is noteworthy that microRNAs can be powerful tools to substitute for 
Yamanaka factors for efficient reprogramming. Ankye-Danso et al. and Miyoshi et al. 
reported that expression of mir302/367 cluster or mir200c/302s/369 cluster can induce 
iPSCs rapidly and efficiently in both human and mouse somatic reprogramming 
(Anokye-Danso et al., 2011; Miyoshi et al., 2011). This finding provides a non-viral, 
transgene-free mediated procedure for pluripotency induction, which permits high 
throughput generation of iPSCs. 
 
1.3.5 Characterization of iPSCs 
As mentioned above, thus far the quality of iPSCs generated by somatic cell 
reprogramming varies in their pluripotency potential, and hence characterization of 
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these iPSCs is necessary to ensure that they are completely reprogrammed and 
equivalent to ESCs. A checklist of assessments includes: 
 
1. ESC-like morphology 
Resembling ESCs, iPSCs should be able to form tight, domed colonies with defined 
edges on feeder cells; or form flat, epithelial-like colonies growing on matrigel-coated 
surfaces.  
 
2. Positive for alkaline phosphatase 
Pluripotent cells, like mESCs, hESCs, but not EpiSCs, express alkaline phosphatase 
on their cell membrane. This marker is conventionally used as a quick indicator to 
examine pluripotency. Given that this marker is not exclusive to ESCs, it must be 
used in conjunction with other tests. 
 
3. Pluripotency marker expression 
A panel of molecular markers have been identified for undifferentiated ESCs (As 
reviewed in section 1.1). The commonly used markers are Oct4, Nanog, Sox2, Rex1, 
SSEA-1, Thy-1 for mouse iPSCs and OCT4, NANOG, TRA-1-81, SSEA4, REX1, 
SOX2 and telomerase for human iPSCs. Generally, examination of three or four 
markers by immunostaining is sufficient to determine pluripotency. In some cases, 
promoter methylation analysis of key pluripotency genes are needed, which is to 
confirm that the promoters of key pluripotency genes have been reactivated. 
 
4. Transgene activity 
Expression of transgene is silenced in fully reprogrammed iPSCs. Transgene activity 
should be checked by qRT-PCR, as residual expression of the reprogramming factors 
may indicate incomplete or impaired reprogramming (Panepucci et al., 2012). 
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5. Karyotype analysis 
Induction of reprogramming factors subjects the cells to high pressure, resulting in 
genomic instability. Fully reprogrammed healthy iPSCs should have normal 
karyotype, i.e. correct number of chromosomes and correct arm morphology. 
 
6. Pluripotency evaluation 
The ability to differentiate into all three germ layers, i.e. the endoderm, mesoderm and 
ectoderm is the key feature of pluripotent cells. Demonstration of their differentiation 
potential can be achieved by in vitro EB formation assay or in vivo teratoma 
formation assay and subsequent analysis using immunohistochemistry, qRT-PCR or 
histological staining method. Chimaera assay is the most stringent and golden method 
to evaluate the pluripotency of mouse iPSCs. Pluripotent iPSCs should be competent 
to produce viable chimeras when they are injected into blastocysts. However, 
considering that it is time-consuming and not applicable to most laboratories, chimera 
formation is not a commonly used approach. 
 
1.3.6 Application potentials of iPSCs 
The discovery of somatic reprogramming allows the generation of patient-specific 
stem cells, which circumvents the immune response and ethical issues that embryo-
derived stem cells are confronted with. iPSCs show the advantage of an unlimited cell 
source and the potential to give rise to any cell types for specific clinical purposes. 
 
Patient-specific iPSCs provide a unique and promising platform for cell therapy and 
disease modeling in the field of regenerative medicine, as presented in Figure 5 
(Robinton and Daley, 2012). A patient with neurodegenerative disorder is shown as 
an example. Briefly, with ectopic expressions of transcription factors, the cells 
isolated from a skin biopsy of the patient can generate patient-specific iPSCs. These 
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iPSCs can be maintained and propagated with defined medium in vitro. If there is any 
known gene defect, iPSCs can be modified with genetic engineering. Gene-corrected 
iPSCs would then be transplant into the affected tissue for treatment. Alternatively, 
iPSCs can be differentiated into the specific neuronal cell type, which can be used as 
an in vitro model of the patient’s disease. This model would subsequently be used for 
pathological study of the disease, in vitro drug screening and evaluation of novel 
therapeutics. 
 
However, there are several concerns to be addressed before iPSCs can be used 
clinically.  
 
Firstly and most importantly, the safety of iPSC-derived cells should be treated with 
caution. Up to now, the generation of iPSCs is more or less involved the virus-
mediated induction or genomic integration of oncogenes. Indeed, some studies have 
report the tumorigenicity of the iPSC-derived cells (Liu et al., 2013b). Significant 
progress has been made to solve this problem. For example, Warren et al. introduced 
a safer, viral-free and nonintegrating strategy for human cell reprogramming. With 
repeated administrations of synthetic OKSM mRNA cocktails, multiple human cells 
can be reprogrammed to iPSCs with efficiencies that greatly surpass established viral 
methods (Warren et al., 2010). Thus the transient RNA-based protein expression may 
deliver important clinical benefits for application of iPSCs. 
 
Secondly, The low efficiency and slow kinetics of reprogramming and direct 
differentiation would introduce genetic alterations and delay clinical use. It is 
necessary to develop a procedure that can generate iPSC-derived cells in a simpler 




Thirdly, the purity of iPSCs and iPSC-derived cells could be improved. Both the 
reprogramming and direct differentiation could be incomplete, thus generating 
immature cell types. Efficient methods should be designed for purification or quality 
control of the desired cell population. 
 
Lastly, evaluation of the functionality of iPSC-derived cells is necessary. For 
transplantation purpose, iPSC-derived cells should be able to integrate, survive and 
engraft in the damaged tissue. Thus it is required to examine whether these cells are 
functional that can truly contribute to the recovery of affected tissues. 
 




Although iPSCs show remarkable practical implications in regenerative medicine, 
induced pluripotency is largely restricted by the time length it takes to first reprogram 
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the cells and then subsequently differentiate them to a specific cell fate, which limits 
the output of the final cells.  In this regard, transdifferentiation arises as a promising 
alternative approach to solve the issue. 
 
Transdifferentiation, which is also known as direct reprogramming, refers to the 
conversion from one differentiated cell type to another while bypassing an 
intermediate pluripotent state or progenitor cell type (Jopling et al., 2011). The first 
instance of transdifferentiation was reported by Davis et al. in 1987. They found that 
forcing expression of MyoD in MEFs was sufficient to switch these cells to a 
myoblast cell type (Davis et al., 1987). Yet the progress in this field moved rather 
slow until the discovery of somatic cell reprogramming by Takahashi and Yamanaka, 
which has spurred rapid advances in cell transdifferentiation research. Since then 
there have been multiple reports that achieve such direct lineage conversion in various 
cell types by transinduction of specific transcription factors, defined medium and even 
microRNAs (Margariti et al., 2014). Human dermal fibroblasts, for example, can be 
transdifferentiated to monocytic, erythroid, megakaryocytic and granulocytic lineages 
via ectopic expression of Oct4 with specific cytokinine treatment (Szabo et al., 2010).  
 
Compared with techniques of somatic reprogramming, transdifferentiation displays 
several advantages: 1) this process is faster,  simpler and higher-yielding, which 
avoids of the two-step process of reprogramming and lineage commitment; 2) 
bypassing the pluripotent state, which eliminates the risk of tumorigenicity; 3) 
potential utilization for cell transdifferentiation in vivo, as has been demonstrated in 
cardiomyocyte induction (Qian et al., 2012). However, so far the underlying 
mechanism for direct reprogramming remains unclear. Thus detailed analysis of the 
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properties of directly induced cells and mechanisms of cell transdifferentiation is 
necessary to advance this technology for future clinical applications. 
 
1.5 Zinc finger proteins 
1.4.1 Zinc finger protein family 
Zinc finger proteins (Zfps) which usually contain tandem zinc finger domains, are 
found in DNA binding domains of nearly half of human transcription factors (Messina, 
2004). These zinc fingers can be stabilized by a zinc ion, forming a secondary 
structure for specific cis-regulatory DNA elements binding to regulate gene activity 
(Dang et al., 2000). Differential use of the Cys and His residues for the Zinc ion 
interaction gives rise to different subtypes of zinc finger, such as C2H2, C5HC2, C2C2, 
C2HC, C2HC, C2C2, etc. Of these, C2H2 is known as the classical zinc finger and is 
characterized by the presence of a beta hairpin at the N-terminus and an alpha helix at 
the C-terminus (Nagashima et al., 2009). A large number of proteins from this family 
are found to be crucial transcription repressors or activators to regulate gene 
expressions in diverse cellular processes (Luchi, 2001). However, the functions of 
majority of these Zfps remain poorly understood. 
 
In the past several years, several studies have reported the novel implications of Zfps 
in pluripotency in multiple aspects. Zfp206, Zic3 and Sall4, for example, can activate 
the transcriptions of core regulatory factors Oct4, Nanog and have been integrated as 
key components of the transcription regulatory network (Lim et al., 2007; Wang et al., 
2007b; Wu et al., 2006). Zfp296 and Glis1 were reported as enhancers in somatic cell 
reprogramming via the direct induction of Oct4, Nanog or Myc (Fischedick et al., 
2012; Maekawa et al., 2011); while Zfp281 were found to mediate Nanog 
autorepresssion by recruitment of NuRD complex and thus inhibits the 
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reprogramming process (Fidalgo et al., 2012).  ZFP57, a maternal-zygotic effect 
protein, is essential for maintaining the DNA methylation imprint in ESCs through 
interaction with its co-factor KAP1/TRIM28/TIF1β(Zuo et al., 2011). Zfp521, 
however, has been found negatively regulate pluripotency, as its forced expression in 
ESCs directs neuronal differentiation (Shen et al., 2011).  
 
Zfp322a and Patz1, our genes of interest in this study, are two proteins from this 
family, which have shown their emerging roles in ESCs. 
 
1.4.2 Zfp322a 
Zfp322a (Zinc finger protein 322a) contains 10 C2H2 type zinc finger motifs in total 
and the amino acid sequences within these domains are highly conserved with other 
zinc fingers. In human, ZFP322A has a counterparter ZFP322B (Zfp322 psuedogene 
1), while mouse not. Using phylogenetic tree analysis, previous studies have shown 
that mouse Zfp322a is closely related to its human orthologous protein ZFP322A in 
evolution (Li et al., 2004). Alignment of the amino acid sequences further revealed 
that human ZFP322A protein is highly identical to mouse Zfp322a (Li et al., 2004). 
Thus the high conservation of Zfp322a in mammals indicates that Zfp322a could have 
some essential biological functions. Yet so far little has been known regarding the 
functions of Zfp322a in mammals. 
 
1.4.3 Patz1 
Patz1, also known as Zfp278 or MAZ-related factor (MAZR), contains 7 C2H2 type 
zinc fingers. Besides, it possesses an AT hook DNA binding motif and a BTB/POZ 
domain, which is essential for protein-protein interactions (Fedele et al., 2000). It 
48 
 
belongs to POK (POZ and Krüppel-like zinc finger) family of transcription repressors. 
Interestingly, the biological functions of POK proteins are generally associated with 
other proteins interacting with the POZ domain (Costoya, 2007). Patz1 has been 
reported as a transcription regulator that can activate Myc through its interaction with 
Bach2, or act as a corepressor that attenuates RNF4-mediated androgen receptor-
dependent transcription activation (Kobayashi et al., 2000; Pero, 2001). Through 
binding with nuclear receptor corepressor (NCoR) complex, Patz1 negatively 
regulates CD8 expression(Sakaguchi et al., 2010). Patz1 is also found to participate in 
BCL6-mediated transcription repression by direct interaction with BCL6 (Pero et al., 
2012). Therefore Patz1 may function as an architectural transcription factor that can 
act either as activator or repressor depending on the protein it interacts with. 
 
Indeed Patz1 has displayed diverse functions in various cellular processes. Patz1 may 
be implicated in carcinogenesis, as its level is up-regulated in colorectal, glioma, 
testicular and breast tumors (Fedele et al., 2008; Li et al., 2010b; Tian et al., 2008; 
Tritz et al., 2008). On the other instances, the observations of rearrangement of 
PATZ1 allele in small round cell sarcoma, tumor development in Patz1-knockout mice 
and its involvement in p53 pathway support a potential tumor suppressor role of Patz1 
(Mastrangelo et al., 2000; Pero et al., 2012; Valentino et al., 2013a). Besides, Patz1 
has an emerging role of inhibiting cellular senescence in endothelial cells and MEFs 
(Cho et al., 2011; Valentino et al., 2013a).  All these results indicate that functions of 
Patz1 are context dependent. 
 
Interestingly, Patz1 also has a critical role in embryo development. Majority of Patz1-
knockout mice underwent prenatal death with severe defects in central nervous 
system and cardiovascular system; the knockout mice that survived showed a general 
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growth retardation compared to WT mice (Pero et al., 2012; Valentino et al., 2013b). 
Patz1 is also a regulator of limb bud development and spermatogenesis (Kobayashi et 
al., 2000) (Fedele et al., 2008). Given its predominant expression in ICM and ESCs, 
Patz1 has been identified as an important regulator of pluripotency that is required for 
maintaining ESC in undifferentiated state (Ow et al., 2014; Yoshikawa et al., 2006). 
However, the role of Patz1 in reprogramming process is still unknown. 
 
1.5 Purpose and scope 
Despite their known functions, here we propose that Patz1 and Zfp322a are potential 
regulators of pluripotency based on these observations: First, using whole mount in 
situ hybridization, Yoshikawa et al. demonstrated that both Zfp322a and Patz1 are 
highly expressed in mouse blastocysts and at higher levels in inner cell mass (ICM) 
than trophoblast (Yoshikawa et al., 2006). Besides, single cell RNA-seq results also 
suggested higher expression of Zfp322a and Patz1 in Oct4
+
 cells than Oct4
-
 cells 
(Tang et al., 2010). Secondly, it is noteworthy that ChIP-seq data from Chen et al. ’s 
study indicated that many important pluripotency factors, including Oct4, Myc, Klf4 
etc., bind to the genomic region of Zfp322a and Patz1, which suggests that they are 
potential targets of other pluripotency factors (Chen et al., 2008). In addition, previous 
work in our lab has revealed that Patz1 regulates pluripotency genes Oct4 and Nanog 
to sustain pluripotency in mESCs (Ow et al., 2014).  
Together with the known roles of other zinc finger proteins in ES cells that have been 
reviewed above, we propose that Zfp322a and Patz1 are engaged in pluripotency 
maintenance or acquisition. However, their functions in pluripotency regulation have 
been poorly studied.  
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Therefore, the purpose of this study is to explore novel functions of Zfp322a and 
Patz1 in pluripotency regulation. In this thesis I aimed to: 
1. Investigate the functions of Zfp322a in mESC identity and reprogramming 
process 
 Examine whether Zfp322a is required for maintaining ESCs in the 
pluripotent state; 
 Identify the potential targets of Zfp322a through genome-wide ChIP-seq 
analysis and global gene profile analysis of knocked-down cells; 
 Detect the crosstalk between Zfp322a and other pluripotency factors and 
dissect its integration within the pluripotency regulatory network; 
 Explore the roles of Zfp322a in the reprogramming process. 
2. Intensively study the role of Patz1 in somatic cell reprogramming 
 Determine whether Patz1 overexpression or depletion has an impact on 








 Examine gene expression files of Patz1+/+, Patz1+/- and Patz1-/- MEFs by 
microarray analysis and search for novel downstream pathways of Patz1 
in MEFs; 
 Investigate the mechanism of Patz1 in reprogramming modulation. 
Through investigating the roles of the two novel zinc finger proteins Zfp322a and 
Patz1, in pluripotency regulation, this study will contribute to a better conception of 
diverse functions of zinc finger proteins. Genome-wide studies, such as microarray 
analysis and ChIP-seq, would shed light on their novel functions. Moreover, based on 
these explorations, we expect to expand the pluripotency regulatory network and gain 
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more hints on interactions among these pluripotency factors. Overall, the relevant 
studies on mechanisms of their functions could provide more insights into our current 




















MATERIALS AND METHODS 
2.1 Cell culture 
Murine ES cells (E14) were cultured in ES cell medium consisting of Glasgow 
Minimum Essential Medium (GMEM; Invitrogen), 15% ES cell qualified fetal bovine 
serum (FBS; Invitrogen), 0.055 mM β-mercaptoethanol (Sigma), 100 mM sodium 
pyruvate (Invitrogen), 0.1 mM MEM nonessential amino acid (NEAA, Invitrogen) 
and 1,000 units/ml of leukaemia inhibitory factor (LIF) (Millipore). 
Platinum-E (Plat-E) cells were maintained in Plat-E medium consisting of Dulbecco’s 
Modified Eagle Medium (DMEM; Invitrogen) containing 10% FBS, 1% penicillin 
and streptomycin (P/S). For cells transfected with retroviruses, medium were 
supplemented with 1 μg/ml puromycin (Sigma-Aldrich) and 10 μg/ml blasticidin 
(Invitrogen).  
SNL feeder cells were maintained in GMEM, 10% FBS and 1% 
Penicillin/Streptomycin. Medium was changed every 2 days and cells were passaged 
every 2-3 days. Inactivated SNL feeder cells were prepared by incubating the cells in 
mitomycin C solution (12 μg/ml, Sigma) for 2.5 h at 37 °C in a 5% CO2 incubator. 
The inactivated cells were then passaged and seeded at 80% confluence for iPS cell 
culture. 
MEFs were cultured in mESC medium without LIF. For iPSC formation, MEFs that 
have been infected with retroviruses were maintained in mESC medium without LIF 
till 5 days post infection and then maintained in Knockout Serum Replacement (KSR) 
medium. KSR medium contains DMEM, 15% KSR (Invitrogen), 2 mM L- Glutamine 
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(PAA), 1 mM sodium pyruvate, 1000 units/ml of LIF, 1% P/S, 0.055 mM β-
mercaptoethanol and 0.1 mM MEM NEAA.   
All the cells were cultured at 37 °C in a 5% CO2 incubator. 
2.2 Plasmid construction 
For RNAi design and construction of plasmids for shRNA synthesis, Eurofins MWG 
Operon online software was used to design nucleotide sequence for targeting specific 
genes. All sequences were analysed by BLAST to ensure specificity and avoid off-
target effects. Oligonucleotides were cloned into pSuper.puro vector (Oligoengine).  
For overexpression in ES cells, full-length cDNA PCR products were amplified by 
PCR and inserted into BamH1 and Xho1 site of pPyCAGIP. 
For plasmids used in luciferase assays, Pou5f1 CR4 region and CR1 region was 
amplified and cloned into the pGL3-Promoter vector (Promega) upstream of the 
firefly luciferase gene to generate the Pou5f1 CR4-pSV40-Luc and Pou5f1 CR1-
pSV40-Luc luciferase reporter plasmids respectively; Nanog proximal promoter was 
amplified and inserted into pGL3-Basic vector to generate the pNanog PP-Luc plasmid.  
For retrovirus packaging plasmids, full-length cDNA products was amplified by PCR 
and ligated into MunI and NotI restriction sites of pMX plasmid (Addgene).  
The ligated products were transformed into competent DH5α Escherichia coli cells by 
heat shock at 42°C for 90 s and subsequent rescued in 1 ml of Lysogeny broth (LB) 
medium at 37°C for 45 min before being selected on ampicillin agar plates at 37
o
C 
overnight. Single colonies were picked on the next day and plasmids were extracted 
for sequencing with specific primers to verify the insertion.  
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Successfully inserted plasmids were isolated using PureYield™ Plasmid Miniprep 
System (Promega) or PureYield™ Plasmid Midiprep System (Promega) for large 
scale production according to manuals provided by the kit. In brief, the bacteria were 
pelleted down, lysed with blue cell lysis buffer, which was stopped by addition of 
neutralization solution. After centrifuging the cell lysate, the supernatant were 
transferred to PureYield™ column. After binding and washing, plasmids were then 
eluted with elution buffer that are provided.  
The primers and shRNA sequences being used are listed in the Appendix 1. 
2.3 Transfection, RNA extraction, reverse transcription and quantitative real-
time PCR  
Transfection of ES cells was conducted using Lipofectamine 2000 (Invitrogen) 
according to the manual provided.  For RNAi assays, cells were selected in 6-well 
culture plate for 3 days using puromycin. ES cells transfected with overexpression 
vectors were selected using puromycin for 1 week before transferring to 100 mm 
plates for further selection for another 1 week. Single colonies were picked up and 
passaged to 6-well dishes. The cells were then harvested for extraction of either 
protein or RNA.  
Total RNAs were isolated using TRIzol Reagent (Invitrogen) followed by purification 
with RNAeasy Mini Kit (Qiagen) according to the provided protocol. In brief, cells 
were lysed with TRIzol reagent and protein was removed using chloroform. RNA was 
precipitated from the water phase by addition of isopropanol. After washed with 75% 
ethanol, RNA pellet was finally dissolved in diethyl pyrocarbonate (DEPC)-treated 
water (Ambion). The Superscript III First-Strand Synthesis System with oligo (dT) 
primer (Invitrogen) was used to convert messenger RNA (mRNA) to complementary 
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DNA (cDNA). The cDNA was diluted 20 times with nuclease-free water for 
quantitative real-time PCR, which was performed with CFX96TM Real-Time System 
(Bio-Rad) and SYBR Green Master Mix (Bio-Rad). Relative expression levels of 
target genes from sample cDNA were normalized against β-actin levels and reflected 
as a fold change compared to control. For ChIP experiments, relative occupancy 
values were calculated by determining the apparent IP efficiency (ratios of the amount 
of ChIP enriched DNA over that of the input sample) and normalized to the level 
observed at a control region.  
All the qPCR primers are listed in Appendix 2. 
2.4 Gene expression microarray assay 
E14 cells were transfected as described above with plasmids expressing shRNA 
targeted against either Zfp322a, Patz1, or control. Cells were harvested after selection 
for 4 days. Total RNA was extracted and purified as described above. Then the RNA 
was diluted to 200 ug/ul and was analysed using Affymetrix Mouse Genome MG430 
Plus 2.0 Array according the manufacture’s instruction by our collaborator Dr. Li Hu.  
Microarray data was processed to extract the representative intensities from each 
probe set using RMA (Irizarry et al., 2003). Appropriate cut-off values were 
determined and used to identify differential expression between sample and control 
groups. Only those differentially expressed genes were subjected for further analysis. 
Prior to hierarchical clustering, log2 transformation was first performed and the 
transformed data were subtracted from the mean of the means of the two sample 
groups. To identify the enriched “Gene Ontology” (GO) terms in the differentially 
expressed genes, the GO TermFinder was applied (Boyle et al., 2004). For 
presentation of enriched KEGG pathways in the differentially expressed genes, the 
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GATHER was used (Chang and Nevins, 2006). The p value cut-off of 0.05 was 
employed for both significant enriched GO terms and KEGG pathways. For 
overlapping genes between ChIP-seq predicted targets and microarray altered gene 
targets, two sets of genes were analysed using VLOOKUP functions in Microsoft 
Excel.   
2.5 Chromatin immunoprecipitation (ChIP) 
ES cells or MEFs were cross-linked with 1% formaldehyde at 150 rpm for 10 min at 
room temperature and then quenched by 0.2 M glycine. After washing twice with cold 
PBS, the cells were harvested by scrapping and centrifuging at 3000 rpm for 15 min at 
4
o
C. The cell pellet was further washed in cold PBS and lysed with SDS cell lysis 
buffer (10 mM Tris-HCl, pH 8.0, 10 mM EDTA, 0.1 M NaCl, 0.25% Triton X-100) 
containing protease inhibitor cocktail (Roche). The cell nuclei were pelleted by 
centrifugation at 2000 rpm for 10 min at 4
o
C, and then lysed in nuclear lysis buffer 
(50 mM HEPES-KOH, pH 7.5, 15 0mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% 
sodium deoxycholate, 1% SDS) with protease inhibitor cocktail. The chromatin was 
then extracted by spinning down at 20,000 rpm for 30 min at 4
o
C. The chromatin 
pellet was subsequently washed twice with ChIP buffer (50 mM HEPES-KOH, pH 
7.5, 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% 
SDS) containing protease inhibitor cocktail. Prior to sonication, 1 ml of 0.5 mm glass 
beads were added to the chromatin extract, which was re-suspended in 8 ml of ChIP 
buffer. Sonication was carried out at 30% amplitude with pulses of 30 sec on and 30 
sec off for about 16 cycles, on the Vibra-Cell VCX750 (Sonics). Size of the sonicated 
chromatin was determined by de-crosslinking (100 μl chromatin extract, 90 μl TE 
buffer [10 mM Tris-HCl, pH 8.0, 1 mM EDTA], 30 μl pronase, 200 μl ChIP elution 
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buffer [50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS]) at 42 
°
C for 2 h followed 
by 67°C for 6 h. After phenol-chloroform extraction, the size of DNA was determined 
by agarose gel electrophoresis. If the average size was about 300 to 500 base pairs, 
the chromatin was continued with immunoprecipitation. Dynabeads Protein G 
(Invitrogen) beads were washed with ChIP buffer twice before being coated with 
specific antibody by incubating for 2 h at room temperature. The coated beads were 
then added to chromatin extract which was pre-cleared by incubation with beads. 
After overnight incubation, the beads were washed thrice with ChIP buffer, once with 
ChIP buffer plus 0.35M NaCl, once with ChIP washing buffer (10mM Tris-HCl, pH 
8.0, 250 mM LiCl, 1 mM EDTA, 0.5% Nonidet P-40 [NP-40], 0.5% sodium 
deoxycholate), and finally eluted with ChIP elution buffer (50 mM Tris-HCl pH 8.0, 
10 mM EDTA, 1% SDS) while agitating at 1,400 rpm at 68 °C for 45 min. The eluent 
was decrosslinked by pronase. ChIP DNA was then exacted with phenol-chloroform, 
precipitated and dissolved in 80 ul TE buffer for real-time PCR analysis. 
2.6 ChIP-sequencing (ChIP-seq) 
For ChIP-seq, ChIP DNA was resupended with 20 μl TE buffer and sent out for 
sequencing. Briefly, ChIP DNA library was prepared by utilizing the ChIP-seq 
Sample Prep Kit (Illumina). Sequencing was then performed using the Genome 
Analyzer IIx (Illumina) and reads were mapped to the M. musculus genome assembly 
mm9.   
ChIP-seq analysis was performed by our collaborative bioinformatics group. In brief, 
ChIP-seq peak detection was done using Partek software with an average fragment 
size of 300 bps and 0.05 as the cut-off p-value of Mann-Whitney U test for the 
separation of forward and reverse reads in a peak. In fact, the Partek software 
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combined several methods of fragment size estimation, peak identification and peak 
filtering using the Mann-Whitney U test (Ji et al., 2008; Kharchenko et al., 2008). We 
further enriched the peaks by using the fold change of Zfp322a peak heights to IgG 
peak heights (fold change 3 as cut-off), and a minimal Zfp322a peak height at 9 reads 
as a further cut-off criterion. The final list of the inferred peaks was subjected to motif 
finding. MEME-ChIP in the MEME suite (http://meme.nbcr.net/meme/cgi-bin/meme-
chip.cgi) was applied to the inferred peaks. Clustering of Zfp322a with other 
transcription factors (TFs) was used to evaluate the similarity of the TF targeting. The 
co-localization between the TFs was first computed and the correlation coefficients 
between each pair of co-localization vector were then determined. With the 
completion of all pair-wise correlation, a correlation matrix was obtained. With the 
matrix, a heatmap reflecting the hierarchical clustering of the correlation coefficients 
was generated.  
2.7 Co-immunoprecipitation (Co-IP) 
Cells were harvested and resuspended in cell lysis buffer (50 mM Tris-HCl pH 8.0, 1 
mM ethylenediaminetetraacetic acid (EDTA), 150 mM sodium chloride (NaCl), 1% 
NP-40, 10% glycerol) with protease inhibitor cocktail (Roche) for 2 h at 4 °C. The 
cold cell lysate obtained was first precleared with Protein G Agarose beads 
(Invitrogen) and then incubated overnight with beads coated with specific antibody at 
4°C. The beads were washed for six times using cell lysis buffer before boiled in 80 
μl of 2X loading dye for 10 min at 95°C. Western blotting was performed using the 
supernatant obtained from the boiled beads with specific antibodies. Control IP was 
performed using anti-IgG antibody (Chemicon). 
 
Antibodies that are used are listed in Appendix 3.  
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2.8 Western blotting 
The cells were harvested, washed twice in PBS and re-suspended in Laemmli sample 
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 5% glycerol, 1% β-
mercaptoethanol, 5 mM EDTA, pH 8.0, 0.002% bromophenol blue) with protease 
inhibitor cocktail (Roche) by boiling at 95°C for 5 min. The cell lysate was then 
centrifuged at 14,000 rpm for 15 min. The supernatant, containing the total protein 
was harvested. Appropriate amounts of protein were loaded into a 10% sodium 
dodecyl sulfate (SDS) polyacrylamide gel and ran in SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) running buffer (25 mM Tris, pH 8.3, 0.192 M glycine, 
0.1% SDS) at 120V.  Proteins were then transferred to a methanol-activated 
polyvinylidene fluoride (PVDF) membrane (Bio-Rad) by running at 320 mA for 3 h 
in Western Blot transfer buffer (25 mM Tris, pH 8.3, 0.192 M glycine). Subsequently, 
the membrane was blocked using PBST (0.1% Tween-20 in PBS) with 5% skim milk 
for 1 h at room temperature, incubated with primary antibody (diluted in PBST with 5% 
skim milk) overnight at 4
o
C. The membrane was washed thrice in 0.1% PBST before 
probed with secondary antibody conjugated to horseradish peroxidase (GE Healthcare) 
at room temperature for 45 min. After washing thrice with 0.1% PBST, the membrane 
was then incubated in Immobilon Western Chemiluminescent HRP Substrate 
(Millipore) for 5 min. The chemiluminescent signal was detected with CL-Xposure 
Film (Thermo Scientific) in dark.  
 






2.9 Immunofluorescence staining 
Cells cultured in 24-well dishes were fixed in 4% paraformaldehyde and 
permeabilized with 0.25% Triton X-100, followed by blocking with 3% BSA in PBS. 
The cells were then probed with primary antibody in 3% BSA for 1 h at 4 °C and 
secondary antibody conjugates (Life Technology) in 3% BSA for 30 min at room 
temperature. A drop of Vectashield mounting medium with 4', 6-diamidino-2-
phenylindole (DAPI; Vector Laboratories) was placed on the microscope slide and the 
cover slip was sealed with nail polish in a way that the cells were in contact with the 
mounting medium. Staining signal was then observed through the Axio Observer A1 
inverted light microscope (Zeiss).  
Antibodies that were used are listed in Appendix 3.  
 
2.10 Flow cytometry 
Cells were collected by centrifugation and resuspended in PBS with 4% formaldehyde 
for 10 min at 37°C. After chilled on ice for 1 min, the cells were resuspended in 90% 
methanol. The cells were then incubated on ice for 30min for permeabilization. The 
cells were rinsed with incubation buffer (0.5% BSA in PBS). The cells were 
incubated with primary antibody overnight at 4°C. The cells were rinsed twice and 
then incubated with secondary antibody for 1 h at room temperature in dark. The cells 
were rinsed twice before analysed on the flow cytometer (BD FACS Canto). The flow 
cytometry results were analysed with Flow Software 2.5.0. 
2.11 Dual-luciferase assays 
Gene-specific shRNA plasmids or overexpression plasmids (600 ng) were 
cotransfected with Pou5f1CR4-Luc reporter (600 ng), Pou5f1 PP-Luc or Nanog pp-
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Luc reporter (600 ng) and an internal control pRL-TK (30 ng, Promega) encoding 
Renilla luciferase. Firefly and Renilla luciferase activities were measured with the 
dual-luciferase reporter system (Promega) 72 h post-transfection by Ultra 384 
Microplate Reader (Tecan). In brief, after rinsed with cold PBS, the cells were lysed 
with Passive Lysis Buffer (PLB), and firefly luciferase activity was measured upon 
addition of the Luciferase Assay Reagent II. Then the Stop & Glo Reagent was added and 
Renilla luciferase activity was measured immediately. The readings generated from cells 
transfected with RNAi or OE plasmids were calculated as relative to control 
transfection, after normalization to Renilla luciferase readings. Transfections were 
performed in duplicate and on three independent occasions. 
 
2.12 Alkaline phosphatase (AP) staining 
AP staining was performed using Alkaline Phosphatase Detection Kit (Millipore) 
according to manufacturer’s instructions and results were obtained using the Axio 
Observer A1 inverted light microscope (Zeiss). In brief, cells were fixed in 4% 
paraformaldehyde in PBS, washed twice in 0.05% PBST (20 mM Tris-HCl, pH 7.4, 
0.15 M NaCl, 0.05% Tween-2) and incubated in dark with staining solution (mixture 
of Fast Red Violet, Naphthol AS-BI phosphate solution and deionized water with a 
ratio of 2:1:1) for 15 min at room temperature. Cells were then washed with 0.05% 
PBST and observed with the Axio Observer A1 inverted light microscope (Zeiss). 
2.13 Retrovirus packaging, infection and iPSC induction 
Plat-E cells were seeded onto a 10-cm tissue culture plate at 50-70% confluency and 
transfected with specific retrovirus packaging plasmids 4-6 h later. Transfection was 
performed as normal RNAi assays but in this experiment, 24 μg of plasmid, 60 μl of 
Lipofectamine 2000, and 1.5 ml of Opti-MEM (Invitrogen) were used instead. Cells 
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were incubated overnight at 37°C in a 5% CO2 incubator before changing to fresh 
medium. Virus-containing medium was collected 48 h post transfection, filtered using 
a 0.22 μm cellulose acetate filter (TPP) and concentrated 100x using Amicon 
Centrifugal Filter Units-100 kDa (Millipore) by centrifugation at 3800 rpm for 45 min. 
The concentrated viruses were stored in -80°C for infection. Pou5f1-GFP MEFs were 







 MEFs were seeded into 24-well pates at a number of 
300x10
3
 6 h before infection.  10 μl of each concentrated retrovirus, supplemented 
with 8 μg/ml polybrene (Sigma), were added to the MEF cells. MEFs were then 
passaged onto the inactivated feeder layer 2 days post infection (dpi) and maintained 
in mESC medium without LIF before replacing with KSR medium at 5 dpi. KSR 
medium was replaced every day and the number of GFP
+
 colonies was counted till the 
end of the experiment. Alkaline phosphatase staining assay was then performed using 
Alkaline Phosphatase Detection Kit (Millipore) as described above and results were 
captured with the Axio Observer A1 inverted light microscope (Zeiss). 
2.14 Embryoid body (EB) formation assay 
For ES cells, embryoid bodies were formed in suspension culture system. Cells were 
dissociated as per passaging and re-suspended in LIF withdrawal medium before 
transferred to Ultra-Low Attachment Surface culture plate (Corning). Embryoid 
bodies induced from Patz1 over-expressing stable cell line were cultured in LIF 
withdrawal medium supplemented with puromycin (1μg/ml). Medium was changed 
every two days and RNAs were extracted from the embryoid bodies at specific days 




For iPS cell differentiation, iPSCs were dissociated as per passaging and re-suspended 
with LIF withdrawal medium in Ultra-Low Attachment Surface culture plates. After 
culturing for 4 days in suspension, embryoid bodies were transferred to gelatin-coated 
coverslips placed in 24-well plates. The adherent EBs were cultured with EB medium 
(DMEM containing 15% KSR, 2 mM glutamine, 0.1 mM MEM) for another 10 days. 
Immunostaining was then performed with antibodies against specific lineage markers. 
Images were captured under a confocal microscope (Olympus FV1000) at 60X 
magnification. Antibodies that are used are listed in Appendix 3.  
 
2.15 Teratoma assay 
iPSCs were suspended at concentration of 1x10
7
 cells/ml and sent to our collaborative 
lab for teratoma assays. Briefly, 100 μl of suspended cells were injected into the 
dorsal flanks of SCID mice that were anesthetized with Avertin. Teratomas formed 
after 2 to 3 months were surgically dissected, fixed, sectioned and analysed with 
Mallory’s Tetrachrome staining. Briefly, the tumors were dissected in PBS, fixed with 
Bouin’s solution for 3 days, and decalcified in Jenkin’s solution for three times.  The 
tumors were then embedded in fresh paraffin and sectioned using a microtome. The 
sections were immersed in toluene, washed with ethanol, stained with Groat solution, 
Acid Fuschine and Aniline solution, followed by washing with ethanol and toluene. 








CHAPTER 3  
ZFP322A REGULATES MESC PLURIPOTENCY AND ENHANCES 
REPROGRAMMING EFFICIENCY 
3.1 Results 
3.1.1 Zfp322a is expressed in undifferentiated mESCs. 
Chen et al. demonstrated that Oct4, Zfx, E2F1, Klf4 and Myc bound to an 800bp-
region in the third intron of Zfp332a (Chen et al., 2008)
 
(Figure 3.1A). Our ChIP 
results confirmed the association of Oct4 to this region (Figure 3.1B). This suggested 
that Zfp322a could be a direct target of regulation by these transcription factors. In 
previous studies Zfp322a was discovered to be expressed at a higher level in ICM 
compared to trophectoderm (Yoshikawa et al., 2006). We further examined the 
expression of Zfp322a in mESCs by immunostaining assay (Figure 3.1C), using the 
antibody specific for Zfp322a protein (Figure 3.1 D). We found that Zfp322a was 
mainly localized in the nucleus, which indicates that, as a zinc finger protein, Zfp322a 
may function as a transcription factor in mESCs.  
Zfp322a expression during mESC differentiation was next determined. mESCs were 
induced to differentiate by culturing in LIF withdrawal medium. The level of 
pluripotency factor Oct4 and Nanog serve as positive controls. As shown in Figure 
3.1E, Zfp322a mRNA level was reduced during the differentiation process, dropping 
to 20% at 7 days after LIF removal (Figure 3.1E). Similarly, Zfp322a protein also 
decreased upon mESC differentiation (Figure 3.1F). The expression of Zfp322a in 
undifferentiated mESCs and its repression upon ESC differentiation further suggested 




Figure 3.1 Zfp322a is expressed in undifferentiated mESCs. (A) Zfp322a intronic 
region is bound by multiple transcription factors. The black box represents the 
amplified product from the primer pairs along the intronic region. Open boxes 
represent exons of Zfp322. (B) Oct4 binds to Zfp322a intronic region. ChIP DNA 
with anti-Oct4 antibody was analyzed by qPCR. Fold enrichment was obtained after 
comparing the values of ChIP DNA to that of the input DNA and normalized against 
a control region. The control region is an intergenic region on chromosome 6. (C) 
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Zfp322a is distributed in nucleus and cytoplasm in ESCs. ESCs were stained with 
anti-Znf322 antibody (green). DAPI (blue) served as nucleus marker. (D) Zfp322a 
antibody is specific to Zfp322a protein. E14 cell lysate was prepared for western blot 
assay. (E) qPCR was performed to determine relative levels of Zfp322a (red) and Oct4 
(blue) transcripts in ESCs cultured in LIF withdrawal medium for different time 
periods, compared to ESCs cultured in normal ESC medium and normalised against 
β-actin. (F) Western blot was done to show the change in Zfp322a protein level as 
mESCs differentiated. β-actin serves as the loading control. 
 
3.1.2 Zfp322a is required for the maintenance of mESC self-renewal and pluripotency 
In order to investigate the role of Zfp322a in mESC pluripotency, we examined the 
effect of Zfp322a depletion in mESCs by RNAi.  mESC line E14 cells were 
transfected with two independent Zfp322a shRNAs targeting different regions of 
Zfp322a gene. Both shRNAs were effective in depleting the level of Zfp322a mRNA 
to 30% of the control. Upon knock-down of Zfp322a, mESCs lost their characteristics, 
including the round colony-like morphology and AP activity. Instead, RNAi-treated 
cells exhibited flattened, differentiated cell morphology (Figure 3.2A). These results 
indicated that Zfp322a depletion caused differentiation and impaired self-renewal of 
mESCs. 
We further examined the alteration in gene expression induced by Zfp322a depletion. 
The mRNA levels of pluripotency genes Pou5f1, Nanog, Sox2 and Zfp42 were 
significantly reduced in RNAi-treated E14 cells (Figure 3.2B). Consistently, protein 
levels of these pluripotency factors were also reduced upon Zfp322a depletion (Figure 
3.2C, D). In addition, immunofluorescence (IF) of Oct4 and Nanog were performed to 
examine their expression at cellular level. The fluorescence intensities of Zfp322a 
knocked-down cells and control cells were measured with flow cytometry. Upon 
Zfp322a RNAi, there was a significant reduction of the fluorescence intensities 
observed both in anti-Oct4 antibody and anti-Nanog antibody stained cells (Figure 
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3.2E). Further we examined the population mean value of fluorescence intensities. We 
found that Zfp322a depletion supressed Oct4 and Nanog IF mean intensities by 50%, 
40% respectively as compared to control (Figure 3.2F).   
Since Oct4 and Nanog are essential for maintenance of pluripotency, these results are 
consistent with the observation that Zfp322a RNAi induces differentiation. The 
differentiation of mESC was further supported by the dramatic increase in various 
lineage markers after Zfp322a depletion (Figure 3.2G). Upon knock-down of Zfp322a 
in mESCs, we observed an up-regulation of endodermal markers: Gata6 (4 fold), 
Foxa2 (8 fold) and Sox17 (3 fold), which indicated that Zfp322a could maintain 
mESC pluripotency by repressing endodermal specification. Trophectoderm maker 
Cdx2 displayed a 16 fold increase while mesoderm markers, Fgf5, Hand1 and Nkx2.5 
increased by 7, 8 and 10 fold respectively (Figure 3.2G). Thus consistent with the AP 
staining results, this suggested that Zfp322a is required to suppress lineage specific 






Figure 3.2 Zfp322a is required for maintaining mESC pluripotency. (A) Zfp322a 
RNAi results in AP lose and differentiated morphology. AP staining was conducted 
on the fourth day of selection after the cells were transfected with Zfp322a shRNAs. 
Zfp322a RNAi cells displayed a lighter colour compared to the dark red colour of 
mock RNAi cells. (B) Depletion of Zfp322a down-regulates mRNA levels of 
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pluripotency genes Oct4, Sox2, Nanog and Rex1. Two different shRNAs targeting 
distinct regions of Zfp322a  (namely Zfp322a RNAi-1 and Zfp322a RNAi-2) were 
transfected into ESCs to knock-down Zfp322a. ESCs transfected with empty 
pSUPER.puro vector were used as a control and gene expression levels were 
normalized against β actin. (C) Knock-down of Zfp322a resulted in decreased Oct4, 
Nanog, Sox2 and Rex1 protein. β-actin served as loading control. (D) Quantification 
of the protein level changes. Protein levels of Zfp322a depleted cells were normalized 
against β-actin and compared to control RNAi cells using software ImageJ. (E) 
Representative flow cytometry results showed that fluorescence intensities of Oct4 
and Nanog were repressed in Zfp322a RNAi cells as compared to control cells.  (F) 
Zfp322a depletion led to reductions of Oct4 and Nanog expression at cellular levels. 
The mean of fluorescence intensity was calculated using software flow software 2.5.0. 
Relative fluorescent intensities of Zfp322a RNAi cells were normalized against 
control knocked-down cells. Standard deviations were derived from three independent 
experiments. (G) Zfp322a RNAi caused up-regulation of lineage specific markers for 
endoderm, mesoderm and trophectoderm. Specific primers were used to check the 
respective gene expression levels by real-time PCR. 
 
3.1.3 Depletion of Zfp322a activates developmental genes while repressing 
pluripotency related genes 
To further understand how Zfp322a depletion led to mESC differentiation, we used 
gene expression microarrays to investigate the global gene expression profile changes 
induced by Zfp322a depletion. qPCR experiments were performed to validate the 
results of the microarray analysis (Figure 3.3A). As an internal control, we examined 
the level of Zfp322a by the microarray, and consistent with real-time PCR results 
(Figure 3.2B), we found an approximately 3-fold reduction in the mRNA level of 
Zfp322a.  Upon Zfp322a depletion, 1574 genes were up-regulated (increased by >1.5 
fold) and 904 genes were down-regulated (reduced by >1.5 fold) (Figure 3.3B). 
Importantly, the microarray data analysis revealed that many known pluripotency 
genes were down-regulated. This indicated that Zfp322a is a high-level regulator in 
the mESC gene regulatory network, which does not only regulate a subset of genes 
required for pluripotency, but is an essential component of the core network required 




Figure 3.3 Changes of global gene expression upon Zfp322a knock-down in mESCs. 
(A) Validation of gene expression microarray analysis of Zfp322a RNAi. 11 down-
regulated genes and 10 up-regulated genes were selected from microarray analysis. 
ESCs transfected with empty pSUPER.puro vector were used as a control and gene 
expression levels were normalized against β-actin. Relative expression level of each 
gene in qPCR was compared to microarray analysis results. (B) Microarray heat map 
generated from relative gene expression levels. Zfp322a was knocked down in E14 
cells and the cells were selected for 96 hours before whole genome cDNA microarray 
hybridization was performed. Duplicates were performed to ensure reproducibility of 
results.  Relative highly expressed genes were shown in red and low expressed genes 
in green. Gene onthology analysis was performed relating to “biological process” for 
the up- or down-regulated genes respectively. The enriched terms were classified into 
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several function groups and listed in the figure. Examples of down-regulated 
pluripotency-related genes upon Zfp322a knock-down in ESCs. Genes were selected 
according to their known functions in pluripotency or ESCs. Each selected gene was 
taken as individual tiles from the thumbnail-dendogram duplicates. 
To determine whether Zfp322a regulated specific types of gene, we conducted gene 
ontology (GO) analysis of up-regulated and down-regulated genes. The enriched terms 
were summarized in Figures 3.3B. For the up-regulated genes, many terms related to 
development were enriched. This is consistent with the role of Zfp322a as a repressor 
of differentiation. Furthermore, Zfp322a depletion activated cell apoptosis related 
genes, also explained the increased apoptosis in Zfp322a RNAi-treated cells. 
Interestingly, many terms were related to chromosome remodelling, suggesting that 
Zfp322a may contribute to maintenance of the unique mESC chromatin structure. 
Notably, several signaling pathways implicated in pluripotency such as MAPK 
pathway, Wnt signaling pathway, Ras signal cascade were also affected after Zfp322a 
depletion (Figure 3.3B).   
3.1.4 Zfp322a represses MAPK/ERK pathway 
It has been shown that inhibition of MAPK/ERK pathway is important for mESC 
ground state pluripotency (Nichols et al., 2009; Zheng et al., 2008). Activation of Ras-
MAPK pathway promotes trophectoderm induction and is specifically suppressed by 
Oct4 in undifferentiated mESCs(Li et al., 2010a). ERK pathway has been found to 
promote the onset of mESC differentiation and it is involved in multiple 
developmental processes (Schübeler et al., 2012). Therefore, Zfp322a may maintain 
mESC in an undifferentiated state via repression of the MAPK/ERK cascade.  
Some important factors involved in MAPK/ERK pathway were found within the gene 
clusters under the term “MAPK signaling pathway” in KEGG pathway analysis. Fgf1, 
Kras, Crk and Fgf13, which induces MAPK/ERK pathway, and the MAPK/ERK 
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pathway downstream targets, Atf2 and Jun, are all up-regulated in Zfp322a depleted 
cells (Blaukat et al., 1999; Castellano and Downward, 2011; Cohen, 2006; Ouwens et 
al., 2002; Ramos et al., 2010). In this regard, western blotting was performed to check 
ERK level in Zfp322a knocked-down cells. Indeed, Zfp322a depletion caused an up-
regulation of phosphorylated ERK (p-ERK) level while the total levels of ERK (t-
ERK) expression was not affected (Figure 3.4B).  This substantiated that Zfp322a 
could be implicated in the repression of MAPK/ERK cascade without changing ERK 
expression in mESCs. 
To further investigate the role of Zfp322a in MAPK pathway, we next examined 
whether inhibition of the MAPK pathway could rescue the effects caused by Zfp322a 
depletion. Zfp322a depleted mESCs were subjected to 50 nM, 250 nM and 1 uM of 
ERK inhibitors (Ei; PD0325901, Sigma). We found that the addition of ERK 
inhibitors could not rescue the down-regulated Pou5f1, Sox2 and Zfp42 upon Zfp322a 
depletion, and the Ei-treated mESCs exhibited differentiated morphology same as 
DMSO treated control cells (Figure 3.4C). However, with the addition of ERK 
inhibitors, levels of Nanog, Sox2 and Rex1 were higher than that of Zfp322a depleted 
cells without ERK inhibitors and the endoderm and ectoderm lineage markers were 
lower. This is consistent with previous findings in which the blocking of ERK 
pathway induces elevated expression of Nanog in ESCs (Luo et al., 2012; Wu et al., 
2013). Nevertheless, ERK inhibitor did not rescue stem cell differentiation caused by 
Zfp322a knocked-down cells. Interestingly, addition of ERK inhibitors seemed to 
facilitate Zfp322a knocked-down cells to differentiate into mesoderm lineage, other 
than endoderm or ectoderm lineages cells. This is in consistent with previous finding 
that Erk2-null mESCs tend to differentiate to mesoderm lineage more efficiently than 




Figure 3.4 Zfp322a represses MAPK pathway in mESCs. (A) List of up-regulated 
MAPK pathway related genes upon Zfp322a RNAi. Genes were selected as they fell 
into the cluster “MAPK signaling pathway” according to gene ontology analysis for 
enriched KEGG pathways. Each selected gene was taken as individual tiles from the 
thumbnail-dendogram duplicates. (B) p-ERK level was elevated in Zfp322a depleted 
cells as compared to control cells, while the total ERK (t-ERK) level was not affected. 
β-actin served as a control for normalization. (C) ERK inhibitors could not rescue the 
down-regulated pluripotency genes in Zfp322a depleted cells.  (D) ERK inhibitors 
could bring down the up-regulated endoderm and ectoderm lineage markers in 
Zfp322a knocked-down cells. Mesoderm markers were elevated with the addition of 




Taken together, it appears that Zfp322a depletion leads to activation of MAPK/ERK 
pathway, which could drive mESCs towards differentiation. However, the inhibition 
of MAPK/ERK pathway could not rescue the differentiation phenotype caused by 
Zfp322a loss, implying that Zfp322a may be implicated in other pathways to sustain 
mESC pluripotent. 
 
3.1.5 Zfp322a regulates transcriptions of Pou5f1 and Nanog.  
Oct4 and Nanog are master regulators of mESC pluripotency (Liu et al., 2007; Niwa 
et al., 2000a). Many pluripotency factors were found to bind to promoters of Pou5f1 
and Nanog to regulate their transcriptions (Chen et al., 2008). Since Nanog and 
Pou5f1 were down-regulated upon Zfp322a depletion, we speculated that Zfp322a 
may bind to Pou5f1 and Nanog promoters to regulate their transcription.  
To test whether Zfp322a binds to cis-regulatory elements of Pou5f1 and Nanog, ChIP 
experiments were performed using an anti-Zfp322a antibody to pull-down wild type 
mESC chromatin. Real-time PCR was used to determine whether Zfp322a 
preferentially bound to known enhancer elements upstream of Pou5f1 and Nanog 
promoters. We found a clear peak in the Pou5f1 distal enhancer, which is also known 
as CR4 (conserved region 4), showing a 28 fold enrichment (Figure 3.5A). CR4 is the 
main enhancer that drives Pou5f1 expression in mouse ESCs and early embryos, and 
it is the site bound by many transcription factors, including Nanog, Sox2 and Oct4 
itself (Chew et al., 2005; Loh et al., 2006; Zheng et al., 2008). Similarly, Zfp322a was 
also shown to bind to the Nanog proximal promoter. Strong enrichment for amplicon 
4 was found in the multiple transcription factor binding locus of Nanog promoter 
(MTL) (Scotland et al., 2009) (Figure 3.5B). These results showed that Zfp322a could 
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directly bind to Pou5f1 distal enhancer and Nanog proximal promoter in mESCs and 
may cooperate with other transcription factors in the regulation of Pou5f1 and Nanog 
transcription. 
To determine whether Zfp322a regulates the transcription of Pou5f1 and Nanog, dual-
luciferase assays were performed using two constructs Pou5f1 CR4-pSV40-Luc and 
pNanog pp-Luc. Interestingly, upon knock-down of Zfp322a, the luciferase activities 
were strikingly reduced to 20% and 30% respectively in constructs carrying the CR4 
or the Nanog proximal promoter (Figure 3.5C, E). To determine whether this 
reduction was led by Zfp322a loss directly, Pou5f1 CR1 was chosen as negative 
control. ChIP experiments showed a relatively lower enrichment fold at this region as 
compared to CR4 (Figure 3.5A).  As expected, in the experiment with Pou5f1 CR1-
pSV40-Luc construct, the luciferase activity was only reduced by 15% upon Zfp322a 
depletion, much less than the 80% reduction observed in CR4 experiment (Figure 
3.5D). These strongly suggested that Zfp322a directly regulated Pou5f1 and Nanog 
through binding to these cis-regulatory elements. Interestingly, it was also observed 
that compared to single knock-down of Pou5f1, double knock-down of Pou5f1 and 
Zfp322a further suppressed enhancer activities (Figure 3.5F, G). Given that Oct4 also 
binds to CR4 and Nanog MTL to regulate the transcriptions (Loh et al., 2006), we 




Figure 3.5 Zfp322a positively regulates Oct4 and Nanog transcription. (A) Zfp322a 
binds to Oct4 distal enhancer regions. Zfp322a ChIP DNA was analyzed by real-time 
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PCR. Locations of primers used in qPCR were mapped to the Pou5f1 genomic region.  
(B) Zfp322a binds to Nanog proximal promoter, with a highest enrichment fold at 
TSS starting site. Locations of primers were pictured on mouse Nanog genomic 
region. Relative luciferase activities were down-regulated upon Zfp322a RNAi using 
Pou5f1 CR4-pSV40-Luc construct (C) and pNanog PP-Luc construct (E), but not 
Pou5f1 CR1-pSV40-Luc construct (D).  Schematic structures of the constructs were 
presented. Empty pSUPER.puro vector were transfected in ESCs as a control RNAi. 
Renilla luciferase vector were transfected simultaneously and relative luciferase 
activities were normalized against Renilla luciferase activity.  
 
3.1.6 Genome-wide mapping of Zfp322a reveals that it is a part of the pluripotency 
regulatory network 
To gain more insights into the downstream pathways through which Zfp322a 
functions, we identified genome-wide binding sites of Zfp322a in mESCs. Following 
chromatin immunoprecipitation using anti-Zfp322a antibody to enrich the DNA 
fragments bound by Zfp322a, we used high-throughput sequencing (ChIP-seq) to 
analyse the ChIP-enriched DNA. Genomic regions defined by multiple overlapping 
DNA fragments derived from the ChIP enrichments were considered as putative 
binding sites. To confirm the validity of these putative binding sites, genomic loci 
with peaks of various fold changes were arbitrarily selected and tested by qPCR. The 
final threshold value was determined based on enrichment of 2 fold in qPCR 
validation (Figure 3.6A), which corresponded to 9-fold or higher enrichment in the 
ChIP-seq experiment. This gave a total of 4382 putative binding sites of Zfp322a that 
were associated with 4056 genes. 
The location of the binding site within the gene was mapped as well (Figure 3.6B). 
Notably, after putative Zfp322a binding sites were mapped to nearest genes, 62% fall 
within 1kb of the nearest gene, showing an obvious preference for TSSs (Figure 3.6C). 
19% of the loci were within gene intronic regions, followed by 5’ UTR, distant 
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promoter (>3kb from TSS) and promoter (<3kb from TSS) which occupied 6% each. 
Thus, we proposed that Zfp322a is primarily associated with gene promoters. 
Among highly enriched binding sites-associated genes, there were many known key 
components of ESC pluripotency regulatory network, such as Ino80d, Zfp206, Zfx, 
Nrf1, Smarce1, implying that Zfp322a could directly regulate transcription of these 
pluripotency genes (Appendix 4). To further examine whether Zfp322a targets have 
preferentially any particular biological functions in mESCs, genes associated with the 
putative binding sites were subjected to Gene Ontology to search for enriched 
biological process terms. Large numbers of terms were found to be related to cellular 
metabolic and biosynthetic processes. Other enriched terms were classified into 
function groups (Appendix 5). Similar to GO analysis of our microarray data, 
Zfp322a targets were involved in regulation of gene transcription and translation, 
especially transcription from RNA polymerase II promoter. Notably, Zfp322a binding 
sites were found near genes encoding core components of RNA polymerase, such as 
Polr2a, Polr2j, Polr3e. We also found that the targets of Zfp322a were related to 
developmental processes, implying that Zfp322a may participate in mouse embryo 
development through regulation of these genes. In addition, many terms surrounding 
the functions “DNA repair”, “protein modifications”, “cellular component 
localization”, and “RNA processing”, were enriched.  
Besides Pou5f1 and Nanog, we sought to refine our prediction of Zfp322a targets by 
combining ChIP-seq and microarray data in pluripotent mESCs. We analysed the 
ChIP-seq in concert with microarray dataset. Overlapping genes between these two 
sets of data indicated that these genes could be potential targets of Zfp322a. We found 
that 401 of the 1574 up-regulated genes in the Zfp322a-RNAi microarray data 
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analysis were directly repressed by Zfp322a in mESCs (p<0.05), while 223 genes 
were activated directly (Figure 3.6D). Further GO analysis of the directly repressed 
targets, showed that MAPK pathway related genes was enriched (p value=0.006). 
This reaffirmed our hypothesis that Zfp322a represses MAPK signalling pathway to 
maintain mESC pluripotency. 
Next, we aimed to identify the Zfp322a binding motif. Through bioinformatic 
computation, we found three different motifs which repeatedly occurred in Zfp322a 
binding sites; albeit at low frequencies (Figure 3.6E). Motif 1 had the highest 
frequency, presenting in 9% of all the binding sites. Motif 2 was a 12bp-polyA-
sequence with a frequency of 5%. The third motif, which was found in 4% of all 
binding sites, showed a high similarity to the Oct4/Sox2 binding motif (Chen et al., 
2008). This suggested that Zfp322a, Oct4 and Sox2 often bind to the same enhancer 
element, either acting as a complex or interacting in other ways. Notably, the first and 
the third element are present in the CR4 element of Pou5f1 and the proximal promoter 
of Nanog. It is expected that the actual Zfp322a binding site was not identified as a 
consensus binding motif, given that Zfp322a protein harbours 10 zinc fingers, while 
only 3-5 zinc fingers were needed for specific DNA binding . Therefore, different 
zinc fingers of Zfp322a possibly recognise distinct sequences, leading to a wide 
variety of Zfp322a binding motifs.  
In view of the observation that Oct4/Sox2 binding sites tended to be present near 
Zfp322a binding sites, we compared Zfp322a binding sites with target sequences of 
other transcription factors mapped in previous studies (Chen et al., 2008). All the 
transcription factors were clustered according to the similarity of the co-localization 
with other factors. The results showed that Zfp322a was closer to the Myc cluster 
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(Figure 3.6F). But with a closer check of the results, Zfp322a actually had a 
ubiquitous comparable correlation with all the 12 transcription factors, and did not 
show any significant preference for either Myc or Oct4/Sox2 centred clusters. Indeed 
Zfp322a showed a slightly higher co-localization frequency with Oct4 cluster target, 
from which it was inferred that Zfp322a may facilitate or cooperate with Oct4 in 
mESCs. 
Given the correlation between Zfp322a targets and Oct4 targets, similarities between 
Oct4/Sox2 and Zfp322a binding motifs, together with our observation that both 
Zfp322a and Oct4 bind to the CR4 region of Pou5f1 distal promoter and Nanog 
proximal promoter at the same regions, we sought to determine whether Zfp322a 
could physically interact with Oct4. Co-IP experiments were performed with either 
anti-Zfp322a antibody or anti-Oct4 antibody. Western blots were then carried out with 
anti-Oct4 antibody or anti-Zfp322a antibody. We observed an Oct4 band in Zfp322 IP 
lane and Zfp322a band in Oct4 IP lane, indicating that Zfp322a physically interacts 
with Oct4 in mESCs (Figure 3.6G). This confirmed our hypothesis that Zfp322a 
functions as a partner of Oct4 in the regulation of gene transcription, though previous 





Figure 3.6 Genomic-wide analyses of Zfp322a binding sites. (A) Validation of ChIP-
seq data to determine fold change threshold. Genomic loci harbouring peaks with 
various fold changes were randomly selected from the ChIP-seq data and categorized 
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into three groups: peak height with 9, 11 or more (>11). These selected loci were 
validated using qPCR. The resultant enrichment fold were shown in the vertical axis 
of the graph. (B) Schematic definitions of locations of the putative Zfp322a binding 
sites relative to the nearest transcriptional unit. TSS referred to -1000 to +100 bp from 
5’-end of annotated RNA. (C) Genomic distributions of Zfp322a binding loci. (D) 
Identification of genes that were predicted to be directly regulated by Zfp322a. The 
datasets from microarray analysis and ChIP-Seq targets were calculated for 
overlapping genes. The results revealed 1574 tentative genes that likely were 
activated (p<0.05) and 223 tentative genes repressed directly by Zfp322a. p value 
highlights statistical significance as compared to random chance (CGI scripts based 
website: Statistical significance of the overlap between two groups of genes) (E) 
Predicted binding motifs for Zfp322a. Motifs were computationally determined based 
on the ChIP-Seq data. Three different motifs were identified, namely motif 1, motif 2, 
motif 3, with frequencies of 9%, 5%, 4% respectively. (F) Zfp322a can be integrated 
within ESC transcription regulatory network. Shown was co-occurrence of 
transcription factors at the multiple binding loci. Colours in the heat map reflected the 
co-localization frequency of each pair of transcription factors (the darker the color 
was, the more frequently colocalized). All the transcription factors were clustered 
according to the colocalization frequency with other factors, which was calculated 
based on their co-occurrence at the same binding loci. (G) Zfp322a can interact with 
Oct4. Cell lysate of wild type ESCs were immunoprecipitated using either anti-
ZNF322A antibody or anti-Oct4 antibody. Western blot was subsequently carried out 
with anti-Oct4 antibody or anti-ZNF322a antibody. Control IP was performed using 
anti-IgG antibody. 
 
3.1.7 Zfp322a can enhance OKSM-induced reprogramming of MEFs into iPSCs 
Since Zfp322a is involved in mESC self-renewal and pluripotency regulation, it 
would be interesting to investigate whether overexpression of Zfp322a can enhance 
OSKM-induced reprogramming or act as a novel reprogramming factor to replace any 
of the OSKM factors in generating iPSCs. MEFs transfected with a Pou5f1-GFP 
reporter were used to identify putative iPSC colonies (Kim et al., 2008). It was 
observed that MEFs infected with OSKM plus Zfp322a showed a more efficient and 
faster reprogramming process than OSKM alone (Figure 3.7A). Addition of Zfp322a 
could enhance the kinetics of OKSM-induced reprogramming as GFP expressing 
colonies were detected earlier than OKSM control. The number of iPSCs, when 
counted as GFP
+
 colonies formed by OKSM plus Zfp322a was higher than OKSM 
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throughout the whole reprogramming process. By day 14 of reprogramming process, 
the number of GFP
+
 colonies generated from OKSM plus Zfp322a was 1.4 fold 
higher than control. Further examination of these iPSC colonies by AP staining also 
showed more AP positive colonies formed by OKSM plus Zfp322a as compared to 
OKSM alone (Figure 3.7B).  
Next, the pluripotency of the iPSCs generated by OKSM plus Zfp322a were evaluated. 
The expression of GFP suggested that Pou5f1 promoter was strongly reactivated in 
iPSCs generated from OKSM plus Zfp322a. IF staining results confirmed that these 
iPSCs expressed pluripotency markers Oct4, Nanog, Sox2 and Rex1. mESC marker 
SSEA-1 was also expressed in the iPSCs generated from OKSM plus Zfp322a (Figure 
3.7C). To further characterize the pluripotency of these iPSCs, embryoid body (EB) 
formation assays were performed to examine whether these reprogrammed cells were 
able to differentiate into three germ layers. iPSCs were cultured in suspension to form 
EBs and then transferred to coated plate with EB differentiation media for 14 days 
before they were stained with lineage markers. We found that EBs derived from those 
iPSCs were able to express endoderm marker Gata4, mesoderm marker alpha smooth 
muscle actin (SMA) and ectoderm marker Nestin (Figure 3.7D). Therefore, it was 
demonstrated that iPSCs generated from OKSM plus Zfp322a were pluripotent and 
closely resembled mESCs. Taken together, we concluded that Zfp322a could enhance 




Figure 3.7 Zfp322a can enhance reprogramming inducted by OKSM. (A) Zfp322a 
enhanced reprogramming efficiency and accelerated the onset of reprogramming 
process. OSKM serves as control experiment. (B) The iPSCs generated from OSKM 
plus Zfp322a presented alkaline phosphatase activity. There were more AP stained 
colonies generated from OKSM+Zfp322a compare to OKSM. (C) The iPSCs 
expressed endogenous Oct4, Nanog, Sox2, Rex1 and SSEA-1, indicating that they 
were ES-cell like. Immunostaining using anti-Oct4, anti-Nanog anti-Sox2, anti-Rex1 
and anti-SSEA-1 antibodies were performed with GFP
+
 iPSCs generated from 
OKSM+Zfp322a.  (D) GFP
+
 iPSCs generated by OKSM+Zfp322a were able to 
express ectoderm, mesoderm and endoderm lineage markers in the EB formation 
assay. iPSCs were stained with anti-Nestin, anti-Gata4 and anti-alpha smooth muscle 
actin (SMA) antibodies and pictures were taken at 60X magnification. DAPI (blue) 






3.1.8 Zfp322a can replace Sox2 in the OKSM-induced reprogramming 
We then investigated whether Zfp322a can replace the core reprogramming factors in 
addition to enhancement of reprogramming efficiency. Given that c-Myc is 
dispensable for reprogramming (Nakagawa et al., 2007; Wernig et al., 2008), we only 
investigated whether Zfp322a can replace any of the OKS factors to generate iPSC 
colonies from MEFs. Zfp322a was unable to replace Oct4 or Klf4, however, there 
were GFP
+
 colonies observed in the MEFs infected with Zfp322a plus OKM (Figure 
3.8A). This indicated that exogenous Zfp322a could replace Sox2 in OKSM-induced 
reprogramming, albeit at a lower efficiency than OKSM. The first GFP
+
 colony 
generated from Zfp322a plus OKM was observed later as compared to OKSM control. 
In addition, the expression of GFP was weaker and the number of GFP
+
 colonies was 
fewer (Figure 3.8A, B). Similar to iPSCs formed from OKSM plus Zfp322a, these 
iPSC colonies were positive for AP staining (Figure 3.8B, D). Further examination of 
the pluripotency profile of these iPSCs showed that these iPSC colonies could be 
stained with anti-SSEA-1, anti-Oct4, anti-Nanog, anti-Sox2 and anti-Rex1 antibodies, 
and were able to express all three lineage markers when they were induced to 
differentiate in the EB formation assays (Figure 3.8E, F). These suggested that 
Zfp322a could replace Sox2, but the combination of OKM plus Zfp322a might have 




Figure 3.8 Zfp322a can replace Sox2 in OKSM-mediated somatic reprogramming. (A) 
Zfp322a was able to replace Sox2, but not Oct4 or Klf4 in OSKM reprogramming 
process. Results from three independent experiments were presented. (B) iPSCs 
generated from OKM plus Zfp322a expressed weak GFP and were positive for AP 
activity. (C) iPSCs generated from OKM plus Zfp322a were positive with AP staining 
and more AP positive colonies were observed in OKM+Zfp322a as compared to 
OKSM. (D) iPSCs generated by OKM plus Zfp322a expressed pluripotency markers 
Oct4, Nanog, Sox2, Rex1 and SSEA-1. (E) iPSCs derived from OKM+Zfp322a could 
differentiate into ectoderm, mesoderm and endoderm lineages, which were showed by 







3.2.1 Zfp322a is a novel pluripotency factor 
The unique properties of ESCs are governed by the master regulators Oct4, Nanog 
and Sox2, along with a variety of transcription factors (Chen et al., 2008). These 
transcription factors form a complex network to regulate ESC identity. So far, a lot of 
transcription factors have been identified to be important for mESC pluripotency and 
self-renewal, such as Esrrb, Zfp281, Zic3, Sall4, Nr5a2, etc. (Festuccia et al., 2012; 
Fidalgo et al., 2012; Lim et al., 2007; Wu et al., 2006; Heng et al., 2010).  
Interestingly, depletion of a single transcription factor will alter mESC pluripotency 
(Chambers and Tomlinson, 2009; Yeo and Ng, 2012). Thus it would be vital to 
identify novel transcription factors to decipher the delicate transcription regulation of 
pluripotent state in mESCs. Our research revealed for the first time that Zfp322a is a 
transcription factor which is important in maintaining mESCs in an undifferentiated 
state.  
Our results have demonstrated that depletion of Zfp322a through RNAi induced 
differentiation of mESCs. The differentiation of mESCs could be due to the 
suppression of Pou5f1 and Nanog expression after Zfp322a was depleted. Zfp322a 
was shown to actively regulate Pou5f1 transcription through binding to the CR4 
region, and activate Nanog transcription via Nanog MTL, which are the co-binding 
sites of other pluripotency factors.  Our ChIP-seq and microarray analysis further 
revealed the binding of Zfp322a to the locus of many other key pluripotency genes 
that were down-regulated upon Zfp322a depletion. It is interesting that Zfp322a can 
regulate Pou5f1 and Nanog transcription, while Zfp322a itself may also be a target of 
Oct4 and other pluripotency genes. It appears that these pluripotency factors can form 
88 
 
a regulatory loop within the transcriptional network controlling the pluripotency of 
mESCs. Thus it can be inferred that Zfp322a is a regulator of mESCs by targeting or 
possibly cooperating with other pluripotency factors. 
Notably over-expression of Zfp322a in mESCs did not significantly change cell 
morphology. Interestingly, Nanog level was activated via Nanog proximal promoter 
in Zfp322a over-expressing mESCs, while Pou5f1 level showed no significant change 
over control (Figure 3.9). Nanog is a well-known core regulator of ESCs, which can 
sustain ESC pluripotency in the absence of LIF (Chen et al., 2008; Liu et al., 2007).  
The activation of Nanog was also observed in a lot of other pluripotency factors, such 
as Zfp296, Nr5a2, Zic3 etc. (Heng et al., 2010; Lim et al., 2010; Muotri et al., 2012). 
All of these factors are required for maintaining ESCs in their undifferentiated state 
and can induce Nanog expression when over-expressed in ESCs. Moreover, our 
microarray data and ChIP-seq results showed that Zfp322a can repress MAPK/ERK 
pathway. It is highly possible that Zfp322a, when over-expressed, may serve as an 
ERK pathway repressor which results in elevated Nanog expression, mimicking  high 
and homogeneous Nanog expression in “2i+LIF” ESC culturing media containing 
ERK inhibitors (Luo et al., 2012; Wu et al., 2013; Zheng et al., 2008). Therefore we 
hypothesize that Zfp322a can activate Nanog expression either directly or indirectly 




Figure 3.9 Zfp322a overexpression activates Nanog transcription. (A) Zfp322a 
overexpressing cells maintained ESC undifferentiated, displaying ESC typical 
morphology and AP activity. (B) Zfp322a overexpressing cells showed elevated 
Nanog expression. ESCs transfected with empty pPCAGIP vector were used as a 
control and gene expression levels were normalized against β-actin. (C) Zfp322a 
activates Nanog expression via Nanog proximal promoter. Dual luciferase assay were 
performed using Nanog pp-Luc construct in control (empty pPyCAGIP vectors 
transfected) and Zfp322a overexpressing cells. Renilla luciferase vector was 
transfected simultaneously and relative luciferase activities were normalized against 
Renilla luciferase activity. 
 
3.2.2 Zfp322a is integrated within the pluripotency regulatory network 
In our results, we also discovered the interaction between Oct4 and Zfp322a and the 
presence of a similar binding motif for Zfp322a and Oct4/Sox2. This is in concert 
with the observed higher co-occurrence frequency between Oct4 and Zfp322a binding 
loci based on the ChIP-seq analysis. Indeed, when we compared the gene expression 
profile changes after Zfp322a RNAi with Pou5f1 RNAi, a large number of high 
overlapping targets were identified (p<0.05; Figure 3.10) (Loh et al., 2006). Gene 
ontology analysis of these co-targeting genes displayed a large number of terms 
related to cellular, organic, embryonic development, cell proliferation and apoptosis, 
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chromatin remodelling, DNA transcription etc. (Appendix 6). In addition, many Oct4-
interacting proteins were also affected in the microarray data analysis (Appendix 7). 
These implied such a close correlation between Zfp322a and Oct4 that Zfp322a may 
synergize Oct4 functions in maintaining ESCs pluripotency. 
Furthermore, the observation of replacement of Zfp322a to Sox2 in OKSM-induced 
reprogramming verified Zfp322a facilitation of Oct4 functions. Sox2 was discovered 
as a transcription factor that binds next to Oct4 motif, thus acting synergistically to 
active gene transcriptions (Boyer et al., 2005; Loh et al., 2006). But subsequent 
studies have indicated that Sox2 functions redundantly in the activation of Oct-Sox 
element (Masui et al., 2007). It is then suspected that Zfp322a could have roles 
partially redundant with Sox2 to interact with Oct4 and participate in Oct4/Sox2 gene 
regulations. Besides, it is noteworthy that Zfp322a knock-down also depleted 
expression of Sox2, which suggested that Zfp322a is required for Sox2 activation 
(Figure 1D, 1E). Therefore, Zfp322a may play a similar function of Sox2 or activate 
Sox2 expression to mediate its functions. 
 
Figure 3.10 Zfp322a share many targets with Oct4. Genes that displayed altered 
expression levels in gene expression microarray analysis upon Zfp322a RNAi were 
compared to genes altered upon Oct4 RNAi in previous study. p value highlights 
statistical significance as compared to random chance (CGI scripts based website: 




However, as a Krüppel-like zinc finger transcription factor, Zfp322a may have more 
complex roles in mESCs since these zinc finger transcription factors have evolved to 
fill roles in many different biological processes (Huntley, 2006). Indeed, our further 
analysis of genome-wide Zfp322a target sequence revealed that Zfp322a displayed a 
non-preferential consensus sequence binding and ubiquitously co-localized with other 
key pluripotency regulators. Therefore, the ubiquitous association with other factors 
and diverse implicated functions from microarray and ChIP-seq analysis render 
Zfp322a functions more complicated. Given that Zfp322a protein contains 10 zinc 
finger motifs, it might associate with a wide variety of co-factors through different 
fingers, and therefore its function is depending on the co-factors it interacts with. This 
pattern may be similar to other C2H2 Zfps harbouring multiple zinc fingers (Brayer 
and Segal, 2008; Nowick et al., 2013). Taken together, we hypothesize that Zfp322a 
function as a coordinator that fine tunes the association and recruitments of various 
factors, including Oct4. It would be interesting to further examine the association of 
Zfp322a with other components of Oct4/Sox2 regulatory cluster and also Myc cluster 
proteins to examine their interactions. 
3.2.3 Zfp322a may enhance reprogramming efficiency in multiple ways 
Considering the relatively low efficiency and considerable time for the OKSM-
induced reprogramming process, many studies focused on finding new factors or 
developing new methods that can accelerate the kinetics of reprogramming process or 
defining the reprogramming mechanism. Our results from iPSC formation assays 
identified Zfp322a as a novel reprogramming enhancer that can replace Sox2, thus 
expanding the current reprogramming code. Sridharan et al reported that Zfp322a 
expression levels were comparable between miPSC and mESC, which was 
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significantly higher than MEFs and partially reprogrammed iPSCs (Sridharan et al., 
2009). Addition of Zfp322a make OKSM-induced reprogramming more efficiently 
and faster than OKSM alone, suggesting that Zfp322a, as a partner of Oct4 and a key 
regulator of mESC pluripotency, can accelerate and enhance the efficiency of this 
process. To our understanding, Zfp322a seems to have a more remarkable role in 
increasing the portion of GFP
+
 colonies than increasing the number of AP
+
 colonies. 
Since the expression of GFP indicates the reactivation of ESC marker Pou5f1, this 
implies that Zfp322a could facilitate the transition of partially reprogrammed AP
+
 
colonies towards fully reprogrammed GFP
+
 colonies.  
There are several possible ways in which Zfp322a can enhance reprogramming. 
Firstly, overexpression of Zfp322a has been shown to activate Nanog expression. 
Although Nanog is not one of the canonical quartets of transcription factors used for 
reprogramming, it is essential for the transition from dedifferentiated intermediates to 
ground state pluripotency (Silva et al., 2009). Thus the enhancement and acceleration 
of reprogramming brought by Zfp322a could be partially facilitated by Nanog 
induction. This may also be the same mechanism shared by Nr5a2 and Zfp296 in their 
enhancement of reprogramming efficiency (Heng et al., 2010; Muotri et al., 2012). 
Secondly, reprogramming process consists of down-regulation of lineage specific 
markers, activation of ESC genes and widespread chromatin remodelling to re-
establish the unique chromosomal confirmation of ESCs. As mentioned previously, 
Zfp322a was shown to repress the lineage specific markers and act as an activator for 
mESC pluripotency genes. ChIP-seq analysis revealed that Zfp322a has many targets 
involved in chromosome assembly and modifications. Recruitment of epigenetic 
modifiers, such as histone acetyltransferases, and inhibition of DNA 
methytransferases and histone deacetylases, can promote reprogramming by 
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loosening the condensed chromatin and thus enabling the exogenous reprogramming 
factors to access and transcribe pluripotency genes and jumpstart the pluripotency 
transcriptional network.  Therefore, Zfp322a could possibly aid in reprogramming by 
activating directly or establishing a permissive chromatin state to allow the 
transcriptions of mESC-specific genes. Thirdly, Zfp322a may promote the 
reprogramming via facilitating Oct4/Sox2 functions. Given our observation that 
Zfp322a is an interacting partner of Oct4 that can replace Sox2 in the OKSM-induced 
reprogramming, it can be inferred that Zfp322a has similar functions of Sox2. 
Fourthly, the suppression of MAPK/ERK pathway is implicated in the predicted 
Zfp322a direct repressed targets. Although the total ERK level was not affected, the 
elevated p-ERK level upon Zfp322a RNAi indicates that Zfp322a could repress ERK 
pathway but not ERK expression. ERK pathway has been shown to trigger mESC 
differentiation (Lanner and Rossant, 2010). Inhibition of this pathway is important for 
maintaining the ground pluripotent state of mESCs and can improve somatic cell 
reprogramming efficiency as well(Nichols et al., 2009). Thus Zfp322a could also 
possibly enhance the reprogramming efficiency via the suppression of MAPK/ERK 
cascade. Therefore, Zfp322a can maintain mESC properties and promote 
reprogramming process in many aspects, yet the underlying mechanisms warrant 
further investigations.  
 
3.3 Future work 
Zfp322a is a novel protein which function remains to be further investigated. 
Therefore more efforts are needed to unravel the deeper mechanism of Zfp322a in 
pluripotency regulation, as well as its potential roles in other biological processes as 
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indicated by our genome wide studies, such as transcription initiation, chromatin 
regulation, MAPK/ERK pathway etc.  
Our gene ontology analysis of ChIP-seq and microarray data strongly suggested that 
Zfp322a targets are involved in embryonic development process and related pathways. 
Zfp322a is implicated as a pluripotency factor because of its relatively high 
expression in ICM and undifferentiated mESCs. Since the general reduction trend of 
Zfp322a expression correlates with a commitment to differentiation and a transient 
up-regulation of Zfp322a at third day of differentiation possibly indicates a specific 
role of Zfp322a in regulating early lineage commitments. We speculate that Zfp322a 
not only simply maintains mESC in their undifferentiated state but also has certain 
roles in lineage specifications in embryo development.  Therefore, it is important to 
knockout Zfp322a in mESCs, which serves as a better model to study intensively 
whether the absence of Zfp322a could alter mESC self-renewal and differentiation. 
Moreover, it would be interesting to generate Zfp322a knockout mice and explore the 
mutant phenotype in embryos. These investigations would deepen our understanding 
regarding the functions of Zfp322a. 
Although human and mouse ESCs are differed in the signaling networks and 
epigenetic landscapes, it has been revealed that they share the same core regulators 
Oct4/Sox2/Nanog and similar transcriptional regulatory network, and the well-known  
Yamanaka factors OKSM are able to drive reprogramming of both human and mouse 
somatic cells (Jaenisch and Young, 2008; Schnerch et al., 2010; Takahashi and 
Yamanaka, 2006; Whitworth et al., 2014). Given that Zfp322a is a conserved zinc 
finger protein in human and mouse (Li et al., 2004), we propose that Zfp322a is 
extremely possible to have similar functions regarding the maintenance and 
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acquaintance of pluripotency in human cells, which is very worthy to be elucidated in 

























THE DOSAGE OF PATZ1 MODULATES REPROGRAMMING PROCESS 
4.1 Results 
4.1.1 Patz1 inhibits reprogramming process 
Patz1 has been found predominantly expressed in ICM and ESCs (Tang et al., 2010; 
Yoshikawa et al., 2006). Previously we have identified Patz1 as an important 
regulator of pluripotency that is required for maintaining ESC in undifferentiated state 
(Ow et al., 2014). In view of the versatility of Patz1 functions and its critical role in 
embryo development (as discussed in chapter 1.4.3), we question its role in 
reprogramming process. 
To explore the role of Patz1 in the reprogramming process, we first added Patz1 
together with the canonical reprogramming factors OKSM to infect MEFs. The same 
Pou5f1-GFP MEFs which will express GFP if Pou5f1 promoter is reactivated were 
used. The number of GFP
+
 colonies served as an evaluation of reprogramming 
efficiency (Kim et al., 2008). 
As shown in Figure 4.1A, the number of GFP
+
 colonies that were generated with 
OKSMP infection is 70% less than OKSM control. Alkaline phosphatase (AP) 
staining also showed a significant reduction of iPS colony formation with the addition 
of Patz1 (Figure 4.1B). This indicates that Patz1 represses reprogramming process. To 
confirm the inhibitory role of Patz1 in reprogramming, Patz1-knockdown retrovirus 
was generated and infected MEFs together with OKSM. We observed that MEFs 
deficient in Patz1 were reprogrammed with higher efficiency than in WT MEFs, as 
indicated by both the yield of GFP
+
 colonies and AP staining results (Figure 4.1C, D). 
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Figure 4.1 Patz1 inhibits OKSM reprogramming process. (A) Addition of Patz1 significantly 
reduces Pou5f1 promoter activity induction, measured as GFP+ colonies number, in OKSM 
mediated reprogramming. The numbers of GFP+ colonies were counted daily from D7 till 
D14. Data represent means ± SD of two independent experiments. (B) AP staining results 
indicate that there are less iPSC generated with OKSMP. (C) OKSMshP showed a higher 
reprogramming efficiency than OKSM control. The numbers of GFP+ colonies were counted 
98 
 
daily from D6 till D12. Data represent means ± SD of two independent experiments. (D) 
More AP colonies were obtained from OKSMshP than OKSM. Please note that the numbers 
of MEFs used for each assay were different, therefore giving rise to different number 
of colonies. Thus OKSM serves as a control for each assay. (E) iPSCs derived from 
OKSMP express pluripotency marker genes Oct4, Nanog and SSEA1. (F) iPSCs derived from 
OKSMshP express pluripotency marker genes Oct4, Nanog and SSEA1. (G)iPSCs derived from 
OKSMP were able to express lineage markers when induced to differentiation in EB 
formation assays. Green fluorescence showing the expression of Nestin (ectoderm), SMA 
(mesoderm) and Gata4 (endoderm) were merged with DAPI (blue). The scale bar represents 
100 um. (H) iPSCs derived from OKSMshP were able to express lineage markers Nestin 
(ectoderm), SMA (mesoderm) and Gata4 (endoderm) when induced to differentiation in EB 
formation assays. The scale bar represents 100 um. (I) Representative view of teratoma 
sections generated from OKSMP-derived iPSCs. iPSCs derived from OKSMP were able to 
form tumors in teratoma assays, which however did not have representative tissue 
structures. (J) iPSCs derived from OKSMshP were able to form teratomas with distinctive 
structures of three lineages, represented by ciliated epithelial tissue (endoderm), Adipose 
tissue (mesoderm), epithelial tissue (ectoderm). 
 
iPSCs generated from OKSMP and OKSMshP expressed pluripotency marker genes 
Oct4, Nanog and SSEA-1 (Figure 4.1E, F). The pluripotency of these iPSCs were 
next examined by EB formation assays, showing that all these iPSCs were able to 
express all three germ layer markers upon differentiation (Figure 4.1G, H). However, 
further teratoma assay found that although OKSMshP-derived iPSCs were able to 
produce teratomas with representative structure of all three developmental layers, 
iPSCs generated from OKSMP were defective to differentiate, as they generated 
tumors containing no distinctive structures of germ layers (Figure 4.1I, J). This is 
consistent with the previous finding that Patz1 is required to prevent ESC 
differentiation and its overexpression represses lineage markers during EB formation 
from mESCs (Ow et al., 2014). Given that teratoma assay, which shows the presence 
of well-differentiated cells other than the mere detection of lineage-specific markers 
in EBs, is a more stringent assessment of pluripotency, we suspect that Patz1 
overexpression may lead iPSCs more resistant to differentiate, thereby limiting germ 
layer derivation in teratoma formation (Daley et al., 2009).   
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4.1.2 Addition of Patz1 blocks reactivation of Pou5f1 promoter in OKSM-induced 
reprogramming 
To further investigate Patz1’s inhibitory role during reprogramming process, we 
infected Pou5f1-GFP MEFs with Patz1 overexpressing retrovirus 0 h, 24 h, 48 h and 
72 h after OKSM infection (Figure 4.2A). GFP
+
 colonies were counted daily until 
D12 when AP staining was performed. As shown in Figure 4.2B, compared to 
OKSM+P/0h, there were more AP
+
 colonies formed if Patz1 was added at a later 
stage of reprogramming process. OKSM+P/72h gave rise to the highest number of 
AP
+
 colonies in Patz1 overexpressed MEFs, but it was still obviously less than OKSM 
control (Figure 4.2B). This implies that Patz1 is a strong inhibitor for the initiation of 
reprogramming.  
 
We observed more than 70% reduction in Pou5f1 promoter activity with addition of 
Patz1 into OKSM, which was consistent with previous results. Moreover, Pou5f1 
promoter activity is still reduced and tends to be further decreased when Patz1 was 
added 24 h, 48 h or 72 h later, suggesting that Patz1 can significantly repress Pou5f1 
promoter regardless of its addition point (Figure 4.2C). Previous studies have revealed 
that AP marker can be gained during the initial stage while expression of endogenous-
Oct4 is an indicator for a maturation phase of reprogramming (David and Polo, 2014). 
Therefore, it could be inferred that Patz1 acts not only as an inhibitor for the initiation 
of reprogramming, but also as a potential roadblock for the progression from the 




Figure 4.2 Patz1 represses Pou5f1 reactivation during reprogramming process. (A) 
Schematic figure to show that Pou5f1-GFP MEFs were infected with Patz1 
overexpressing retrovirus 0h, 24h, 48h and 72h after OKSM infection. The numbers 
of GFP+ colonies were counted everyday till D12, at which time point AP staining 
assays were performed. (B) Addition of Patz1 at different reprogramming points 
inhibits AP colony formation. (C) Overexpression of Patz1 represses activation of 
Pou5f1 promoter, measured as GFP+ colonies number, in OKSM reprogramming. 
Data represent means ± SD of two independent experiments. 
 
4.1.3 Heterozygous knockout of Patz1 promotes reprogramming 
Given that overexpression of Patz1 inhibits reprogramming while knockdown of 
Patz1 enhances reprogramming, we surmised that lower Patz1 may facilitate iPSC 
generation and deletion of Patz1 may further significantly enhance reprogramming. 
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To test our hypothesis, we next investigated the impact of heterozygous knockout and 
homozygous knockout of Patz1 on cellular reprogramming. 
Patz1
+/-
 MEFs and Patz1
-/-
 MEFs were generated as previously described (Valentino 
et al., 2013b). The expression levels of Patz1 were confirmed at both protein and 
mRNA levels (Figure 4.3A, B). We infected these three types of MEFs with OKSM. 
As expected, Patz1
+/-
 MEFs produced the greatest number of Oct4
+
 colonies and AP
+
 
colonies (Figure 4.3C, D). Surprisingly, iPSC formation was obviously repressed in 
Patz1
-/-
 MEFs. Similar to previous observations, when Patz1 is overexpressed in WT 
MEFs, the generation of iPS colonies was inhibited (Figure 4.3E, F). This again 
reaffirmed the repressive impact of Patz1 in cellular reprogramming. 
Patz1
-/-
 MEFs derived iPSCs displayed characteristics of pluripotent cells. They 
expressed pluripotency markers and were able to differentiate to express all three 
lineage markers in EB formation assay (Figure 4.3G, H). However, the iPSCs derived 
from Patz1
+/-
 MEFs were difficult to passage and died gradually. This fragility of 
iPSCs suggests that the rapid cell division of Patz1
+/-
 MEFs may dilute the effect of 
virus infection and introduce more variations in the generated iPSCs, which, however, 
are necessary for a successful reprogramming. Yet how Patz1 dosage impacts on the 





Figure 4.3 Heterozygous knockout of Patz1 promotes iPSC generation while Patz1-/- 
MEFs are difficult to be reprogrammed. (A) Relative mRNA level of Patz1 in 
Patz1+/+, Patz1+/- and Patz1-/-
 
MEFs as demonstrated by real time PCR. The relative 
expression level was normalized against β-actin and Patz1+/+ MEFs were used as 
control. (B) Patz1 protein expression in Patz1+/+, Patz1+/- and Patz1-/-
 
MEFs as 
assessed by western blot. β-actin protein levels were analyzed as a loading control. 
(C) AP staining results of iPSCs inducted from Patz1+/+, Patz1+/- and Patz1-/-
 
MEFs. 
Patz1+/- MEFs showed the highest reprogramming efficiency, while lowest number of 
iPSCs was generated from Patz1-/-
 
MEFs. (D) Quantification of AP colonies generated 
from Patz1+/+, Patz1+/- and Patz1-/-
 
MEFs. The numbers of AP colonies were counted 
under microscope after AP staining.  Data represent means ± SD of two independent 
experiments. (E) Representative results of AP staining of iPSC colonies generated by 
OKSM reprogramming in Patz1+/+ MEFs with or without overexpression of Patz1 (F) 
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Quantification of the experiment shown in e. Data represent means ± SD of two 
independent experiments. ) (G) iPSCs derived from Patz1-/- MEFs expressed 
pluripotency marker genes Oct4, Nanog and SSEA-1. The green fluorescence 
indicates expressions of specific proteins. The lower panel shows the figures merged 
with DAPI (blue). The scale bar represents 100 um. (H) iPSCs derived from Patz1-/- 
MEFs were differentiated to express lineage markers Gata4 (endoderm), SMA 
(mesoderm) and Nestin (ectoderm). The scale bar represents 100 um.  
 
4.1.4 Patz1 acts through repression of c-Myc to inhibit iPSC induction   
Previous studies have shown that Patz1 acts either as an activator or a repressor for c-
Myc transcription based on the cellular context. c-Myc, which is involved in many 
cellular process during reprogramming, can robustly enhance the reprogramming 
efficiency (David and Polo, 2014; Wernig et al., 2008). We therefore asked whether 
the inhibitory effect of Patz1 is mediated through regulating c-Myc. We first infected 
Pou5f1-GFP MEFs with OKSP or OKSshP to examine the impact of Patz1 on 
reprogramming in the absence of c-Myc retrovirus. As indicated in Figure 4.4, more 
iPSCs were generated from OKSshP and less iPSCs were derived from OKSP. In 
addition, the repressive effect of Patz1 seems to be more striking in the absence of c-
Myc. This suggests that c-Myc may counteract the inhibitory effect of Patz1 
overexpression during reprogramming.  
Our previous ChIP-seq results in mESCs revealed that c-Myc is one of the binding 
targets of Patz1 (OW et al., 2014). ChIP using anti-Patz1 antibody showed that indeed 
Patz1 was bound to an intronic region of c-Myc in MEFs (Figure 4.4E). We next 






 MEFs, showing 
that c-Myc was significantly repressed in Patz1 OE MEFs, whereas it was  obviously 




 MEFs (Figure 4.4 F). Interestingly, the level of 
p16, a major marker for cellular senescence, and p53 were up-regulated in Patz1 OE 
MEFs (Figure 4.4G). p53 and c-Myc are known to have opposite roles in diverse 
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cellular processes (Ceballos et al., 2005; Ho et al., 2005; Zheng et al., 2008; Sachdeva 
et al., 2009). Based on these results, it appears that the inhibitory effect of Patz1 in the 
reprogramming process could be partially rescued by overexpression of c-Myc, 
implying that Patz1 could act through repressing c-Myc to inhibit iPS cell induction.  
 
Figure 4.4 Patz1 acts through c-Myc to repress reprogramming. (A) Representative 
results of AP staining after reprogramming of Pou5f1-GFP MEFs with OKS and 
OKSP. There were less iPSCs generated when Patz1 was added to the OKS cocktail. 
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(B) Pou5f1 promoter activity, as assessed by GFP+ colonies number, was highly 
decreased in OKSP versus OKS inducted iPSCs. (C) Patz1 knockdown increased AP 
colony formation in OKS reprogramming. (D) More GFP+ colonies were generated 
with OKSshP compare with OKS. (E) Patz1 binds to c-Myc in WT MEFs. (F) 
Overexpression of Patz1 repressed c-Myc protein level in MEFs; while c-Myc 
expression was up-regulated in Patz1+/- or Patz1-/-
 
MEFs. (G) Overexpression of Patz1 
induced up-regulation of p16 and p53. β-actin served as loading control. 
 







To deeper understand how Patz1 is involved in the reprogramming process, we 







 MEFs. As shown in Figure 4.5A, 
compared to WT MEFs, 1286 genes were down-regulated by more than 40% and 740 
genes were up-regulated by more than 2 fold in Patz1
+/-
 MEFs. The same cutoff 
values gave 1353 down-regulated genes and 677 up-regulated genes in Patz1
-/-
 MEFs 
(Appendix). These up-regulated or down-regulated genes were further grouped into 2 




 MEFs respectively. 
Gene ontology (GO) analysis was conducted for each cluster of genes (Figure 4.5A). 
Transcription regulation was one of the enriched terms in both up-regulated and 
down-regulated genes, which supports the role of Patz1 as a transcription regulator.  
Many genes related to development, cell specification or differentiation was found to 
be altered, reaffirming the requirement of Patz1 for a proper embryo development. 
Many neurophysiological terms are enriched, which is consistent with previous 
finding that Patz1 is essentially involved in nervous system development and 
functions (Valentino et al., 2013b). Interestingly, a number of MET inducing genes 





 MEFs, indicating that Patz1 could be a potential regulator in MET induction 
during reprogramming process (Figure 4.5B). 
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Moreover, some genes related to chromatin organization and epigenetic regulation of 
gene expressions were found within the up-regulated cluster. Interestingly, 
expressions of many histone deacetylases and acetylases were altered (Figure 4.5C). 
Histone deacetylases, such as Hdac2, Hdac4, Hdac11, were generally down-regulated 
upon Patz1 loss, while histone acetylase Hat1, Kat2a were up-regulated. This implies 
that Patz1 may crosstalk with many epigenetic factors and influence chromatin 
modification. 





 MEFs, as indicated in cluster iii in Figure 4.5A. GO analysis 





MEFs, were enriched in programmed cell death and apoptosis 
(Figure 4.5D). Indeed previous studies have shown that Patz1
-/- 
MEFs usually 
underwent premature cellular senescence and grew significantly slower compared to 
their WT counterparts, while Patz1
+/-
 MEFs showed a much faster growth rate than 
WT MEFs (Figure 4.6A). Overexpression of Patz1 did not show any significant 
change in cell proliferation rate (data not shown). Therefore, we concluded that Patz1
-
/-
 MEFs are distinguished from Patz1
+/-











Figure 4.5 Gene expression profiles in Patz1+/+, Patz1+/- and Patz1-/- MEFs. (A) 
Heatmaps of genes selected according to the fold change (>2.0 or <0.6) in Patz1
+/-
 
compared to Patz1+/+ MEFs. Relative highly expressed genes are shown in red and 
low expressed genes in green. Compared to WT MEFs, 1286 genes (clusters i and ii) 
were down-regulated by more than 40% and 740 genes (clusters iii and iv) were up-
regulated by more than 2 fold in Patz1+/- MEFs. The two different clusters for each 
up-regulated or down-regulated group of genes were created with Cluster 3.0 
according to their different levels in Patz1+/- and Patz1-/- MEFs. Heatmaps were 
visualized using Java Treeview. GO analysis (GATHER) was performed with each 
cluster of genes and enriched GO terms (p<0.05) were selected and classified into 
groups accordingly. (B) List of EMT or MET inducing genes, which expressions were 
A 
B C D 
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changed in Patz1+/- and Patz1-/-
 
compared to WT MEFs. The trend indicates that EMT 
inducing genes were generally repressed whereas MET inducing genes were up-
regulated upon Patz1 loss. (C) List of histone deacetylase and acetylase genes, which 
expression is changed in Patz1+/- and Patz1-/-
 
compared to WT MEFs. Histone 
deacetylases were generally down-regulated, while histone acetylases were up-
regulated, in Patz1+/- and Patz1-/-
 
MEFs compared to WT control. (D) List of cell 
death related genes differentially expressed in Patz1+/- and Patz1-/- compared to WT 
MEFs. All these genes belong to the cluster iii, i.e. up-regulated in Patz1
-/- 
MEFs 
whereas down-regulated in Patz1+/-
 
compared to WT MEFs. Each selected gene was 




 MEFs but not Patz1
-/-
 MEFs surpass Ink4a/Arf locus barrier in 
reprogramming 
Among those reversely changed genes, we found that Cdkn2a was significantly up-
regulated in Patz1
-/-
 MEFs, but not in Patz1
+/-
 MEFs. Cdkn2a (also known as p16), 
encoded by Ink4a, is a key effector of cellular senescence. Recent studies have 
revealed that H3K27me3 level at Ink4a/Arf is decreased in response to expressions of 
reprogramming factors and silencing of this locus allows for an efficient 
reprogramming (Banito et al., 2009; Li et al., 2009; Utikal et al., 2009b). Therefore 
we hypothesized that Patz1 may regulate this Ink4a/Arf locus to induce cell 
senescence, thus inhibiting reprogramming process.  




MEFs by WB. 
Indeed the level of p16 was reduced in Patz1
+/-
 MEFs, but up-regulated in Patz1
-/-
 
MEFs (Figure 4.6B). We then performed ChIP experiments using anti-H3K27me3 
and anti-H3K4me3 antibodies to check their levels at this locus. As presented in 
Figure 4.6C, in Patz1
+/-
 MEFs the active histone mark H3K4me3 was significantly 
repressed, whereas the level of repressive mark H3K27me3 was robustly increased 
than in wt MEFs. This reaffirmed that the roadblock of Ink4a/Arf locus was bypassed 
in Patz1
+/-




Figure 4.6 Ink4a/Arf locus is activated in Patz1-/- MEFs. (A) Patz1+/- MEFs showed 
the highest cell proliferation rate whereas Patz1-/- MEFs was the lowest. The number 
of cells increases fastest in Patz1+/- MEFs. Same number of cells were seeded into 96-
well plates and cell numbers were counted and calculated every day. Data represent 
means ± SD of three independent experiments. (B) WB results showed increased 
expression of CDkn2a in Patz1-/- MEFs, but lower level in Patz1+/- MEFs. Β-actin was 
used as a loading control. (C) ChIP results showed a lower level of active histone 
mark H3K4me3 and elevated level of repressive histone mark H3K27me3 in Patz1+/- 
MEFs. Realtime PCR primers were designed along the Ink4a/Arf locus as the 
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schematic figure shows. The fold enrichment was quantified as relative to input, and 
the fold changes were normalized against an intragenic control region on chromosome 
17. (D) Relative mRNA levels of senescence markers in Patz1+/+, Patz1+/- and Patz1-/- 
MEFs 5 days after OKSM infection. Note that at day 5 of reprogramming, Cdkn2a 
and Cdkn1b mRNA levels were significantly increased in Patz1-/- MEFs compared to 
the WT counterparts, whereas their levels were clearly reduced in Patz1+/- MEFs. 
 






 MEFs 5 days after 
OKSM infection to examine the levels of Cdkn2a in response to reprogramming 
factors. We found that at day 5 of reprogramming Cdkn2a mRNA levels were 
significantly increased in Patz1
-/-
 MEFs compared to the WT counterparts, whereas 
their levels were clearly reduced in Patz1
+/-
 MEFs (Figure 4.6D). Similar trend was 
observed for another senescence related protein Cdkn1b (also known as p27). This 
reinforced our hypothesis that the Ink4a/Arf locus is silenced in Patz1
+/-
 MEFs, thus 
contributing to the faster cell division and higher reprogramming rate of these cells 
compared to wild-type controls. Conversely, Patz1
-/-
 MEFs cannot overcome the 
Ink4a/Arf barrier and undergo cellular senescence during reprogramming process, 
resulting in the limited formation of iPS colonies.  
 
4.1.7 Patz1 negatively regulates reprogramming possibly via modulating global 
histone modifications in MEFs 
 As a number of terms related to chromatin assembly, organization and epigenetic 





 MEFs (Figure 4.5A, C), we next explored the roles of Patz1 in the 
epigenetic regulation.  
Patz1 belongs to POK family of transcription repressors and the POZ domain is 
known to interact with corepressor complexes to negatively regulate gene 
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transcriptions. Since Patz1 has been shown to interact with Ncor1 and Sirt1, we first 
examined the histone acetylation levels (Cho et al., 2011; Sakaguchi et al., 2010). 
H3Ac level was higher in Patz1
+/-
 MEFs and was significantly repressed in Patz1 OE 
MEFs (Figure 4.7A). This suggested that the level of Patz1 is correlated with histone 
acetylation level. In addition, our microarray results also revealed that a number of 
histone acetylases and deacetylases were altered in Patz1
+/- 
MEFs (Figure 4.5C). 
Using ChIP analysis, we also found that Patz1 could bind to many histone 
deacetylation related genes, indicating that Patz1 may potentially regulate these genes 
to modulate histone acetylation (Figure 4.7B). Indeed when Patz1 was overexpressed, 
the level of Hdac2, Hdac3 and Sin3a were significantly increased, suggesting that 
Patz1 overexpression increases histone deacetylation via activation of these epigenetic 
factors (Figure 4.7C).  
We also examined the level of marks associated with euchromatin- H3K36me3 and 




 and Patz1 
-/- 
MEFs. As shown in Figure 4.7D, the levels of active histone marks were generally 
increased, while the repressive histone mark were decreased, in Patz1
+/-
 compared to 
wt. HP1α, well-known for its role in heterochromatin formation, was also decreased 
in Patz1
+/-
 MEFs. Notably, the level of H3K4me2 was significantly upregulated in 
Patz1
+/-
 MEFs and reduced in Patz1 overexpressed MEFs (data not shown). 
Acquisition of H3K4me2 at the pluripotency genes occurs at the initial stage of 
reprogramming that primes the gene for activation later on, which is a prerequisite for 
pluripotency induction (Koche et al., 2011). Thus, heterozygous loss of Patz1 may 
promote a globally more open chromatin state accessible for activation of 




Figure 4.7 Level of Patz1 modulates chromatin modifications in MEFs. (A) H3 
acetylation level was increased in Patz1+/- MEFs. (B) ChIP using Patz1 antibody 
showed that Patz1 can bind to histone deacetylation related genes, such as Corest, 
Ncor1 and Chd4. The fold enrichments of Patz1 on these potential sites were higher in 
WT MEFs than Patz1-heterozygous knockout MEFs. (C) H3 acetylation was 
repressed by Patz1 overexpression. H3Ac was significantly repressed, while the levels 
of histone deacetylation related factors Hdac2, Hdac3, Sin3a were increased in Patz1 
OE MEFs. (D) Up-regulated H3K4me3, H3K4me2, H3K36me3 levels and repressed 






We previously demonstrated that Patz1 is an essential pluripotency factor. It is 
therefore intricate to investigate whether it has a role in pluripotency reacquisition. In 
this study, we revealed the first evidence for the involvement of Patz1 in 
reprogramming process: (i) overexpression of Patz1 inhibits the acquisition of 
pluripotency, while interference or heterozygous loss of Patz1 enhances iPSC 
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generation; (ii) knockout of Patz1 hinders the reprogramming process by inducing 
cellular senescence. This suggests that a critical control of Patz1 dosage is essential 
for the generation of iPSCs (Figure 4.8). 
 
Figure 4.8 Proposed role of Patz1 during somatic cell reprogramming. Briefly, 
overexpression of Patz1 creates a condensed chromatin which represses the 
reprogramming process; Patz1 overexpression also represses c-Myc and induces cell 
senescence to inhibit reprogramming. Heterozygous knockout of Patz1 can promote 
MET, activate c-Myc, overcome Ink4a/Arf barrier to surpass senescence and also 
create an open, hyperdynamic chromatin structure accessible for pluripotency gene 
reactivation, thus enhancing cellular reprogramming. Patz1-/- MEFs undergo cell 
senescence and are hard to be reprogrammed. 
 
4.2.1 The role of Patz1 is dosage- and possibly p53- dependent  
Patz1 has emerged as a fascinating transcription factor that have been implicated in 
various cellular or developmental processes, such as transcription regulation, 
carcinogenesis, spermatogenesis, thymocyte development, neurological process, 
pluripotency maintenance, cellular senescence and apoptosis. The involvement of 
PATZ1 in tumor suppression or carcinogenesis has been a debating issue for decades. 
Patz1 is previously known as MAZR (Myc-associated zinc finger related protein), 
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which can activates c-Myc promoter (Kobayashi et al., 2000). But subsequent studies 
reported the implications of Patz1 in tumor suppression. Here we showed that Patz1 
possibly acts as a repressor of c-Myc in MEFs. c-Myc protein level was the highest in 
Patz1
-/- 
MEFs. Overexpression of Patz1 significantly repressed c-Myc, but induces 
p53 and p16. Previous studies have found that c-Myc and p53 negatively regulates 
each other in tumorigenesis, cell differentiation and cell apoptosis etc. (Ceballos et al., 
2005; Ho et al., 2005; Zheng et al., 2008; Sachdeva et al., 2009). p53 is known to 
negatively regulate c-Myc transcription through a mechanism that involves histone 
deacetylation (Ho et al., 2005). Given that Patz1 is an interacting partner of Ncor1 and 
Sirt1 and modulates histone acetylation level (Sakaguchi et al., 2010; Cho et al., 
2011), it is therefore suggested that ectopic Patz1 could act via repression of c-Myc, 
possibly via cooperation with p53, to inhibit reprogramming efficiency.  
A more recent finding revealed that the tumor suppressor role of PATZ1 is p53-
dependent (Valentino et al., 2013a). In the presence of p53, PATZ1 interacts with p53 
to enhance its functions in tumor suppression; in the absence of p53, PATZ1 is more 
likely to enhance cell survival and proliferation. Previous studies have proposed some 
mechanisms by which p53 inhibits reprogramming, such as inducing cell cycle arrest 
and apoptosis, inhibiting mesenchymal to epithelial transition (Banito et al., 2009; 
Brosh et al., 2012; Wang et al., 2012). Here we show that the level of Patz1 is also 
critical for reprogramming process. In the absence of Patz1, p53/p16 axis is activated, 
and the cells undergo cellular senescence. When only one of Patz1 alleles is disrupted, 
p53 level is not that affected but Ink4a/Arf locus is repressed, whereby preventing the 
cells from senescence induction. Overexpression of Patz1, however, robustly activates 
p53 and p16, whereby eliciting cell cycle arrest in MEFs. Given that p53 is a known 
inhibitor of reprogramming, we therefore speculate that excessive expression of Patz1 
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may act through p53/p16 to induce cell senescence, and thus inhibiting 
reprogramming process. The observation of higher proliferation rate in Patz1
+/-
 MEFs 
indicates that there are other pathways involved. It could not be ruled out that when 
Patz1 level is reduced in Patz1
+/-
 MEFs, the anti-proliferative effects of p53 could no 
longer be stabilized. This may somewhat indicates that the role of Patz1 relies on its 
expression levels and possibly is p53-dependent as well. 
 
4.2.2 Patz1 is implicated in cell senescence 
We also propose that the restriction of iPSC generation in Patz1
-/-
 MEFs may be 
associated with cellular senescence. We have shown that knockout of Patz1 up-
regulates senescence effectors p16 and p21, driving cellular senescence in MEFs. 
Patz1 may be involved in cellular senescence by regulating epigenetic status of 
Ink4a/Arf locus. The absence of Patz1 induces higher H3K4me3 in this locus; but 
with a haploinsufficient level of Patz1, H3K27me3 is significantly increased, resulting 
in repressed expression of Ink4a/Arf. Ink4a/Arf locus needs to be repressed for the 
transition from somatic cell to pluripotent state (Banito et al., 2009; Li et al., 2009; 
Utikal et al., 2009b). Jmjd3 for example, which possesses tumor suppressor character, 
inhibits the reprogramming process by demethylation of H3K27me3 at Ink4a/Arf 
(Agger et al., 2009; Zhao et al., 2013). Similarly, haploinsufficient loss of Patz1 may 
accelerate the reprogramming kinetics by pre-repressing of Ink4a/Arf locus. This is 
consistent with the concept that somatic cells need to overcome cellular senescence to 
acquire pluripotency.  But it is not clear whether Patz1 is directly involved in the 




4.2.3 Patz1 may be a novel negative regulator of MET 
Since many MET inducing genes were up-regulated while EMT inducing related 




 MEFs, we propose that Patz1 could 
be implicated in MET inhibition. MET, a reversed process to EMT, is one of the key 
cellular events during early stage of reprogramming process (Li et al., 2010b). Factors 
that promote MET, including Klf4 and E-cad can enhance pluripotency acquisition; 
while factors that drive EMT or prevent MET, such as TGF-β and some mesenchymal 
markers, impede the reprogramming at the initial stage (Li et al., 2010b; Samavarchi-
Tehrani et al., 2010). Interestingly our Patz1 ChIP results revealed that many MET 
and EMT associated genes are bound by Patz1 in ES cells (Figure 4.9A). Thus Patz1 
may help to activate the epithelial program and suppress mesenchymal genes to 
overcome the EMT epigenetic barrier of fibroblasts. Since Klf4 is one of the major 







 MEFs. Klf4 levels seemed to be similar in those 
MEFs (Figure 4.9B). Hence we reckon that Patz1 may act independently from Klf4, 




Figure 4.9 Patz1 may be implicated in MET. (A) Many EMT and MET related genes 
were bound by Patz1 in MEFs. ChIP using anti-Patz1 antibody was performed with 
WT Patz1 MEFs. Primers were designed based on Patz1 ChIP-seq results in mESCs. 
The fold enrichment was quantified as relative to input, and the fold changes were 
normalized against an intragenic control region on chromosome 17.  (B) Klf4 protein 
levels were not affected by Patz1 in MEFs. Β-actin was used as a loading control. 
 
 
4.2.4 Patz1 modulate histone acetylation to enhance reprogramming 
Somatic cells utilize a large number of epigenetic regulations to prevent the 
expression of unwanted genes. Pluripotent cells however possess a rather open 
chromatin configuration which allows transcriptional programs to switch rapidly upon 
induction of differentiation. How to overcome the epigenetic barriers of somatic cells 
in reprogramming remains a key question. In this report we provide some evidence 
that heterozygous loss of Patz1 enhances reprogramming possibly through promoting 
a more active chromatin state ready for reprogramming onset.  
One possible way for Patz1 modulating chromatin status is via histone acetylation. 
Previous studies have reported the interaction of Patz1 and NCoR complex and Sirt1. 
Our results show that Patz1 is possibly a supreme factor regulating histone acetylation, 
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not only by participating directly to recruit HDAC complexes, but also as a regulator 
of HDAC related genes. The acetylation of histones serves as a marker for active or 
open chromatin, and its level is higher in plastic pluripotent chromatin. In view of 
previous finding that inhibitors of HDAC activity significantly improve the 
reprogramming efficiency (Huangfu et al., 2008a), we propose that the inhibitory 
effect of Patz1 OE could be attributed to the repressed histone acetylation level, which 
hinders the chromatin resetting for efficient reprogramming. This is consistent with 
the general notion that Patz1 is a transcriptional repressor. Moreover, the repression of 
Patz1 OE on histone acetylation could be one of the possible mechanism by which 
Patz1 OE inhibits expression of lineage genes during differentiation, as histone 
acetylation are increased during differentiation, leading to rises in gene expression 
from all germ layers. 
 
4.2.5 The stochastic model of reprogramming and Patz1 dosage 
A model has been proposed that reprogramming is stochastic at the early stage 
(Buganim et al., 2012; Yamanaka, 2009). At reprogramming initiation, the 
reprogramming factors induce global gene activation and in response to that somatic 
cells acquire one type of cell fate, which could be senescence, transdifferentiation, 
dedifferentiation etc. Only those cells which tend to dedifferentiate, i.e. 
reprogrammable cells, will subsequently undergo a second more deterministic phase, 
during which a cascade of molecular events occurs and finally iPSCs are generated. 
The stochastic cell fate transition, which has a long latency and a low efficiency, has 
been considered as the major rate-limiting step for reprogramming. Reprogramming 
factors are known to induce senescence, thus the cells are more likely to undergo cell 
senescence other than dedifferentiation (Banito et al., 2009). Hence the 
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reprogramming efficiency is very low. Here we suspect the dosage of Patz1 may 
affect the stochastic phase of reprogramming.  
As shown in Figure 4.6, Patz1
+/- 
MEFs expressed lower level of Cdkn2a at day 5 of 
reprogramming, while Cdkn2a was robustly activated in Patz1
-/-
 MEFs. It seems that 
Patz1
-/-
 MEFs have a higher tendency to acquire cell senescence for the stochastic 
transition, thus very limited iPSCs were generated. But once these cells have 
surpassed the stochastic phase and become reprogrammable cells that are 
deterministic to be reprogrammed, they can generate healthy iPSCs. This indicates 
that although Patz1 is not essentially required for pluripotency induction, its absence 
will drive cell senescence and impairs the stochasticity of cell fate transition at the 
early reprogramming stage. 
On the other hand, Patz1
+/-
 MEFs display a distinct story. Based on our observation of 
Patz1’s role in chromatin modulation, heterozygous knockout of Patz1 creates a 
hyperdynamic chromatin state, rendering the global promoters more permissive for 
the stochastic gene activation. Thus the cells can be rapidly activated for cell fate 
conversion in response to the reprogramming factors, thus the reprogramming process 
is accelerated. Moreover, the lower level of Cdkn2a observed at day 5 of 
reprogramming implies that there was a smaller percentage of cells undergoing cell 
senescence compared with wt and knockout MEFs. Thus the stochasiticity of cell fate 
transition is biased against cell senescence in Patz1
+/-
 MEFs, leading to a higher 
reprogramming efficiency. Yet, the defective iPSCs generated from Patz1
+/-
 MEFs 
indicates that a proper level of Pazt1 might be required for the deterministic 
reprogramming phase. This is consistent with our previous report that depletion of 
Patz1 impairs mESC pluripotency and self-renewal (Ow et al., 2014). Therefore, 
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Patz1 may affect some key molecular events for pluripotency induction, which yet 
warrant further studies. 
Overexpression of Patz1 seems to result in a globally closed chromatin configuration, 
which impedes the binding of reprogramming factors to the promoters for gene 
activation. The stochastic transition at single-cell level is therefore inefficient. This is 
support by our finding that if Patz1 was added at a later time point after OKSM 
induction, there were more cells that had passed through the stochastic phase, and 
gained some early features of pluripotency, such as AP activity. But the reactivation 
of pluripotency factors such as Oct4, which occurs at a later stage, remained blocked 
by addition of Patz1. Moreover, it seems that overexpression of Patz1 hinders the 
deterministic phase of reprogramming as well. When Patz1 was added at a later stage, 
a further suppression of GFP
+
 colony formation was observed than Patz1 co-inducted 
with OKSM, indicating that these cells were subjected to the inhibitory effect of 
ectopic Patz1 all along the road towards pluripotency.  
 
4.3 Future work 
It has been proposed that the functions of Patz1 are cellular context- and dosage- 
dependent, largely because it is an architecture protein which may interact with 
different proteins to exert specific roles in different types of cells. This has been 
reaffirmed by our studies of Patz1 in mESC identity and somatic reprogramming, 
which uncover that Patz1 has different roles in pluripotency regulation. Besides, it is 
quite obscure regarding why ectopic expression and homozygous knockout of Patz1 
result in a similar phenotype that is distinct to that of Patz1-heterozygous knockout.  
Hence, it would be necessary to identify the interactome of Patz1 and their targets by 
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genomic wide studies in different Patz1 level background, which may give a better 
understanding of its functions in various cellular processes. 
Through the exploration of Patz1’s roles in somatic reprogramming, we provide new 
evidence that the level of Patz1 is closely related to cell cycle regulation, chromatin 
conformation and MET, thus modulating reprogramming process. These results shed 
some lights on novel functions of Patz1, especially in chromatin regulation. Our 
results revealed a strong evidence of the interplay between Patz1 dosage and histone 
acetylation level, which points out the direction of future studies. As a transcription 
factor, Patz1 may potentially recruit epigenetic factors to a specific locus to regulate 
gene transcriptions. Notably, Patz1 seems to be able to modulate the chromatin 
configuration and epigenetic modifications, leading to global gene transcription 
repressions. This will shed some light on future studies of Patz1 in cancer cells. Since 
altered epigenetic regulations have been found in many cancer types, especially at the 
early stage of cancer, dissection of the relationship between Patz1 and chromatin 
would be one of the new directions for future research. In regard of these, it would be 
of great significance and interest to illustrate the deeper mechanisms of how Patz1 is 











CHAPTER 5  
CONCLUDING REMARKS 
ESC is a unique type of cells, featured by by their ability to self-renew and by their 
potential to differentiate into many different cell types. This specific state is delicately 
governed by a complex network of various factors. With the remarkable breakthrough 
of somatic cell reprogramming, pluripotent cells have shown emerging potentials in 
regenerative medicine. However, the mechanism underlying the transformation from 
somatic cells to pluripotent cells remains elusive.  
Zinc finger proteins are a big family of proteins that can regulate gene activities by 
interacting directly with specific cis-regulatory DNA elements through their zinc 
fingers; they have evolved to fill roles in many different biological processes (Dang et 
al., 2000; Huntley et al., 2006). Recent studies have revealed that members of this 
family, such as ZSCAN4, Zfp296, Zfp206, Zfp57, and Zfp42 etc., are key 
components of the ESC transcriptional network and are crucial for maintaining 
pluripotent ESCs (Fischedick et al., 2012; Hirata et al., 2012; Scotland et al., 2012; 
Yu et al., 2009; Zuo et al., 2011). In this study, we discovered that Zfp322a and Patz1, 
two zinc finger proteins highly expressed in ICM and ESCs, are critically engaged in 
pluripotency regulation. 
Zfp322a is a highly conserved protein, the functions of which yet remained unclear. 
Here we demonstrated that Zfp322a plays an important role in the maintenance and 
acquisition of pluripotency. Depletion of Zfp322a impairs mESC self-renewal and 
induces them to differentiate. It is suggested that Zfp322a prevents mESC from 
differentiation possibly by activating Pou5f1 and Nanog expression while repressing 
MAPK/ERK pathway. Zfp322a is also an interacting partner of Oct4 and is integrated 
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as a component within the ESC transcriptional network. Further genome wide studies 
identified the targets of Zfp322a which are involved in a variety of biological 
processes, including DNA transcription and translation, chromosome organization, 
development, DNA repair, cell cycle and apoptosis. Additionally, Zfp322a is found to 
be a novel reprogramming factor that can replace Sox2 in the classical Yamanaka’s 
factors. It can be used in combination with Yamanaka’s factors and that addition leads 
to a higher reprogramming efficiency and to acceleration of the onset of the 
reprogramming process. Together, these results established Zfp322a as a novel 
pluripotency factor that can enhance reprogramming process, filling the functions of 
this newly identified protein. 
Patz1, on the other hand, appears to regulate pluripotency in a cellular context- 
dependent and dosage-dependent manner. Similar to Zfp322a, Patz1 is required for 
mESC pluripotency maintenance by activating Oct4 and Nanog. However, Patz1 
displayed a distinct role in the induction of pluripotency. It is observed that 
overexpression of Patz1 inhibits OKSM-mediated process, while depletion of Patz1 
enhances iPSC generation, indicating an inhibitory role of Patz1 in the 
reprogramming process. Complete loss of Patz1, however, resulted in cellular 
senescence that significantly blocks iPSC formation. Through the exploration of 
Patz1’s roles in somatic reprogramming, we provide new evidence that the level of 
Patz1 is closely related to cell cycle regulation, chromatin conformation and MET, 
thereby modulating the induction of pluripotency. We believed our results provide 
some insightful hints on study how genetic factors crosstalk with epigenetic factors in 
reprogramming process. We proposed that the functions of Patz1 are cellular context- 
and dosage- dependent, largely because it may interact with different proteins to exert 
specific roles in different types of cells. It would be of great significance and interest 
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to illustrate more underlying mechanisms in future studies. Nevertheless, this study is 
among a few studies in which different dosages of pluripotency factors play diverse 
roles in reprogramming process. 
Taken together, these data revealed that zinc finger proteins could regulate 
pluripotency in distinct manners, expanding the current knowledge of pluripotency 
maintenance and acquisition, as well as the diverse functions of zinc finger protein 
family. Our studies also shed light on how somatic zinc finger proteins affect 
reprogramming efficiency, opening a new route to reboot pluripotency via modulating 
the level of zinc finger proteins. Moreover, we believe that our findings would point 
new directions for future research on Zfp322a and Patz1, and provide some hints to 
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Appendix 1. Sequences of primers for plasmid constructions 












Oct4 CR4 into pGL3-
promoter vector  
F atataggatcccacaatccataagacaaggttgg 
R tatatgtcgacagcttcctcaatagcagattaag 




Nanog promoter into 
pGL3-promoter vector  
F cgcgtcgactaaagtgaaatgaggtaaagcc 
R cgcggatccggaaagatcatagaaagaagag 




Patz1 shRNA into 
pSuper.retro.puro 
F gatccccctggagatgcacaccatcattcaagagatgatggtgtgcatctccagttttta 
R agcttaaaaactggagatgcacaccatcatctcttgaatgatggtgtgcatctccagggg  

















Appendix 2. Sequences of primers for qPCR 
qPCR primers for Zfp322a RNAi assays 
β-actin accaactgggacgacatggagaa tacgaccagaggcatacagggac 
Pou5f1 ttgggctagagaaggatgtggtt ggaaaagggactgagtagagtgtgg 
Sox2 ccaggagaaccccaagatgcacaact aagcctccgggaagcgtgtacttatcctt 
Rex1 agatggcttccctgacggatacctagagt ctcttgcttcgtcccctttgtcatgtac 
Nanog ggttgaagactagcaatggtctga tgcaatggatgctgggatactc 
Zfp322a tcaaaagggtgaaaaagatttatattcg tcacatctataaggtttctcctcggtata 
Bmp4 gttcctggacacctcatcacacgactact gtaacgatcggctgattctgacatgct 
Cdx2 cgcagaactttgtcagtcctccgcagtacc gtattcggcggggctgctgtagcccatagc 
Pax5 gggcgcagacggcatgtatgataaa agtcgcatctgagcttcatccgagtcttc 
Nestin agaggaagagcagcaaggccatgac tccctgactctgctccttcttcttcat 
Rest cccttccgttgtaagccatgccagtatga tggtgcttcaggtgtgccgtgtagtgat 
Fgf5 gcagatctacccggatggcaaagtcaatg gttctgtggatcgcggacgcataggtatt 
Hand1 cctgcccaaacgaaaaggctcaggacccaa cgaccgccatccgtctttttgagttcagcc 
Brachyury gagctgtggctgcgcttcaaggagctaac ccccaggtacccactccccgttcacata 
Gata2 ggcctcttcttctgcagggggtagtgtag gcacataggagggataggtgggtatcgg 
Nkx2-5 gaaggcagtggagctggacaaagccgaga ggaaccagatcttgacctgcgtggacgtg 
Gata6 tgtgcaatgcatgcggtctctacagca ttcatagcaagtggtcgaggcaccc 
Sox17 tgaaaggcgaggtggtggcgagtag caacgccttccaagacttgcctagcatct 
Foxa2 cctacgccaacatgaactcgatga gtagaaagggaagaggtccatgatccact 
qPCR primers for Zfp322a RNAi gene expression microarray results validation 
Fgf4 gggcatcggattccacctg gctgctcatagccacgaagaa 
Esrrb aaccgaatgtcgtccgaagac gtggctgagggcatcaatg 
Klf4 ggcgagtctgacatggctg gctggacgcagtgtcttctc 
Slc16a3 tcacgggtttctcctacgc gccaaagcggttcacacac 
Tcea2 aggctggacaaaatggtgacc tgcccctcccttgattcct 
G9a ccgccgagagagttcatagc ggttcgtccccgatgagtg 
Prelid2 cagtaccccttcgagcagg gactgagccatgactcttcttc 
Ogt tgagttggcacatcgagaatatc gaacaccagtattgtcaggctc 
Eomes ggcccctatggctcaaattcc cctgccctgtttggtgatg 
Cdkn1b tcaaacgtgagagtgtctaacg ccgggccgaagagatttctg 
Foxa1 acattcaagcgcagctaccc tgctggttctggcggtaatag 
Nrp1 gacaaatgtggcgggaccata tggattagccattcacacttctc 
Pax6 taccagtgtctaccagccaat tgcacgagtatgaggaggtct 
Gadd45 aatatgactttggaggaattc attcggatgccatcaccgttc 
Gm428 acccaactgactgcctta tctgctttctccttcctg 
Nupr1 cccttcccagcaacctctaaa tcttggtccgacctttccga 
Sox17 tgaaaggcgaggtggtggcgagtag caacgccttccaagacttgcctagcatct 
Hsph1 caggtacaaactgatggtcaaca tgaggtaagttcaggtgaaggg 
Igfbp3 ccaggaaacatcagtgagtcc ggatggaacttggaatcggtca 
Cubn tcctcaggaaattaccgcagt gattgccaaatgctgggtgta 
qPCR primers for Zfp322a ChIP 
Amplicon 1 of Pou5f1 regulatory 
region 
gtggtggagagtgctgtctaggccttag agcagattaaggaagggctaggacgagag 





Amplicon 3 of Pou5f1 regulatory 
region 
ggggaggggtgggtgacgaggatga tactcaacccttgaatgggccaggatggct 
Amplicon 4 of Pou5f1 regulatory 
region 
gggggtggttagtgtctaatctaccaacct acccagtatttcagcccatgtccaa 
Amplicon 1 of Nanog promoter region atttcttcttccattgcttagacggctgag ctaccaccatgcccaatttaaggagtgttt 
Amplicon 2 of Nanog promoter region ccaggtttcccaatgtgaagagcaagcaa tggcgatctctagtgggaagtttcaggtca 
Amplicon 3 of Nanog promoter region gaggatgccccctaagctttccctccc cctcctaccctacccaccccctattctccc 
Amplicon 4 of Nanog promoter region ctctttctgtgggaaggctgcggctcactt catgtcagtgtgatggcgagggaaggga 
Amplicon 5 of Nanog promoter region gcgggtgtccttatcactcttctggaaa tccaagctaggatgttaggtctccctgcta 
qPCR primers for Zfp322a ChIP-seq results validation 
Nrf1 gcccagccaaaccgccacc gccgggagaacccgaggc 
Zfx cgcagcgaggccactgggct agctgacaaaaagcggccca 
Arid1b gccatcgagccacggtcg gcgggagggtttcggaga 
Myl4 agggctcgccgaaaggga atgctagcccctgctccgag 
Polr2a tctcggcgcttctgaggag agggagccggagccctag 
Tcea2 tccccctggcattcggtg gaccacaactcccagacgactg 
Axin1 gctggtgagtagtgggagc cttggatctcaggtctccctac 
Btf3 cctgagactcccgtcctcg cgaggcagggaggggacg 
Grk5 gccgaaccccttgctgcc cggaaagcacaagccaagg 
Lrig2 agatgcccggaggctaaacc cgattggctggctgctga 
Hnrnpc ggccagatcaccgcatttc ctagagataactctcctcccttc 
Prpf4 gccagtgacgcacttccact ccggcctctctagggcag 
Wdr62 ccagcacccactcgaatagc acccagccagactcagtaagc 
Nrtn atccgcatctacgacctggg agctcttgcagcgtgtggtag 
Bmyc gcttctcggcctccgccaa tcttacgcccaggatttgag 
Ubc cgtcggagactgtggggtg cctacaaccgagggaaagcta 
Evi5 gatctccccgcctccgtt acgcctcctgctcaggaacc 
Klf2 gctgagcccggagctcgt aaagtggcaaaggacggcaa 
Setd3 ccctcttccaccgggacg caccggaggaaggaaacca 
Ntn5 gagaacctgggcagagaaga tctccactgagtcttccaggc 
Trim28 tgtctcagaagcgaggga caacggccaggcagccg 
Fuz ggacccacaggtgaggcgg tgccaccagcgttccatta 
Cdk5 ttctcgtatttctgcattgc acaagtcccagatgccagtg 
Crat caagcaaacagaacccgacg ccggtgcgaggcactca 
Yes1 taggcagctgacccggacc caggagacgagacactcacg 
Stag1 cagagggcggtcgggacc ccaaaagtctccggtgtgt 
Carm1 gacaaaaagatgcagagcacc cctaggctggcgtgctgc 
Cage1 gccctgctggtggcatactt ctgcttcccacctagaggatc 
qPCR primers for H3K4me3 and H3K27me3 ChIP 
Amplicon 1of Arf/Ink4a locus ctcttgcttcgtcccctttgtcatgtac ggcggagaaatggcttatttc 
Amplicon 2 of Arf/Ink4a locus tgtgacaagcgaggtgagaagc atgggcgtggagcaaagatg 
Amplicon 3 of Arf/Ink4a locus ttcccaggagctgaaattccag aaaaattcccaacacccacttgc 
qPCR primers for Patz1 ChIP 
Corest cccagtagtgtgtggaaccg gaccggaatggggcgcac 
Ncor1 gcgatggctgccacggc agaacggagtgcggctctt 
Tbl1x tgggcgcgctccctgca tgggacgaactgcagagcgt 
Chd4 caggagcagctgggccaat agatgttacctggatggggtg 
147 
 
Mbd3 aaggcgggacgtagccaact gctcgcaggaccagtctgac 
Cdh1 tttggagcttggcggctggtt aaagtaagcaaactggtgacttgag 
Tgfbr2 cctctcaggatgcgggccagatgt tcggcgcccgggtaaagttgatgag 
Zeb2 ttaggactccccccccaagc ggagcggctgtgaaagttaagg 
Tgfb1 gctaatggtggaccgcaacaacg cagcctctttgggacacccac 
Smad3 ctagggggctgggccagtgc caggaggagaagtggtgcgaga 
Smad7 taaaacaaaacgaatgaatgaagc ggaggtgggaggccgagacg 
Snail1 ctgcggggagcctttaccttc gtgggcagtgcctggcaagg 
Smad2 ccagccctaataccaaccgcac ctctgaagcagcctgggtcctg 
qPCR primers for gene expression determination 
Patz1 gagcttcttccgttctaagtcctacttga actaaagatgatgcaaacgctgactg 
Cdkn2a cgcaggttcttggtcactgt tgttcacgaaagccagagcg 
Arf gccgcaccggaatcct ttgagcagaagagctgctacgt 






















Appendix 3. List of antibodies 
Primary antibodies 
Protein specificity Company Catalog# 
β-actin Santa Cruz sc-81178 
Zfp322a Santa Cruz Sc-102205 
Oct4 Santa Cruz sc-8628 
Nanog Santa Cruz sc-33760 
Sox2 Santa Cruz sc-99000 
Rex1 Santa Cruz sc-377095 
t-Erk Cell Signaling sc-7383 
p-Erk Santa Cruz 137F5 
SSEA-1 Millipore mab34301 
SMA Abcam ab5694 
Gata4 Santa Cruz sc-25310 
Nestin R&D mab2736 
Patz1 Santa Cruz sc-292109 
c-Myc Santa Cruz sc-788 
P16 Abcam ab51243 
H3ac Millipore 06-599 
H3K4me3 Abcam ab8580 
H3K27me3 Abcam ab6002 
HP1α Abcam ab77256 
H3K36me3 Abcam ab9050 
Hdac3 Santa Cruz sc-11417 
Sin3a Santa Cruz sc-994 
Hdac2 Santa Cruz sc-7899 
Klf4 Santa Cruz sc-292109 
Secondary antibodies 
Anti-Mouse GE Healthcare Life Sciences RPN4201 
Anti-Rabbit GE Healthcare Life Sciences NA934V 
Anti-Goat Santa Cruz Sc-2020 
Alexa Fluor® conjugated secondary antibodies 
Anti-Mouse Alexa Fluor® 594 Life Technologies A11032 
Anti-Rabbit Alexa Fluor® 594 Life Technologies A11037 
Anti-Goat Alexa Fluor® 594 Life Technologies A11058 
Anti-Mouse Alexa Fluor® 488 Life Technologies A21202 
Anti-Rabbit Alexa Fluor® 488 Life Technologies A21206 













Appendix 4.  50 binding sites with top-ranked peak heights in Zfp322a ChIP-seq 
analysis 
 




reads in region 
Peak 
Height 
NM_008828 Pgk1 0 766 412 
NR_030494 Mir715 0 3048 193 
NM_007697 Chl1 138156 263 159 
NM_001166549 Eif4enif1 -2744 619 117 
NM_001145676 2210408I21Rik 303161 150 111 
NM_001081436 Ino80d 0 133 102 
NM_009340.1 Tcp10a 244752 135 87 
NM_001103165 Pcbp2 0 118 81 
NM_001044751 Hsd11b1 14086 108 81 
NR_028428 2610005L07Rik 0 240 79 
NM_176996 Smo 12222 259 79 
NR_030708 6820431F20Rik 0 193 78 
NM_027293 Dopey2 77011 119 78 
NM_027290 Mcm10 2107 158 72 
NM_001038607 Kcnh1 263008 85 69 
NM_001033425 Zscan10 -1133 100 68 
NM_030207 Sfi1 23320 1364 68 
NM_001040397 Filip1l 37840 113 67 
NM_001080548 Usp6nl 21705 267 66 
NR_027956 1700052K11Rik 0 118 65 
NM_145990 Cdk5rap2 31754 106 65 
NM_148413 Myo3a 293741 282 64 
NM_013846 Ror2 15762 81 64 
NM_172383 Tmem125 -3283 284 62 
NM_130452 Bbox1 11673 72 60 
NM_001159953 Pde1c 128292 71 58 
NM_015764 Greb1 52616 75 57 
NM_008480 Lama1 44042 71 56 
NM_183151 Mid1 105169 2089 55 
NM_019574 Patz1 0 222 55 
NM_153599 Cdk8 29306 103 55 
NM_053011 Lrp1b 756966 60 54 
NR_003518 Pisd-ps3 1097 1815 52 
NM_181595 Ppp1r9a 20440 97 52 
NM_001193266 Mdga2 162555 90 51 
NM_031881 Nedd4l 80407 54 51 
NM_018797 Plxnc1 72016 52 50 
NM_001033266 Gm525 7659 78 50 
NM_009439 Psmd3 0 62 49 
NM_015820 Hs6st3 148662 53 49 
NM_027600 4921504E06Rik 44158 54 48 
150 
 
NM_001111107 Zfp322a 11378 172 48 
NM_018821 Socs6 0 62 47 
NM_146241 Trhde 63572 49 47 
NM_001145676 2210408I21Rik 169384 48 47 
NM_025341 Abhd6 3163 49 46 
NM_177393 Nalcn 175104 47 46 
NR_003519 Pisd-ps2 0 385 45 
NM_021377 Sorcs1 367575 49 45 
NM_053122 Immp2l 491001 51 45 
NM_007525 Bard1 23206 49 44 
























Appendix 5.  Representative enriched gene ontology terms for ChIP-Seq targets 
 










gene expression 916 9.54E-53 
transcription, DNA-dependent 590 2.27E-23 
translation 133 1.71E-12 
posttranscriptional regulation of gene expression 97 9.42E-07 
transcription from RNA polymerase II promoter 247 0.008354 






chromosome organization 175 2.25E-13 
chromatin modification 108 4.21E-05 
chromatin assembly or disassembly 35 0.000161 
nucleosome organization 31 0.000107 





programmed cell death 332 9.29E-12 
cell death 342 5.09E-11 
apoptotic process 328 1.42E-11 









cell cycle 334 4.03E-31 
mitotic cell cycle 148 4.60E-10 
cell division 119 7.60E-08 
cell cycle arrest 75 9.01E-08 
M phase 125 3.17E-08 
chromosome segregation 51 1.20E-06 
DNA replication 72 3.53E-06 






response to DNA damage stimulus 148 5.09E-15 
DNA repair 101 2.58E-09 
signal transduction in response to DNA damage 32 0.003629 
DNA integrity checkpoint 28 0.008639 






protein modification process 586 3.60E-42 
protein modification by small protein conjugation or 
removal 
150 7.19E-19 
protein ubiquitination 119 4.17E-15 
protein phosphorylation 281 6.98E-13 






RNA processing 175 5.14E-21 
RNA splicing 89 2.13E-12 
RNA localization 37 4.96E-06 






cellular component organization 804 4.05E-37 
establishment of localization in cell 735 1.31E-18 
organelle localization 47 1.30E-05 
cytoskeleton organization 163 0.000149 
152 
 
membrane organization 78 0.001318 
Development 
  
developmental process 723 0.002337 






macromolecular complex assembly 216 9.99E-11 
protein complex assembly 172 1.81E-06 
cellular macromolecular complex assembly 108 0.000128 
protein oligomerization 87 0.024279 
 Signal transduction 
  
  
regulation of signaling 357 0.000192 
signal transduction by p53 class mediator 27 0.011558 
























Appendix 6.  Gene ontology of overlapping genes in the gene expression 
microarray analysis of Zfp322a and Oct4 RNAi 
 








































developmental process 196 1.33E-10 
single-organism developmental process 165 3.48E-09 
anatomical structure development 175 3.79E-09 
system development 149 5.56E-07 
regulation of developmental process 84 3.51E-06 
muscle structure development 41 1.02E-06 
in utero embryonic development 35 1.51E-06 
chordate embryonic development 45 7.82E-06 
embryo development ending in birth or egg hatching 45 1.11E-05 
tissue development 73 2.58E-05 
embryo development 60 2.77E-05 
organ development 112 6.97E-05 
heart development 33 8.54E-05 
muscle cell differentiation 30 8.87E-05 
cardiovascular system development 50 9.04E-05 
circulatory system development 50 9.04E-05 
striated muscle cell differentiation 26 9.95E-05 
striated muscle tissue development 31 0.00012 
regulation of multicellular organismal development 64 0.00208 
muscle organ development 28 0.00404 
heart morphogenesis 19 0.00509 
muscle tissue development 31 0.00032 
positive regulation of developmental process 47 0.00038 
negative regulation of developmental process 37 0.00519 
tissue morphogenesis 34 0.00619 
generation of neurons 53 0.01051 
adrenal gland development 6 0.01626 
nervous system development 71 0.01757 
gonad development 16 0.02882 
epithelium development 36 0.03017 
cell migration 44 0.03138 
neurogenesis 54 0.03235 
gland development 21 0.03238 
mammary gland epithelium development 10 0.03408 
anatomical structure formation involved in 
morphogenesis 
71 0.04907 






cellular developmental process 143 2.56E-09 
cell differentiation 135 1.01E-08 
cell development 80 1.11E-05 
regulation of cell differentiation 66 6.17E-06 
positive regulation of cell differentiation 37 0.00092 
154 
 













regulation of gene expression 160 2.28E-11 
negative regulation of biological process 159 2.33E-11 
regulation of transcription, DNA-dependent 138 8.68E-11 
positive regulation of transcription, DNA-dependent 68 1.29E-07 
transcription, DNA-dependent 138 6.81E-10 
positive regulation of gene expression 76 2.41E-09 
gene expression 177 1.17E-08 
regulation of transcription from RNA polymerase II 
promoter 
74 4.99E-06 
transcription from RNA polymerase II promoter 74 2.38E-05 
positive regulation of transcription from RNA 
polymerase II promoter 
46 0.00147 
negative regulation of sequence-specific DNA 
binding transcription factor activity 
14 0.00787 











regulation of cell proliferation 72 5.22E-08 
cell proliferation 81 2.10E-07 
interphase 21 0.00169 
cell cycle 61 0.00407 
fibroblast proliferation 11 0.0041 
regulation of fibroblast proliferation 11 0.00349 
interphase of mitotic cell cycle 20 0.00369 
G1/S transition of mitotic cell cycle 14 0.00635 
negative regulation of cell proliferation 36 0.00018 



















apoptotic process 84 9.15E-08 
programmed cell death 84 1.78E-07 
death 87 3.21E-07 
cell death 86 5.69E-07 
regulation of apoptotic process 71 9.85E-07 
regulation of programmed cell death 71 1.59E-06 
regulation of cell death 72 3.66E-06 
intrinsic apoptotic signaling pathway 15 0.00069 
intrinsic apoptotic signaling pathway in response to 
DNA damage by p53 class mediator 
8 0.00087 
positive regulation of cell death 34 0.00097 
positive regulation of apoptotic process 32 0.00231 
positive regulation of programmed cell death 32 0.00295 
negative regulation of apoptotic process 39 0.00379 
negative regulation of programmed cell death 39 0.0054 
apoptotic signaling pathway 18 0.01203 
regulation of execution phase of apoptosis 18 0.01203 
execution phase of apoptosis 19 0.01433 
negative regulation of cell death 39 0.02187 







cellular response to stress 65 2.31E-07 
response to stress 110 1.66E-06 
response to DNA damage stimulus 37 0.00016 
response to ionizing radiation 14 0.0007 








cellular response to ionizing radiation 8 0.00658 
response to X-ray 7 0.00733 
intrinsic apoptotic signaling pathway in response to 
DNA damage 
9 0.00712 
response to abiotic stimulus 39 0.00821 
response to topologically incorrect protein 11 0.00756 






chromosome organization 49 3.66E-07 
chromatin modification 36 1.20E-05 
chromatin organization 38 3.82E-05 















intracellular signal transduction 85 0.00027 
signal transduction by p53 class mediator 12 0.00257 
response to transforming growth factor beta stimulus 16 0.00259 
cellular response to transforming growth factor beta 
stimulus 
16 0.00259 
regulation of signal transduction 79 0.00289 
transforming growth factor beta receptor signaling 
pathway 
15 0.00313 
regulation of response to stimulus 95 0.00404 
regulation of signaling 87 0.00655 
regulation of cell communication 87 0.00743 
response to growth factor stimulus 23 0.01366 
cellular response to growth factor stimulus 22 0.03141 
positive regulation of cell communication 45 0.04692 
positive regulation of signal transduction 43 0.03831 






macromolecule modification 111 6.59E-05 
cellular protein modification process 108 6.74E-05 
protein modification process 108 6.74E-05 
peptidyl-amino acid modification 40 0.00084 









organelle organization 106 6.62E-08 
cellular component assembly 72 0.00069 
protein complex subunit organization 49 0.00598 
macromolecular complex subunit organization 57 0.00392 
cellular component disassembly 16 0.00973 
cellular component organization 183 3.21E-13 








Appendix 7.  List of Oct4-interacting proteins that are altered upon Zfp322a 
RNAi 
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